Monitoring Hemostatic Therapeutics

Are Your Assays Accurate?

Tuesday, June 24, 2014

Symposium: 12:15PM - 1:45PM
Wisconsin Center, Room 203 C-E, Mezzanine Level
400 West Wisconsin Avenue, Milwaukee, Wisconsin

Program Description

In clinical practice, the activated partial thromboplastin time (aPTT) assay is typically used to screen patients for hemophilia. When the aPTT is abnormally prolonged, levels of Factor VIII (FVIII) or Factor IX (FIX) are usually determined by performing a one-stage clotting assay or a chromogenic assay. In the presence of an appropriate bleeding history, FVIII and IX assays are needed to safely exclude mild hemophilia even in the presence of a normal aPTT. Furthermore, not all cases of mild hemophilia A can be diagnosed using a single type of FVIII assay. Despite the established role of standard assays in the diagnosis and management of hemophilia and other coagulation disorders, the innate limitations of these assays are widely recognized. Furthermore, the conduct of these tests is often less than optimal, further compromising their value.

Global assays have been developed to provide a more detailed assessment of thrombin generation and clot formation than that provided by traditional laboratory assays. Global assays currently under investigation include thrombin generation, viscoelastic (thromboelastography and thromboelastometry), endogenous thrombin potential, overall hemostasis potential, clot waveform analysis, thromboplastin generation, and simultaneous thrombin and plasmin generation assays. Currently, thrombin generation assays and viscoelastic assays are the most important of these global assays. Many experts believe that there is now sufficient understanding of and experience with these assays to advance them from experimental research to use in clinical management of some patients.

There is no fee to participate in this symposium.

Learning Objectives

Upon attending this symposium, the clinician should be better able to:

• Adopt recommended methods for using currently available hemostatic assays to make a diagnosis and assess phenotype severity in patients with hemophilia
• Implement best practices for using currently available hemostatic assays to monitor the effectiveness of prophylactic and on-demand factor replacement therapy for patients with hemophilia
• Incorporate into clinical practice the use of currently available assays that make it possible to optimize the use of bypassing agents in patients with hemophilia with inhibitors
• Discuss the potential of global hemostasis assays to improve the diagnosis and management of patients with hemophilia, including patients with inhibitors

Target Audience

The target audience for this educational activity is hematologists and hematology nurses.

Faculty

Steve Kitchen, PhD
Clinical Scientist
Dept of Coagulation
Royal Hallamshire Hospital
Sheffield, United Kingdom

Mike Makris, MD
Professor of Haemostasis & Thrombosis
University of Sheffield
Sheffield, United Kingdom

Guy Young, MD
Director, Hemostasis and Thrombosis Center
Hematology/Oncology
Children’s Hospital Los Angeles
Associate Professor of Pediatrics
University of Southern California
Keck School of Medicine
Los Angeles, California

Jointly Sponsored/Co-Provided by:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of American Academy of CME, Inc. and Scherer Clinical Communications. American Academy of CME, Inc. is accredited by the ACCME to provide continuing medical education for physicians. American Academy of CME, Inc. designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. American Academy of CME, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. American Academy of CME, Inc. designates this educational activity for 1.5 contact hours.

Disclosure

According to the disclosure policy of the Academy, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any significant relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed. If a conflict is identified, it is the responsibility of the Academy to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The opinions expressed in this educational activity are those of the faculty, and do not represent those of Academy, Scherer Clinical Communications, or American Nurses Credentialing Council’s Commission on Accreditation. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.

Visit our registration site at: www.schererclinc.com/MHT2014
<table>
<thead>
<tr>
<th>Page</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>Welcome Message from the ISTH SSC 2014 Meeting President</td>
</tr>
<tr>
<td>5</td>
<td>Message from the ISTH Chair of Council</td>
</tr>
<tr>
<td>5</td>
<td>Message from the SSC Chair</td>
</tr>
<tr>
<td>6</td>
<td>Committees</td>
</tr>
<tr>
<td>9</td>
<td>ISTH Future Meetings Calendar</td>
</tr>
<tr>
<td>10</td>
<td>Meeting Supporters</td>
</tr>
<tr>
<td>19</td>
<td>General Information</td>
</tr>
<tr>
<td>23</td>
<td>About Milwaukee</td>
</tr>
<tr>
<td>25</td>
<td>Program-at-a-Glance</td>
</tr>
<tr>
<td>26</td>
<td>Day-by-Day Scientific Schedule &amp; Program</td>
</tr>
<tr>
<td>26</td>
<td>Sunday, June 22, 2014</td>
</tr>
<tr>
<td>27</td>
<td>Monday, June 23, 2014</td>
</tr>
<tr>
<td>38</td>
<td>Tuesday, June 24, 2014</td>
</tr>
<tr>
<td>46</td>
<td>Wednesday, June 25, 2014</td>
</tr>
<tr>
<td>57</td>
<td>Thursday, June 26, 2014</td>
</tr>
<tr>
<td>64</td>
<td>Symposia Schedule Overview</td>
</tr>
<tr>
<td>65</td>
<td>Poster Sessions</td>
</tr>
<tr>
<td>90</td>
<td>Sponsor &amp; Exhibitor Profiles</td>
</tr>
<tr>
<td>103</td>
<td>Exhibition Floor Plan</td>
</tr>
<tr>
<td>104</td>
<td>Conference Center Floor Plans</td>
</tr>
</tbody>
</table>
Dear Colleagues and Friends,

On behalf of the Local Organizing Committee, it gives me great pleasure to welcome you to the 60th Scientific and Standardization Committee (SSC) Meeting of the ISTH in beautiful Milwaukee, Wisconsin, USA.

The SSC 2014 meeting will build on the success of previous meetings and bring together renowned experts from around the world to discuss practical issues that require the translation of scientific knowledge into reliable methods for the evaluation of normal hemostasis and the diagnosis and treatment of thrombotic and bleeding disorders. With a dynamic Educational Program that will explore fundamental, clinical and translational issues with plenary presentations, symposia and poster presentations, SSC 2014 promises to be a robust meeting with a long-lasting impact for the field of hemostasis and thrombosis.

Offering exciting discourse among experts while at the same time allowing for the next generation of scientists and clinicians to become engaged, SSC 2014 offers all professionals – regardless of position – the opportunity to build important relationships, participate in engaging discussions, learn from the best and have access to the latest scientific and clinical resources available.

In closing, I’d like to thank each of you for attending the 60th SSC Meeting of the ISTH. You, as experts and leaders in the field, have the vision, the knowledge, the wherewithal and the experience to help us pave our way into the future. You are our greatest asset and we thank you for your support and leadership.

Robert R. Montgomery, M.D.
President, ISTH SSC 2014
Message from the ISTH Chair of Council

Dear Colleagues and Friends,

It is an honor and a great pleasure to welcome you to the 60th Annual SSC Meeting of the ISTH.

The Scientific and Standardization Committee (SSC) through its subcommittees conducts some of the ISTH's most important activities, ranging from standard setting to nomenclature, education and providing guidance on emerging clinical and laboratory matters.

SSC 2014 is an important gathering of the thrombosis and hemostasis community and an outstanding opportunity to network with international experts in our field. During the past 60 years, the increasing number of participants at the ISTH's SSC meetings confirms its ever-expanding importance as the foremost meeting devoted to the discussion of diagnostic standards, disease nomenclature and classification, and the latest research on bleeding and thrombotic disorders.

This year's program brings together key opinion leaders from around the world as well as many locally renowned experts. As such, we encourage your participation and involvement and look forward to talking with you more about your experience while at SSC 2014.

Thank you to everyone who has worked diligently to organize SSC 2014, both in the ISTH and scientists from around the world who have given their time freely.

We are also very grateful to the many generous sponsors of the meeting.

Michael Berndt, M.D., Ph.D.
ISTH Chair of Council

Message from the SSC Chair

Dear Colleagues and Friends,

On behalf of the ISTH SSC, I welcome you to this 60th Annual Meeting of our organization.

As many of you will know, the ISTH was founded in 1969 by the SSC, formerly known as the International Committee on Thrombosis and Haemostasis. What you may not know is that the work of the SSC began in Basel, Switzerland, at the International Conference on Thrombosis and Embolism in 1954. The early Committee work laid the foundation that the Society is built upon, and while the ISTH has grown considerably in size and range of activities, the SSC remains a critical core component of our organization.

The 19 subcommittees of the SSC continue to oversee scientific developments in a broad range of hemostasis and thrombosis subject areas, and the SSC provides guidance relating to standardization of activities in the clinic, diagnostic and research laboratory.

Today, the work of the SSC is more relevant than ever - both in the laboratory and clinical setting. In the clinic, the introduction of new anticoagulants and products for the treatment of inherited bleeding disorders has raised a number of important issues concerning laboratory monitoring that are now being addressed by our respective subcommittees. Similarly, in the research arena, the incorporation of new genomic and proteomic strategies and the application of animal models of disease to hemostasis and thrombosis discovery are now being encompassed by a range of SSC initiatives.

The future of the SSC looks very bright, and following a recent strategic planning exercise for the organization (the first in its 60 years of existence), the SSC will be working to enhance the inclusive nature of its activities to the global thrombosis and hemostasis community.

Finally, the venue for this 60th anniversary of SSC could not be more appropriate given the highly respected colleagues involved with the organization of this event. Meeting President Bob Montgomery, and Vice President Gil White, have both been longstanding enthusiastic supporters of the ISTH and its SSC activities, and it is especially fitting that they should host this 60th anniversary event.

Enjoy the science, the networking and friendships that this meeting offers. I look forward to seeing you in Milwaukee for what I am certain will be a memorable occasion.

David Lillicrap, M.D.
ISTH SSC Chair
### Committees

#### ISTH SSC 2014 Organizing Committee

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert R. Montgomery</td>
<td>President</td>
<td>USA</td>
</tr>
<tr>
<td>Gilbert C. White, II</td>
<td>Vice President</td>
<td>USA</td>
</tr>
<tr>
<td>Peter J. Newman</td>
<td>Scientific Co-Chair</td>
<td>USA</td>
</tr>
<tr>
<td>Debra K. Newman</td>
<td>Scientific Co-Chair</td>
<td>USA</td>
</tr>
<tr>
<td>Alan E. Mast</td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>Roy L. Silverstein</td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>Hartmut Weiler</td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>Thomas C. Abshire</td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>David Lillicrap</td>
<td>SSC Chair 2012-2014</td>
<td>Canada</td>
</tr>
</tbody>
</table>

#### Officers of the Scientific and Standardization Committee

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Lillicrap</td>
<td>Chair: 2012-2014</td>
<td>Canada</td>
</tr>
<tr>
<td>Sabine Eichinger</td>
<td>Secretary/Chair-Elect: 2012-2014</td>
<td>Austria</td>
</tr>
<tr>
<td>Anna Falanga</td>
<td>Immediate Past-Chair: 2012-2014</td>
<td>Italy</td>
</tr>
</tbody>
</table>

#### Subcommittees of the Scientific and Standardization Committee

<table>
<thead>
<tr>
<th>Name</th>
<th>Subcommittees</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Susan S. Smyth</td>
<td>Animal, Cellular and Molecular Models of Thrombosis</td>
<td>USA</td>
</tr>
<tr>
<td>Keith B. Neeves</td>
<td>Bioengineering</td>
<td>USA</td>
</tr>
<tr>
<td>Francesco Rodeghiero</td>
<td>Bleeding Assessment Tool Committee</td>
<td>Italy</td>
</tr>
<tr>
<td>Anthony R. Hubbard</td>
<td>Coagulation Standards Standing Committee</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Walter Agno</td>
<td>Control of Anticoagulation</td>
<td>Italy</td>
</tr>
<tr>
<td>Jecko Thachil</td>
<td>Disseminated Intravascular Coagulation</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Ivo Francischetti</td>
<td>Exogenous Hemostatic Factors</td>
<td>USA</td>
</tr>
<tr>
<td>Flora Peyvandi</td>
<td>Factor VIII, Factor IX &amp; Rare Coagulation Disorders</td>
<td>Italy</td>
</tr>
<tr>
<td>Jonas Emsley</td>
<td>Factor XI and the Contact System</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Helen Philippou</td>
<td>Factor XIII and Fibrinogen</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Nicola J. Mutch</td>
<td>Fibrinolysis</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Alok A. Khorana</td>
<td>Hemostasis &amp; Malignancy</td>
<td>USA</td>
</tr>
<tr>
<td>Bas De Laat</td>
<td>Lupus Anticoagulant/Phospholipid-Dependent Antibodies</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Anthony K. Chan</td>
<td>Pediatric and Neonatal Hemostasis and Thrombosis</td>
<td>Canada</td>
</tr>
<tr>
<td>Richard A. Marlar</td>
<td>Plasma Coagulation Inhibitors</td>
<td>USA</td>
</tr>
<tr>
<td>Yves Gruel</td>
<td>Platelet Immunology</td>
<td>France</td>
</tr>
<tr>
<td>Paul Harrison</td>
<td>Platelet Physiology</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Name</td>
<td>Title/Group</td>
<td>Country</td>
</tr>
<tr>
<td>-----------------------</td>
<td>--------------------------------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Paul A. Kyrle</td>
<td>Predictive Hemostatic Variables in Cardiovascular Disease</td>
<td>Austria</td>
</tr>
<tr>
<td>Rienk Nieuwland</td>
<td>Vascular Biology</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Jorge A. Di Paola</td>
<td>Von Willebrand Factor</td>
<td>USA</td>
</tr>
<tr>
<td>Rezan Abdul Kadir</td>
<td>Women's Health Issues in T&amp;H</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Anne Goodeve</td>
<td>Working Group on Genomics in Hemostasis</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Willem H. Ouwehand</td>
<td>Working Group on Genomics in Hemostasis</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Pieter Reitsma</td>
<td></td>
<td>The Netherlands</td>
</tr>
<tr>
<td>James Douketis</td>
<td>Working Group on Perioperative Thrombosis &amp; Hemostasis</td>
<td>Canada</td>
</tr>
</tbody>
</table>

**Officers**

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Berndt</td>
<td>Chair of Council</td>
<td>Australia</td>
</tr>
<tr>
<td>Nigel Key</td>
<td>Secretary/Chair-Elect of Council</td>
<td>USA</td>
</tr>
<tr>
<td>Nuala Booth</td>
<td>Treasurer</td>
<td>United Kingdom</td>
</tr>
</tbody>
</table>

**Class of 2014**

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nuala Booth</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Françoise Dignat-George</td>
<td>France</td>
</tr>
<tr>
<td>Nigel Key</td>
<td>USA</td>
</tr>
<tr>
<td>Robert R. Montgomery</td>
<td>USA</td>
</tr>
<tr>
<td>Hugo ten Cate</td>
<td>The Netherlands</td>
</tr>
</tbody>
</table>

**Class of 2016**

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marco Cattaneo</td>
<td>Italy</td>
</tr>
<tr>
<td>Björn Dahlbäck</td>
<td>Sweden</td>
</tr>
<tr>
<td>Andreas Greinacher</td>
<td>Germany</td>
</tr>
<tr>
<td>Paula Tracy</td>
<td>USA</td>
</tr>
<tr>
<td>Yukio Ozaki</td>
<td>Japan</td>
</tr>
</tbody>
</table>

**Class of 2018**

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter Lenting</td>
<td>France</td>
</tr>
<tr>
<td>Claire McLintock</td>
<td>New Zealand</td>
</tr>
<tr>
<td>James Morrissey</td>
<td>USA</td>
</tr>
<tr>
<td>Ingrid Pabinger</td>
<td>Austria</td>
</tr>
<tr>
<td>Jeffrey Weitz</td>
<td>Canada</td>
</tr>
</tbody>
</table>
### Ex-Officio Council Members

<table>
<thead>
<tr>
<th>Name</th>
<th>Title/Position</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Javier Batlle</td>
<td></td>
<td>Spain</td>
</tr>
<tr>
<td>Anthony Chan</td>
<td></td>
<td>Canada</td>
</tr>
<tr>
<td>Bas De Laat</td>
<td></td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Françoise Dignat-George</td>
<td></td>
<td>France</td>
</tr>
<tr>
<td>Jorge Di Paola</td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>Sabine Eichinger</td>
<td></td>
<td>Austria</td>
</tr>
<tr>
<td>Jonas Emsley</td>
<td></td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Anna Falanga</td>
<td></td>
<td>Italy</td>
</tr>
<tr>
<td>Elizabeth Gardiner</td>
<td></td>
<td>Australiia</td>
</tr>
<tr>
<td>Neil Goldenberg</td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>Shinya Goto</td>
<td></td>
<td>Japan</td>
</tr>
<tr>
<td>Paolo Gresele</td>
<td></td>
<td>Italy</td>
</tr>
<tr>
<td>Yu Hu</td>
<td></td>
<td>China</td>
</tr>
<tr>
<td>Tur-Fu Huang</td>
<td></td>
<td>Taiwan</td>
</tr>
<tr>
<td>Paula James</td>
<td></td>
<td>Canada</td>
</tr>
<tr>
<td>Dermot Kenny</td>
<td></td>
<td>Ireland</td>
</tr>
<tr>
<td>Manjunatha Kini</td>
<td></td>
<td>Singapore</td>
</tr>
<tr>
<td>Paul Kyrle</td>
<td></td>
<td>Austria</td>
</tr>
<tr>
<td>Howard Liebman</td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>Nigel Mackman</td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>Michael Makris</td>
<td></td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Owen Mccarty</td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>Diego Mezzano</td>
<td></td>
<td>Chile</td>
</tr>
<tr>
<td>Toshiyuki Miyata</td>
<td></td>
<td>Japan</td>
</tr>
<tr>
<td>Robert R. Montgomery</td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>Nicola Mutch</td>
<td></td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Patrizia Noris</td>
<td></td>
<td>Italy</td>
</tr>
<tr>
<td>Diane Nugent</td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>Thomas Ortel</td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>Margareth Ozelo</td>
<td></td>
<td>Brazil</td>
</tr>
<tr>
<td>Ingrid Pabinger</td>
<td></td>
<td>Austria</td>
</tr>
<tr>
<td>Flora Peyvandi</td>
<td></td>
<td>Italy</td>
</tr>
<tr>
<td>Steven Pipe</td>
<td></td>
<td>USA</td>
</tr>
<tr>
<td>Thomas Renne</td>
<td></td>
<td>Sweden</td>
</tr>
<tr>
<td>Elena Santagostino</td>
<td></td>
<td>Italy</td>
</tr>
<tr>
<td>Sentot Santoso</td>
<td></td>
<td>Germany</td>
</tr>
<tr>
<td>Midori Shima</td>
<td></td>
<td>Japan</td>
</tr>
<tr>
<td>Yoshiaki Tomiyama</td>
<td></td>
<td>Japan</td>
</tr>
<tr>
<td>David Varon</td>
<td></td>
<td>Israel</td>
</tr>
<tr>
<td>Hideo Wada</td>
<td></td>
<td>Japan</td>
</tr>
<tr>
<td>Christopher Ward</td>
<td></td>
<td>Australia</td>
</tr>
<tr>
<td>Stephen Watson</td>
<td></td>
<td>United Kingdom</td>
</tr>
</tbody>
</table>

### SSC 2014 Abstract Reviewers

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Javier Battle</td>
<td>Spain</td>
</tr>
<tr>
<td>Anthony Chan</td>
<td>Canada</td>
</tr>
<tr>
<td>Bas De Laat</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Françoise Dignat-George</td>
<td>France</td>
</tr>
<tr>
<td>Jorge Di Paola</td>
<td>USA</td>
</tr>
<tr>
<td>Sabine Eichinger</td>
<td>Austria</td>
</tr>
<tr>
<td>Jonas Emsley</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Anna Falanga</td>
<td>Italy</td>
</tr>
<tr>
<td>Elizabeth Gardiner</td>
<td>Australiia</td>
</tr>
<tr>
<td>Neil Goldenberg</td>
<td>USA</td>
</tr>
<tr>
<td>Shinya Goto</td>
<td>Japan</td>
</tr>
<tr>
<td>Paolo Gresele</td>
<td>Italy</td>
</tr>
<tr>
<td>Yu Hu</td>
<td>China</td>
</tr>
<tr>
<td>Tur-Fu Huang</td>
<td>Taiwan</td>
</tr>
<tr>
<td>Paula James</td>
<td>Canada</td>
</tr>
<tr>
<td>Dermot Kenny</td>
<td>Ireland</td>
</tr>
<tr>
<td>Manjunatha Kini</td>
<td>Singapore</td>
</tr>
<tr>
<td>Paul Kyrle</td>
<td>Austria</td>
</tr>
<tr>
<td>Howard Liebman</td>
<td>USA</td>
</tr>
<tr>
<td>Nigel Mackman</td>
<td>USA</td>
</tr>
<tr>
<td>Michael Makris</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Owen Mccarty</td>
<td>USA</td>
</tr>
<tr>
<td>Diego Mezzano</td>
<td>Chile</td>
</tr>
<tr>
<td>Toshiyuki Miyata</td>
<td>Japan</td>
</tr>
<tr>
<td>Robert R. Montgomery</td>
<td>USA</td>
</tr>
<tr>
<td>Nicola Mutch</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Patrizia Noris</td>
<td>Italy</td>
</tr>
<tr>
<td>Diane Nugent</td>
<td>USA</td>
</tr>
<tr>
<td>Thomas Ortel</td>
<td>USA</td>
</tr>
<tr>
<td>Margareth Ozelo</td>
<td>Brazil</td>
</tr>
<tr>
<td>Ingrid Pabinger</td>
<td>Austria</td>
</tr>
<tr>
<td>Flora Peyvandi</td>
<td>Italy</td>
</tr>
<tr>
<td>Steven Pipe</td>
<td>USA</td>
</tr>
<tr>
<td>Thomas Renne</td>
<td>Sweden</td>
</tr>
<tr>
<td>Elena Santagostino</td>
<td>Italy</td>
</tr>
<tr>
<td>Sentot Santoso</td>
<td>Germany</td>
</tr>
<tr>
<td>Midori Shima</td>
<td>Japan</td>
</tr>
<tr>
<td>Yoshiaki Tomiyama</td>
<td>Japan</td>
</tr>
<tr>
<td>David Varon</td>
<td>Israel</td>
</tr>
<tr>
<td>Hideo Wada</td>
<td>Japan</td>
</tr>
<tr>
<td>Christopher Ward</td>
<td>Australia</td>
</tr>
<tr>
<td>Stephen Watson</td>
<td>United Kingdom</td>
</tr>
</tbody>
</table>
XXV ISTH Congress and 61st Annual SSC Meeting
Sam Schulman, President
Toronto, Canada
June 20-25, 2015

62nd Annual SSC Meeting
Jean-François Schved, President
Montpellier, France
May 25-28, 2016

XXVI ISTH Congress and 63rd SSC Meeting
Johannes Oldenburg, President
Berlin, Germany
2017

XXVII ISTH Congress and 65th SSC Meeting
Robert Medcalf, President
Melbourne, Australia
2019
The ISTH and the SSC 2014 Local Organizing Committee would like to thank the following companies for their support of the 60th Annual Meeting of the Scientific and Standardization Committee of the ISTH.

**Platinum Level**

Bayer

Novo Nordisk

**Gold Level**

Baxter

Biogen Idec

**Bronze Level**

Immucor
ISTH SSC 2014 wishes to recognize the generous support via unrestricted educational grants from:

**Supporters & Exhibitors**

- Affinity Biologicals / Hemostasis Lab
- Aggredyne, Inc.
- AstraZeneca
- Baxter
- Bayer HealthCare
- Biogen Idec
- BioMed Central
- BloodCenter of Wisconsin
- Chrono-log Corp.
- Cleveland Clinic Laboratories
- CSL Behring GmbH
- DiaPharma
- DVTlite
- Elsevier Hematology
- Enzyme Research / r2 Diagnostics
- George King Bio-Medical, Inc.
- Grifols International
- Haematologic Technologies, Inc.
- Hematology Vision
- Hemostasis Reference Laboratory Inc.
- Hemostasis & Thrombosis Research Society
- HYPHEN BioMed
- Immucor
- Instrumentation Laboratory
- International Society on Thrombosis & Haemostasis
- Janssen
- Journal of Thrombosis and Haemostasis
- Karger Publishers
- Kedrion Biopharma
- Medical College of Wisconsin
- Novo Nordisk Health Care AG
- Octapharma AG
- Precision BioLogic Inc.
- Schattauer Publishers
- Siemens
- Sinnowa Medical Science & Technology Co., Ltd.
- Stago
- Technoclone
- Wiley
- Wolters Kluwer
The ISTH wishes to specifically recognize the following partners for their generous support of the following aspects of the meeting (in alphabetical order):

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Supporter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstracts USB Stick</td>
<td>Novo Nordisk</td>
</tr>
<tr>
<td>Armand J. Quick Memorial Lecture</td>
<td>Armand J. Quick Memorial and Medical College of Wisconsin</td>
</tr>
<tr>
<td>Charging Stations</td>
<td>Biogen Idec</td>
</tr>
<tr>
<td>Conference Capture</td>
<td>Novo Nordisk</td>
</tr>
<tr>
<td>Final Program</td>
<td>Bayer HealthCare</td>
</tr>
<tr>
<td></td>
<td>Novo Nordisk</td>
</tr>
<tr>
<td></td>
<td>Immucor</td>
</tr>
<tr>
<td>Hand Sanitizer Stations</td>
<td>Biogen Idec</td>
</tr>
<tr>
<td>Media Partnerships</td>
<td>Elsevier</td>
</tr>
<tr>
<td></td>
<td>Hematology Vision</td>
</tr>
<tr>
<td></td>
<td>Karger Publishers</td>
</tr>
<tr>
<td></td>
<td>Schattauer Publishers</td>
</tr>
<tr>
<td></td>
<td>Thrombosis Journal</td>
</tr>
<tr>
<td></td>
<td>Wiley</td>
</tr>
<tr>
<td></td>
<td>Wolters Kluwer</td>
</tr>
<tr>
<td>Meeting Stools and Tables</td>
<td>Novo Nordisk</td>
</tr>
<tr>
<td>Mobile App</td>
<td>Bayer HealthCare</td>
</tr>
<tr>
<td>Plenary Session</td>
<td>BloodCenter of Wisconsin</td>
</tr>
<tr>
<td>Pocket Program</td>
<td>Novo Nordisk</td>
</tr>
<tr>
<td>Reach-the-World Travel Stipends</td>
<td>Bayer HealthCare</td>
</tr>
<tr>
<td>Reminder/Informational e-Blasts</td>
<td>Novo Nordisk</td>
</tr>
<tr>
<td>Trainee and Reach-the-World Networking Event</td>
<td>Bayer HealthCare</td>
</tr>
</tbody>
</table>
In recognition of the expanding educational format of the ISTH's SSC Annual Meetings, the Society is extending its Reach-the-World initiative to enable participation by scientists from all areas of the world in the educational and working sessions of the SSC.

We hope that you will find attendance at SSC 2014 fruitful in your continued research and educational activities.

The ISTH SSC 2014 Reach-the-World Travel Awards have been made possible in part through support by Bayer HealthCare.

**ISTH Young Investigator Awards**

The Young Investigators Awards were provided in the form of travel grants to medical trainees and young scientists (under 35 years of age as of June 23, 2014) who submitted highly rated abstracts.

These awards have been made possible thanks to ISTH and the 60th Scientific and Standardization Committee meeting of the ISTH.

**ISTH Reach-the-World Travel Awards**

In recognition of the expanding educational format of the ISTH’s SSC Annual Meetings, the Society is extending its Reach-the-World initiative to enable participation by scientists from all areas of the world in the educational and working sessions of the SSC.

We hope that you will find attendance at SSC 2014 fruitful in your continued research and educational activities.

The ISTH SSC 2014 Reach-the-World Travel Awards have been made possible in part through support by Bayer HealthCare.
**ISTH Reach-the-World Travel Awards**

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Magy Abdelwahab</td>
<td>Egypt</td>
<td></td>
</tr>
<tr>
<td>Samuel Abegunde</td>
<td>Nigeria</td>
<td></td>
</tr>
<tr>
<td>Olutayo Ifedayo Ajayi</td>
<td>Nigeria</td>
<td></td>
</tr>
<tr>
<td>Akubueziuka Anyanwu</td>
<td>Nigeria</td>
<td></td>
</tr>
<tr>
<td>Sidra Asad</td>
<td>Pakistan</td>
<td></td>
</tr>
<tr>
<td>Volha Bichan</td>
<td>Belarus</td>
<td></td>
</tr>
<tr>
<td>Alicia Blanco</td>
<td>Argentina</td>
<td></td>
</tr>
<tr>
<td>Munira Borhany</td>
<td>Pakistan</td>
<td></td>
</tr>
<tr>
<td>Maryna Burlova-Vasylieva</td>
<td>Ukraine</td>
<td></td>
</tr>
<tr>
<td>Altantsetseg Buyanbat</td>
<td>Mongolia</td>
<td></td>
</tr>
<tr>
<td>Beatriz Calderon-Cruz</td>
<td>Mexico</td>
<td></td>
</tr>
<tr>
<td>Agostina Carestia</td>
<td>Argentina</td>
<td></td>
</tr>
<tr>
<td>Xuemei Fan</td>
<td>China</td>
<td></td>
</tr>
<tr>
<td>Rongfeng Fu</td>
<td>China</td>
<td></td>
</tr>
<tr>
<td>Beatriz Grand</td>
<td>Argentina</td>
<td></td>
</tr>
<tr>
<td>Irina Gribkova</td>
<td>Russian Federation</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jian Gu</td>
<td>China</td>
<td></td>
</tr>
<tr>
<td>Mei-Xia He</td>
<td>China</td>
<td></td>
</tr>
<tr>
<td>Hai-Ying Hua</td>
<td>China</td>
<td></td>
</tr>
<tr>
<td>Violeta Jovanoska</td>
<td>Macedonia</td>
<td></td>
</tr>
<tr>
<td>Bat-Erdene Jugder</td>
<td>Mongolia</td>
<td></td>
</tr>
<tr>
<td>Natalia Korotina</td>
<td>Russian Federation</td>
<td></td>
</tr>
<tr>
<td>Rita Marchi</td>
<td>Venezuela</td>
<td></td>
</tr>
<tr>
<td>Hebe Agustina Mena</td>
<td>Argentina</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tzu Shih Lin</td>
<td>Taiwan</td>
<td></td>
</tr>
<tr>
<td>Bo Zhang</td>
<td>China</td>
<td></td>
</tr>
<tr>
<td>Aska C. C.</td>
<td>EU</td>
<td></td>
</tr>
<tr>
<td>Elisa Le Guen</td>
<td>Switzerland</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arshi Naz</td>
<td>Pakistan</td>
<td></td>
</tr>
<tr>
<td>Gordon Ogweno</td>
<td>Kenya</td>
<td></td>
</tr>
<tr>
<td>Marlien Pieters</td>
<td>South Africa</td>
<td></td>
</tr>
<tr>
<td>Jorge Quintero</td>
<td>Colombia</td>
<td></td>
</tr>
<tr>
<td>Xiaofeng Shi</td>
<td>China</td>
<td></td>
</tr>
<tr>
<td>Veronika Shmeleva</td>
<td>Russian Federation</td>
<td></td>
</tr>
<tr>
<td>Markiyan Soloviy</td>
<td>Ukraine</td>
<td></td>
</tr>
<tr>
<td>Liu Bin</td>
<td>Taiwan</td>
<td></td>
</tr>
<tr>
<td>Si Zhang</td>
<td>China</td>
<td></td>
</tr>
</tbody>
</table>

**Best Oral SSC Session Awards**

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
<th>Topic</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Auton</td>
<td>USA</td>
<td>VWF/ADAMTS13</td>
<td>Monday, June 23, 2014</td>
</tr>
<tr>
<td>Marc Blondon</td>
<td>Switzerland</td>
<td>Women’s Health Issues in Thrombosis and Haemostasis</td>
<td>Wednesday, June 25, 2014</td>
</tr>
<tr>
<td>Carolina Cervio</td>
<td>Argentina</td>
<td>Pediatric/Neonatal Hemostasis and Thrombosis</td>
<td>Monday, June 23, 2014</td>
</tr>
<tr>
<td>Mark Crowther</td>
<td>Canada</td>
<td>Control of Anticoagulation</td>
<td>Wednesday, June 25, 2014</td>
</tr>
<tr>
<td>Benilde Cosmi</td>
<td>Italy</td>
<td>Predictive Hemostatic Variables</td>
<td>Tuesday, June 24, 2014</td>
</tr>
<tr>
<td>Jonathan Cowman</td>
<td>Ireland</td>
<td>Bioreheology</td>
<td>Wednesday, June 25, 2014</td>
</tr>
<tr>
<td>Miguel A. Cruz</td>
<td>USA</td>
<td>DIC</td>
<td>Monday, June 23, 2014</td>
</tr>
<tr>
<td>Narine Hakobyan</td>
<td>USA</td>
<td>Animal Models of Thrombosis</td>
<td>Thursday, June 26, 2014</td>
</tr>
<tr>
<td>Debra Hoppenstead</td>
<td>USA</td>
<td>Fibrinolysis</td>
<td>Wednesday, June 25, 2014</td>
</tr>
<tr>
<td>Ian Jennings</td>
<td>United Kingdom</td>
<td>Lupus Anticoagulant/Phospholipid-Dependent Antibodies</td>
<td>Monday, June 23, 2014</td>
</tr>
<tr>
<td>Anne Kelly</td>
<td>United Kingdom</td>
<td>Genomics</td>
<td>Monday, June 23, 2014</td>
</tr>
<tr>
<td>Vladimir Kolyadko</td>
<td>Russian Federation</td>
<td>Factor XI and the Contact System</td>
<td>Thursday, June 26, 2014</td>
</tr>
<tr>
<td>Vera Korneeva</td>
<td>Russian Federation</td>
<td>Plasma Coagulation Inhibitors</td>
<td>Tuesday, June 24, 2014</td>
</tr>
<tr>
<td>Yanan Min</td>
<td>China</td>
<td>Immunology</td>
<td>Wednesday, June 25, 2014</td>
</tr>
<tr>
<td>Satoshi Nishimura</td>
<td>Japan</td>
<td>Platelet Physiology</td>
<td>Tuesday, June 24, 2014</td>
</tr>
<tr>
<td>Rohun U. Palekar</td>
<td>USA</td>
<td>Vascular Biology</td>
<td>Thursday, June 26, 2014</td>
</tr>
<tr>
<td>Qizhen Shi</td>
<td>USA</td>
<td>Factor VIII and Factor IX</td>
<td>Thursday, June 26, 2014</td>
</tr>
<tr>
<td>Mario Von Depka</td>
<td>Germany</td>
<td>Factor XIII and Fibrinogen</td>
<td>Monday, June 23, 2014</td>
</tr>
<tr>
<td>Bo Zhang</td>
<td>China</td>
<td>Hemostasis and Malignancy</td>
<td>Tuesday, June 24, 2014</td>
</tr>
</tbody>
</table>
The ISTH first and foremost stands for leading edge science. As a global membership community of specialists in bleeding and clotting disorders, the Society is dedicated to transformative scientific discoveries to advance clinical practice and improve the lives of millions of people worldwide.

Our focus is the pursuit of greater understanding of normal and abnormal clotting, bleeding processes and the development of treatments for related conditions. Many recent discoveries in thrombosis and hemostasis have been the result of research conducted by ISTH members. The society has also been responsible for the development of nomenclature as well as scientific standards allowing for a common language and translation of basic science into clinical application.

**ISTH by the Numbers**

The ISTH, a global professional individual membership organization, has over 3,500 members in more than 90 countries around the world. Beginning in 1969 with 200 members, the ISTH continues to grow its footprint of collaboration. Furthermore, the ISTH’s impact and contributions to the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders now spans six continents.

**ISTH Membership**

An ISTH membership is an important investment in your own future at every stage in your career. With membership, you receive ISTH’s highly cited publication, *Journal of Thrombosis and Haemostasis (JTH)*, timely information regarding thrombotic and bleeding disorders, targeted educational programs, networking opportunities and more!

**Specifically, membership benefits include:**

- Subscription to *JTH*
- Subscription to the monthly ISTH e-newsletter
- Discounted registration fees for ISTH congresses, SSC meetings and other ISTH-sponsored educational programs and activities
Eligibility for travel grants to attend ISTH congresses and SSC meetings
Access to educational materials and the ISTH Academy, the formal e-learning arm of the Society
Access to the ISTH Career Center (to review job openings and post your CV/resume)
Search for colleagues and network via the online membership directory
Eligibility to hold elected and/or appointed offices
Vote on Society matters and nominate and vote in Society elections
Serve on SSC subcommittees and working groups
Participate in building awareness of thrombosis via the ISTH’s recently launched World Thrombosis Day on October 13

The ISTH offers five categories of membership:

- Regular: for clinicians, researchers and educators ($160)
- Associate: for students, trainees and post-doctoral fellows below the age of 35 ($35)
- Reach-the-World: for clinicians, researchers and educators from developing countries ($35)
- Nurse: for registered nurses ($35)
- Allied-Health Professional: for laboratory and radiological technicians, occupational and physical therapists, and other health professionals distinct from medicine and nursing ($35)

For more information, please email the membership team at membership@isth.org.

The SSC of the ISTH

The SSC is a standing committee of the ISTH. Specifically, the SSC brings together internationally recognized leaders in relevant research areas to:

- Provide a forum for consideration of practical issues related to thrombosis, disorders of hemostasis and their underlying vascular biology.
- Support scientific subcommittees of international expert researchers working on these problems and their application to clinical issues.
- Promote education and the exchange of ideas through scientific meetings and publication of official reports, recommendations and deliberations.
- Standardize nomenclature and research methods as appropriate and timely.
- Offer expert consultation to standards-setting bodies.
- Liaise with other research organizations and collaborate on timely important research matters.
SSC Subcommittees

The SSC is made up of 19 subcommittees and two working groups that respond to and address a variety of challenges in the fields of thrombosis and hemostasis. ISTH membership is not required to participate on a SSC subcommittee, but is encouraged. Subcommittees are very active throughout the year and include:

- Animal, Cellular and Molecular Models
- Biorheology
- Control of Anticoagulation
- Disseminated Intravascular Coagulation
- Exogenous Hemostatic Factors
- Factor VIII, Factor IX & Rare Coagulation Disorders
- Factor XI and the Contact System
- Factor XIII and Fibrinogen
- Fibrinolysis
- Hemostasis & Malignancy
- Lupus Anticoagulant / Phospholipid Dependent Antibodies
- Pediatric Neonatal Hemostasis and Thrombosis
- Plasma Coagulation Inhibitors
- Platelet Immunology
- Platelet Physiology
- Predictive Hemostatic Variables
- Vascular Biology
- Von Willebrand Factor
- Women’s Health Issues in Thrombosis and Hemostasis
- Working Group on Genomics in Hemostasis
- Working Group on Perioperative Thrombosis and Hemostasis

SSC Activities and Programs

The SSC supports the ISTH’s mission of advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders. It also holds annual public meetings and offers opportunities to present work and publish the results of collaborative research, network with other experts in the field, help support numerous registries and databases where information is collected, updated and shared with the scientific community, issue guidance and expert opinion documents and liaise with the World Health Organization (WHO) as a Nongovernmental Organization (NGO) Affiliate providing expert opinions and other requested advice.

Why wait? Become involved in the SSC of the ISTH today!
For general information about the Society, including the SSC, please contact ISTH at:

**ISTH Headquarters**
610 Jones Ferry Road, Suite 205
Carrboro, NC 27510, USA

T +1 919 929 3807
F +1 919 929 3935

headquarters@isth.org
www.isth.org

**SSC 2014 Meeting Secretariat**

**SSC 2014 c/o MCI Suisse**
75, rue de Lyon - C.P. 502,
1211 Geneva 13, Switzerland

T +41 22 33 99 588
F +41 22 33 99 631
ssc2014@mci-group.com

**SSC 2014 Accommodations**

**Ms. Denice Waldhuetter**

**PEC**
9224 W. Burleigh Street
Milwaukee, WI 53222, USA

T +1 414 376 6517
denicew@pecpros.com

---

**Join the Conversation Online!**

Facebook  www.facebook.com/internationalsocietythrombosisandhaemostasis
LinkedIn  www.linkedin.com/groups/International-Society-on-Thrombosis-Haemostasis-3953570/about
Twitter  twitter.com/isth
Abstracts
The ISTH SSC 2014 abstracts are available on USB sticks which will be distributed upon registration. Abstracts will also be available as an online supplement (only) to JTH.

The ISTH SSC 2014 Abstracts USB Stick is supported by Novo Nordisk.

Accommodation
A help desk for participants who have booked their accommodation in advance via the PEC meetings company is located in the registration area. The staff at this counter will also help you to find and book rooms, if required.

Accreditation

ACCMED
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The Medical College of Wisconsin and International Society on Thrombosis and Haemostasis (ISTH). The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.

The Medical College of Wisconsin designates this live activity for a maximum of 9.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Medical College of Wisconsin designates this activity for up to 9.0 hours of participation for continuing education for allied health professionals.

EHA
The European Hematology Association has accredited the 60th Scientific and Standardization Committee (SSC) meeting of the ISTH in Milwaukee, Wisconsin, USA, (June 23 – 26, 2014) with 24 credit points. All participants may print a European Hematology Association CME System approved CME certificate indicating the number of EHA-CME Credit Points awarded, directly from the system on the CME section of the EHA website at www.ehaweb.org. All participants will receive the relevant information by e-mail after the meeting.

Banks & Automatic Teller Machines (ATM)
ATMs can be found within the premises of the conference center.

Car Parking
The closest parking to the venue is the Wisconsin Center District parking. The entrance is located on 500 W. Wells Street, Milwaukee, WI 53203.
**Certificate of Attendance**

Certificates of attendance will be included in the conference bags.

**Charging Stations**

Mobile charging stations are provided throughout the conference venue for attendees to charge their mobile devices.

*The ISTH SSC 2014 charging stations are supported by Biogen Idec.*

**Climate**

Milwaukee has a humid continental climate. Summers are usually very warm and humid. The average temperature in June is 75.3°F (24.1°C) for a high and 57.1°F (13.9°C) for a low.

**Coffee Breaks**

Complimentary coffee and tea will be served in the exhibition hall located in Ballroom A – C on the street level. Coffee breaks are scheduled daily from June 23 – 26, 2014. Please refer to the program details for timings.

**Conference Capture**

Educational and Plenary lectures of ISTH SSC 2014 will be captured and be available online for meeting attendees and ISTH members in the weeks after the meeting.

*The ISTH SSC 2014 Conference Capture is supported by Novo Nordisk.*

**Conference Venue**

**Wisconsin Center**

400 West Wisconsin Avenue
Milwaukee, WI 54203, USA
T +1 414 908-6000
www.wisconsincenter.org

**Cyber Café**

Located in the exhibition hall, it will be for the exclusive use of meeting attendees.

**Delegate Bags**

You will receive your delegate bag at the registration area. Please note that no replacements for lost bags are available.

**Discovery World (Ticketed event—please inquire at the Registration Area)**

The 60th Annual SSC Anniversary Celebration will take place on Tuesday, June 24, 2014, at 19.00. It will take place at the beautiful Discovery World, a science and technology center located in Milwaukee, Wisconsin, at 500 N. Harbor Drive. Bus departures are organized from the Hilton and Hyatt hotels from 18.45 in continuous loops. The last departure from Discovery World is at 23.15. Please see page 45 for more information about the Discovery World celebration.

**Electricity**

The USA uses 120 volts, 60 Hz. Plugs are mainly the two, flat-pin type, although three-pin plugs are also widely used. Appliances without dual voltage capabilities will require an adapter, which can be purchased in most major departure airports.
Hand Sanitizers

Hand sanitizer stations are provided throughout the conference venue for the convenience of our attendees. 
*The ISTH SSC 2014 hand sanitizer stations are supported by Biogen Idec.*

Important Local Numbers

Dial 911 for all emergencies (police, fire, medical). Callers will then be placed through to the appropriate emergency service. Calls are free from pay phones.

Industry Exhibition

The SSC 2014 Industry Exhibition is located in **Ballroom A-C** on the ground level.

**Exhibition hours**
- Monday, June 23, 2014 09.00 – 20.00
- Tuesday, June 24, 2014 09.30 – 18.00
- Wednesday, June 25, 2014 09.00 – 16.30

ISTH Secretariat

The ISTH Secretariat is located in **Room 103C** (Level 1) of the Conference Center. It is open during the same hours as the Registration Desks (see “Registration Desk” for opening hours).

Insurance and Liability

It is recommended that participants obtain adequate insurance coverage for travel, health and accidents before they depart from their countries of residence. ISTH and MCI as organizers cannot accept responsibility for personal injuries, or loss of, or damage to, private property belonging to the conference participants and accompanying persons.

Language

The official language of the meeting is English. There is no simultaneous translation service provided.

Local Currency

The official currency in Milwaukee is the US Dollar ($).

Lunches

Complimentary lunch boxes will be served in the Exhibition Area on the street level as well as in front of the lunch time symposia rooms. Please refer to the program details for timings. Delegates will receive lunch vouchers for each day.

Mobile App

Use your mobile device to navigate the ISTH SSC 2014 meeting. Download the mobile app from your respective app store! *The ISTH SSC 2014 mobile app is supported by Bayer HealthCare.*

Mobile Telephones

As a courtesy to speakers and other participants, all mobile phones and pagers must be muted when attending sessions or symposia.
**Name Badges**

Participants will receive their name badges when collecting their meeting documents on site. You are required to wear your name badge during all meeting events, including the 60th Annual SSC Anniversary Celebration (if you have purchased tickets during your registration process). Please note that admission to scientific sessions and the exhibition is restricted to participants wearing their badges.

**Poster Session**

Posters are presented during the entire duration of the meeting and are accessible at the same times as the exhibition opening hours. The official poster session and reception will take place on Monday, June 23, 2014, from 18.15-20.00. The Poster area is located in the Wisconsin Center **Ballroom A–C**. Poster Session ends on Wednesday, June 25 at 17.30 at which time all posters need to be removed.

**Registration Desk**

The registration desk is located on the ground floor, in front of the main entrance of the exhibition area.

**Opening Hours**

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, June 22, 2014</td>
<td>12.00 – 18.00</td>
</tr>
<tr>
<td>Monday, June 23, 2014</td>
<td>07.30 – 18.00</td>
</tr>
<tr>
<td>Tuesday, June 24, 2014</td>
<td>07.30 – 18.00</td>
</tr>
<tr>
<td>Wednesday, June 25, 2014</td>
<td>07.30 – 18.00</td>
</tr>
<tr>
<td>Thursday, June 26, 2014</td>
<td>07.30 – 13.00</td>
</tr>
</tbody>
</table>

**Restaurants**

Milwaukee offers a variety of restaurants including those with various worldly influences. Please visit: [www.milwaukee.com/restaurants/](http://www.milwaukee.com/restaurants/) for more information.

**Smoking**

Please note that this is a non-smoking meeting. Smoking is neither permitted in or outside the meeting halls nor in the exhibition area.

**Speaker Ready Room**

**Room 103 B** (Level 1)

Speakers were contacted in advance to upload their presentations but should still report to the Speaker Ready Room at least two hours in advance of their presentation to ensure proper viewing. All conference rooms feature state-of-the-art technical equipment. Audiovisual material will be available for your presentation:

**Opening Hours**

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, June 22, 2014</td>
<td>12.00 – 18.00</td>
</tr>
<tr>
<td>Monday, June 23, 2014</td>
<td>07.30 – 18.00</td>
</tr>
<tr>
<td>Tuesday, June 24, 2014</td>
<td>07.30 – 18.00</td>
</tr>
<tr>
<td>Wednesday, June 25, 2014</td>
<td>07.30 – 18.00</td>
</tr>
<tr>
<td>Thursday, June 26, 2014</td>
<td>07.30 – 13.00</td>
</tr>
</tbody>
</table>
Transportation

No transportation is provided during the conference since the conference venue is very centrally located and all official hotels are within walking distance. If you need to arrange for a transfer to the airport, please refer to the “General Information” menu item on the conference website: www.ssc2014.org where you will find more information under “Transportation.”

Wireless Internet

WiFi will be provided throughout the official 2014 SSC meeting space. Information on log-in and passwords will be available at the registration desk.

About Milwaukee

Millions of people visit the greater Milwaukee area every year. They come from around the world for all kinds of reasons: attending a business conference; visiting family and friends; taking in the world’s biggest music festival, Summerfest; or simply enjoying the area’s natural beauty and central Midwestern location. Once they’ve been here—and experienced the excitement of the culture, the warmth of the people and beauty of the city—they’re sold. Departing visitors begin to plan their next trips right away.

The largest city in Wisconsin and located on the west shore of Lake Michigan, Milwaukee has a revived downtown area alongside the Milwaukee Art Museum with new skyscrapers, luxury housing, fine dining and upscale nightlife establishments. Milwaukee has many attractions that display the cultural history of the great city.
Immucor is a global leader of transfusion and transplantation diagnostics. Within transfusion diagnostics, Immucor offers the broadest line of serological products, including traditional and unique specialty reagents, Capture® technology, and a full line of scalable, automated instruments for blood bank laboratories. Our innovative molecular immunohematology assays provide state-of-the-art technology for pre-transfusion compatibility testing. LIFECODES brings a market-leading position in HLA testing for transplantation labs and our specialty diagnostic solutions for platelet testing in transfusion and hemostasis provides important diagnostic information for today’s modern laboratories.

Visit us at ISTH Booth #108 to learn more about:
- Specialty Diagnostic Assays for Hemostasis
- Novel Molecular and Immunoassays for Use in Platelet Work-Ups

The result is life changing for patient outcomes.

www.immucor.com or call 855.IMMUCOR
Program-at-a-Glance

SUNDAY
JUNE 22, 2014

REGISTRATION
12.00 – 18.00

EXHIBITION & POSTERS
9.00 – 20.00

MONDAY
JUNE 23, 2014

REGISTRATION
7.30 – 18.00

EXHIBITION & POSTERS
9.30 – 16.30

TUESDAY
JUNE 24, 2014

REGISTRATION
7.30 – 18.00

EXHIBITION & POSTERS
9.00 – 16.30

WEDNESDAY
JUNE 25, 2014

REGISTRATION
7.30 – 13.00

EXHIBITION & POSTERS
9.30 – 18.00

THURSDAY
JUNE 26, 2014

REGISTRATION
7.30 – 18.00

EXHIBITION & POSTERS
9.00 – 16.30
Day-by-Day Scientific Schedule & Program

Sunday, June 22, 2014

13.00 – 17.00 TRAINEE DAY – WRIGHT BALLROOM AT THE HILTON HOTEL

13.00 – 14.45 Session One
Chair Robert R. Montgomery USA

15.15 – 17.00 Session Two
Chair Gilbert C. White, II USA

17.15 – 18.30 SSC 2014 TRAINEE RECEPTION

13.00 – 17.00 TRAINEE DAY – WRIGHT BALLROOM AT THE HILTON HOTEL

Session 1
Chair Robert R. Montgomery USA

13.00 – 13.30 Identifying and Interfacing with the Right Mentor
Chair Gilbert C. White, II USA

Chair Nigel Key USA

14.00 – 14.45 Negotiating Your First Job: Basic Research-When, Where, and How
Chair Skip Brass USA

14.45 - 15.15 COFFEE BREAK

Session 2
Chair Gilbert C. White, II USA

15.15 – 15.45 Writing Your First Grant
Peter Newman USA

15.45 – 16.15 Career Advancement / Career Planning
Roy Silverstein USA

16.15 – 17.00 Keep Up with the Cusp–Training Never Stops!
Sridhar Rao USA

17.15 – 18.30 SSC 2014 TRAINEE RECEPTION
08.00 – 11.45  EDUCATIONAL SESSION 1

Room 203 C–E  Evolving World of Hemostasis
  Co-Chairs  Sam Schulman  Canada
  Yu Hu  China

Room 202 C–E  Thrombosis 2014
  Co-Chairs  Pieter Reitsma  The Netherlands
  Pantep Angchaisuksiri  Thailand

Room 202 A&B  Vascular Biology of Hemoglobinopathies
  Co-Chairs  Cheryl Hillery  USA
  Isaac Odame  Canada

Room 201 A&B  Vascular Interaction of Collagen
  Co-Chairs  Christopher Ward  Australia
  Alicia Blanco  Argentina

12.00 – 14.00  SPECIAL SYMPOSIA

Room 203 C–E  Clinical Perspectives on Longer-Acting Therapies
  Supported by Bayer HealthCare

Room 201 A&B  FVIII Treatment and Tolerance – With or Without VWF?
  Supported in part by an educational grant from Grifols

14.15 – 18.15  SSC SUBCOMMITTEE SESSION 1

Room 201 C&D  Disseminated Intravascular Coagulation (DIC)
Room 203 A&B  Factor XIII and Fibrinogen
Room 203 C–E  Lupus Anticoagulant / Phospholipid-Dependent Antibodies
Room 201 A&B  Pediatric and Neonatal Hemostasis and Thrombosis
Room 202 C–E  von Willebrand Factor, Part I
Room 202 A&B  Working Group on Genomics

18.15 – 20.00  POSTER RECEPTION  EXHIBITION HALL
### Monday, June 23, 2014

#### Program Details

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
<th>Room/Location</th>
<th>Co-Chairs/Chairs</th>
</tr>
</thead>
</table>
| **08.00 – 11.45** | **EDUCATIONAL SESSION 1**                                                          | **Room 203 C–E** | **Evolving World of Hemostasis**  
Sam Schulman Canada  
Yu Hu China                      |
|               | **The Complexities of Primary Hemostasis**                                         |               | Changgeng Ruan China                                                                |
|               | **Evolving Roles of Platelets Beyond Hemostasis**                                  |               | Yukio Ozaki Japan                                                                   |
|               | **Under-Recognized Roles of Endothelium**                                          |               | Bill Aird USA                                                                       |
| **09.30 – 10.15** | **COFFEE BREAK**                                                                  | **EXHIBITION HALL** |                                                                                 |
|               | **How is Clotting Initiated?**                                                     |               | James Morrissey USA                                                                 |
|               | **The Reactome of Megakaryocytes and Platelets**                                   |               | Augusto Rendon United Kingdom                                                       |
|               | **Interactions of FV Isoforms and TFPI as Cause of Bleeding Disease**              |               | Björn Dahlbäck Sweden                                                               |
| **Room 202 C–E** | **Thrombosis 2014**                                                               |               | Pieter Reitsma The Netherlands  
Pantep Angchaisuksiri Thailand                                                             |
|               | **Interface of Hemostasis and Inflammation with Atherosclerosis**                  |               | Hugo ten Cate The Netherlands                                                       |
|               | **Antithrombotics in Clinical Practice**                                           |               | Walter Ageno Italy                                                                  |
|               | **Filters for PE Prophylaxis**                                                    |               | Mark Crowther Canada                                                                |
| **09.30 – 10.15** | **COFFEE BREAK**                                                                  | **EXHIBITION HALL** |                                                                                 |
|               | **Debate - Aspirin Reduces the Risk of Recurrent VTE— Positive**                   |               | David García USA                                                                   |
|               | **Debate - Aspirin Reduces the Risk of Recurrent VTE— Negative**                   |               | Stephan Moll USA                                                                   |
|               | **Post Thrombotic Syndrome**                                                      |               | Arina ten Cate-Hoek The Netherlands                                                 |
|               | **New Anticoagulants Versus VKA in the Long-Term Secondary VTE Prevention**        |               | Stephan Moll USA                                                                   |
## Monday, June 23, 2014

### Room 202 A&B  
**Vascular Biology of Hemoglobinopathies**

**Co-Chairs**  
*Cheryl Hillery USA  
Isaac Odame Canada*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00 – 08.30</td>
<td>Global Perspective on SCD</td>
<td><em>Isaac Odame</em> Canada</td>
<td></td>
</tr>
<tr>
<td>08.30 – 09.00</td>
<td>Cerebral Vasculopathy in Sickle Cell Anemia (Hgb SS/Sb0)</td>
<td><em>Françoise Bernaudin</em> France</td>
<td></td>
</tr>
<tr>
<td>09.00 – 09.30</td>
<td>Coagulation and Vascular Pathologies in Mouse Models of Sickle Cell Disease</td>
<td><em>Cheryl Hillery</em> USA</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.30 – 10.15</td>
<td><strong>COFFEE BREAK</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.15 – 10.45</td>
<td>Multifactorial Etiology of Arteriopathy in SCD</td>
<td><em>Greg Kato</em> USA</td>
<td></td>
</tr>
<tr>
<td>10.45 – 11.15</td>
<td>Coagulation Activation in Sickle Cell Disease</td>
<td><em>Kenneth Ataga</em> USA</td>
<td></td>
</tr>
<tr>
<td>11.15 – 11.45</td>
<td>Cardiovascular Complication in Thalassemia</td>
<td><em>Suthat Fucharoen</em> Thailand</td>
<td></td>
</tr>
</tbody>
</table>

### Room 201 A&B  
**Vascular Interaction of Collagen**

**Co-Chairs**  
*Christopher Ward Australia  
Alicia Blanco Argentina*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00 – 08.15</td>
<td>The Clinical Approach to Screening</td>
<td><em>Diego Mezzano</em> Chile</td>
<td></td>
</tr>
<tr>
<td>08.15 – 08.45</td>
<td>From the Perspective of Platelets</td>
<td><em>Rob Andrews</em> Australia</td>
<td></td>
</tr>
<tr>
<td>08.45 – 09.00</td>
<td>Platelet–Collagen Interactions Under Flow</td>
<td><em>Keith Neeves</em> USA</td>
<td></td>
</tr>
<tr>
<td>09.00 – 09.30</td>
<td>From the Perspective of von Willebrand Factor</td>
<td><em>Peter Lenting</em> France</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.30 – 10.15</td>
<td><strong>COFFEE BREAK</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.15 – 10.45</td>
<td>Downstream Signalling Events of the Collagen Receptor GPVI</td>
<td><em>Steve Watson</em> United Kingdom</td>
<td></td>
</tr>
<tr>
<td>10.45 – 11.15</td>
<td>Inhibition of Platelet–Collagen Interaction</td>
<td><em>Hans Deckmyn</em> Belgium</td>
<td></td>
</tr>
<tr>
<td>11.15 – 11.45</td>
<td>From the Perspective of Dysfunctional Collagen: Clinical Disorders</td>
<td><em>Shannon Jackson</em> Canada</td>
<td></td>
</tr>
</tbody>
</table>
12.00 – 14.00  SPECIAL SYMPOSIA

Room 203 C–E  Clinical Perspectives on Longer-Acting Therapies

Supported by Bayer HealthCare

Chair  Gilbert C. White, II USA

12.00 – 12.10  Introduction
Gilbert C. White, II USA

12.10 – 12.40  Individualizing Prophylactic Regimens
Johannes Oldenburg Germany

12.40 – 13.10  Technologies to Increase FVIII Half-Life
Gilbert C. White, II USA

13.10 – 13.40  Defining ‘Longer-Acting’ in Hemophilia A
Jerry Powell USA

13.40 – 14.00  Questions and Answers
Gilbert C. White, II USA

Room 201 A&B  FVIII Treatment and Tolerance—
With or Without VWF?

Supported in part by an educational grant from Grifols

Co-Chairs  Augusto Federici Italy
Joan Gill USA

12.05 – 12.30  Interaction of VWF/FVIII and FVIII with Inhibitor Antibodies: In Vitro and In Vivo Studies
Qizhen Shi USA

12.35 – 13.00  Overview of the Clinical Aspects of Treating Hemophilia with Factor VIII Concentrates that Contain von Willebrand Factor
Craig Kessler USA

13.05 – 13.45  Point-Counter Point Debate “Against” VWF in Factor VIII Concentrates
Steven Pipe USA
Point-Counter Point Debate “For” VWF in Factor VIII Concentrates
Elena Santagostino Italy

14.15 – 18.15  SSC SUBCOMMITTEE SESSION 1

Room 201 C&D  Disseminated Intravascular Coagulation (DIC)

Chair  Jecko Thachil United Kingdom

Co-Chairs  Marcello Di Nisio Italy | Satoshi Gando Japan | Takashi Ito Japan
Shinichiro Kurosawa USA | Jorn Nielsen Denmark | Hideo Wada Japan
**Monday, June 23, 2014**

14.15 – 14.30  **Top Rated Abstract in DIC: Isolated a2 Domain of von Willebrand Factor that Binds to Fibrin Inhibits Microvascular Thrombosis and Reduces Mortality of Mice with Endotoxemia-Induced Disseminated Intravascular Coagulation**  
*Miguel Cruz* USA

14.30 – 15.10  **Sepsis in Developing Countries — Challenges and Solutions**  
*Niranjan “Tex” Kissoon* Canada

15.10 – 15.50  **Platelet and von Willebrand Factor Dynamics in DIC**  
*Bernd Jilma* Austria

**15.50 – 16.15**  **COFFEE BREAK**  **EXHIBITION HALL**

16.15 – 16.55  **Role of Nucleosomes in the Pathogenesis of DIC**  
*Sacha Zeerleder* The Netherlands

16.55 – 17.35  **Histones and DIC**  
*Simon Abrams* United Kingdom

17.35 – 18.15  **Anticoagulant Therapy for Septic DIC in Japan**  
*Toshiaki Iba* Japan

---

Room 203 A&B  **Factor XIII and Fibrinogen**

**Chair**  *Helen Philippou* United Kingdom

**Co-Chairs**  *Zsuzsa Bagoly* Hungary | *Vytautas Ivaskevicius* Germany  
*Marlien Pieters* South Africa | *Sanj Raut* United Kingdom  
*Verena Schroeder* Switzerland | *Alisa Wolberg* USA

14.15 – 14.30  **Top Rated Abstract in Factor XIII and Fibrinogen: Identification of Sequence Variations in Fibrinogen Genes Causing Haemorrhagic or Thrombotic Diathesis**  
*Mario von Depka* Germany

14.30 – 14.45  **Standardisation of Turbidity Measurements as Part of the Standardisation Process of the Fibrin Structure Measurement Techniques**  
*Marlien Pieters* South Africa

14.45 – 15.00  **Assessment of Clauss Assays in Measurement of Fibrinogen in Therapeutic Concentrates**  
*Sanj Raut* United Kingdom

15.00 – 15.15  **FXIII-B Standardisation Update and Change of Free FXIII-B in a FXIII-A Deficient Patient on Recombinant FXIII-A2 Therapy**  
*Éva Katona* Hungary

15.15 – 15.30  **Importance of the Activation Peptide for FXIII Expression**  
*Helena Handrkova* Switzerland | *Verena Schroeder* Switzerland  
*Hans P. Kohler* Switzerland
15.30 – 15.45  **The Effect of Factor XIII and Other Regulators of Fibrinolysis on the Outcome of Thrombolysis in Ischemic Stroke Patients**  

15.45 – 16.05  **COFFEE BREAK  EXHIBITION HALL**

16.05 – 16.20  **Recommendations for Criterion and Algorism of Laboratory Tests for Autoimmune Hemorrhaphilia Due to Anti-Factor XIII/13 Antibodies**  
Akitada Ichinose Japan | Hans P. Kohler Switzerland | László Muszbek Hungary | Helen Philippou United Kingdom  
*On behalf of the Factor XIII and Fibrinogen SSC Subcommittee of the ISTH*

16.20 – 16.35  **Modification of the ISTH/SSC Bleeding Assessment Tool ver. 2010 and Its Field Test for Japanese Patients with Acquired Hemorrhaphilia due to Anti-F13 Autoantibodies**  
Akitada Ichinose Japan | Mayumi Sugiura-Ogasawara Japan | Alberto Tosetto Italy | Francesco Rodeghiero Italy | Paula James Canada

16.35 – 16.50  **FXIII and the Pathogenesis of Inflammatory Arthritis**  
Matthew Flick USA

16.50 – 17.05  **Alloantibodies Formed During Replacement Therapy in FXIII Deficient Patients**  
Georges-Etienne Rivard Canada

17.05 – 17.20  **Fibrin Accumulation Secondary to Loss of Plasmin-Mediated Fibrinolysis Drives Inflammatory Osteoporosis?**  
Richard Allen USA

17.20 – 17.35  **Factor XIII as a Determinant of Thrombosis**  
Alisa Wolberg USA

17.35 – 17.50  **The likely Role of Plasma Protransgutaminase (Factor XIII) in Cross-linking Alpha 2-antiplasmin to Circulating Fibrinogen**  
Michael Mossesson USA

17.50 – 18.15  **SSC Discussion and Project Updates**

---

**ROOM 203 C–E**  
**Lupus Anticoagulant/Phospholipid-Dependent Antibodies**

**Chair**  
Bas de Laat The Netherlands

**Co-Chairs**  
Tatusya Atsumi Japan | Maria Laura Bertolaccini United Kingdom | Katrien Devreese Belgium | Thomas Ortel USA | Rolf Urbanus The Netherlands | Denis Wahl France

14.15 – 14.20  **Introduction**  
Bas de Laat The Netherlands
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 14.20 – 14.35 | **Top Rated Abstract in Lupus Anticoagulant/Phospholipid-Dependent Antibodies: Solid Phase Assays in Antiphospholipid Syndrome (APS): Variation between Results amongst UK NEQAS (Blood Coagulation)** Participants  
*Ian Jennings* United Kingdom |
| 14.35 – 15.00 | **Recommendation for Solid Phase Assays**  
*Katrien Devreese* Belgium |
| 15.00 – 15.25 | **Solid Phase Assay Standards**  
*Hilde Kelchtermans* The Netherlands |
| 15.25 – 15.50 | **Solid Phase Assay Standards**  
*Maria Laura Bertolaccini* United Kingdom |
| 15.50 – 16.00 | **Discussion on Solid Phase Standards** |
| 16.00 – 16.20 | **CLSI H60-Lupus Anticoagulant Guidelines**  
*Gary Moore* United Kingdom |
| 16.20 – 16.35 | **Standards for Determining Lupus Anticoagulant, an Update**  
*Elaine Gray* United Kingdom |
| 16.35 – 16.50 | **Influence of Medication on the Detection of Antiphospholipid Antibodies**  
*Rolf Urbanus* The Netherlands |
| 16.50 – 17.05 | **Treatment of APS Patients with Rivaroxaban**  
*Vittorio Pengo* Italy |
| 17.05 – 17.25 | **The Prospective Value of Detecting Anti-domain I Antibodies**  
*Denis Wahl* France |
| 17.25 – 17.40 | **Detection of PT-PS Antibodies in Different Patient Populations**  
*Tatsuya Atsumi* Japan |
| 17.40 – 18.00 | **Detection of Annexin A5 Resistance in Different Patient Populations**  
*Jacob Rand* USA |
| 18.00 – 18.15 | **Closing Remarks**  
*Bas de Laat* The Netherlands |
| Room 201 A&B | **Pediatric and Neonatal Hemostasis and Thrombosis** |
| Chair | *Anthony Chan* Canada |
| Co-Chairs | *Mariana Bonduel* Argentina  
*Leonardo Brandao* Canada  
*Elizabeth Chalmers* United Kingdom  
*Neil Goldenberg* USA  
*Paolo Siminoi* Italy  
*Heleen van Ommen* The Netherlands |
| 14.15 – 14.30 | **Introduction and Update on the Work of the SSC**  
*Anthony Chan* Canada |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.30 – 14.45</td>
<td>Top Rated Abstract in Pediatric/Neonatal Hemostasis and Thrombosis:</td>
</tr>
<tr>
<td></td>
<td>Venography (VE) in Children with Clinical Assessment of Post-Thrombotic</td>
</tr>
<tr>
<td></td>
<td>Syndrome (PTS) Following Upper Venous System Thrombotic Event (UVSTE)</td>
</tr>
<tr>
<td></td>
<td><em>Carolina Cervio</em> Argentina</td>
</tr>
<tr>
<td>14.45 – 15.15</td>
<td>Thrombosis in Neonate: A Standardized Approach</td>
</tr>
<tr>
<td></td>
<td><em>Heleen van Ommen</em> The Netherlands</td>
</tr>
<tr>
<td>15.15 – 15.45</td>
<td>Antithrombin Deficiency: Proposal</td>
</tr>
<tr>
<td></td>
<td><em>Riten Kumar</em> USA</td>
</tr>
<tr>
<td>15.45 – 16.15</td>
<td>Pediatric VTE Prevention and Risk Scores: A Systematic Review of the</td>
</tr>
<tr>
<td></td>
<td>Literature</td>
</tr>
<tr>
<td></td>
<td><em>Brian Branchford</em> USA</td>
</tr>
<tr>
<td>16.15 – 16.30</td>
<td>COFFEE BREAK</td>
</tr>
<tr>
<td>16.30 – 16.50</td>
<td>Pediatric Arterial Thromboembolism: A Systematic Review of the Literature</td>
</tr>
<tr>
<td></td>
<td><em>Mattia Rizzi</em> Switzerland</td>
</tr>
<tr>
<td>16.50 – 17.00</td>
<td>Purpura Fulminans Registry</td>
</tr>
<tr>
<td></td>
<td><em>Adrian Minford</em> United Kingdom</td>
</tr>
<tr>
<td>17.00 – 17.15</td>
<td>Pulmonary Embolism in Pediatrics: A Systematic Review of the Literature</td>
</tr>
<tr>
<td></td>
<td><em>Madhvi Rajpurkar</em> USA</td>
</tr>
<tr>
<td>17.15 – 17.30</td>
<td>Diagnostic Imaging in the Diagnosis of Children with Pulmonary Embolism</td>
</tr>
<tr>
<td></td>
<td><em>Leonardo Brandao</em> Canada</td>
</tr>
<tr>
<td>17.30 – 17.50</td>
<td>Liver and Renal Biopsies in Coagulopathic Children</td>
</tr>
<tr>
<td></td>
<td><em>Maria Magnusson</em> Sweden</td>
</tr>
<tr>
<td>17.50 – 18.05</td>
<td>Radiological Aspects in the Diagnosis of Neonatal CSVT</td>
</tr>
<tr>
<td></td>
<td><em>Mahendranath Moharir</em> Canada</td>
</tr>
<tr>
<td>18.05 – 18.15</td>
<td>Conclusion</td>
</tr>
<tr>
<td></td>
<td><em>Anthony Chan</em> Canada</td>
</tr>
<tr>
<td>Room 202 C–E</td>
<td>von Willebrand Factor, Part I</td>
</tr>
<tr>
<td>Chair</td>
<td><em>Jorge Di Paola</em> USA</td>
</tr>
<tr>
<td>Co-Chairs</td>
<td><em>Sandra Haberichter</em> USA</td>
</tr>
<tr>
<td>14.15 – 14.30</td>
<td>Welcome and Introduction of Best Scoring Abstract in VWF/ADAMTS13:</td>
</tr>
<tr>
<td></td>
<td>Misfolding of the von Willebrand Factor A1 Domain in Type 2 von</td>
</tr>
<tr>
<td></td>
<td>Willebrand Disease</td>
</tr>
<tr>
<td></td>
<td><em>Jorge Di Paola</em> USA</td>
</tr>
<tr>
<td>Co-Chairs</td>
<td><em>Francesco Rodeghiero</em> Italy</td>
</tr>
</tbody>
</table>
Monday, June 23, 2014

14.30 – 14.40  Introduction
   Francesco Rodeghiero Italy | Barry Coller USA

14.40 – 15.00  Use of the ISTH-BAT to Record Bleeding Symptoms of Normal Individuals
   Barry Coller USA

   “Self-Administered Bleeding Assessment Tool” and “Normal Range of Bleeding Scores for the ISTH-BAT: Adult and Pediatric Data from the Merging Project”
   Paula James Canada

   The Rebel Study (Retrospective Evaluation of Bleeding Etiology)
   Alberto Tosetto Italy

15.00 – 15.15  New Projects
   Performance of ISTH-BAT in Type 3 VWF within the 3Winters-IP Project
   Augusto Federici Italy

   Retrospective Multicenter Study on Adults with a Platelet Function Defect Diagnosed by a Senior Physician According to the SSC Guideline
   Paul Harrison United Kingdom

**VWF/ADAMTS 13 Assays**

   Co-Chairs  Sandra Haberichter USA | Johanna Kremer Hovinga Switzerland

15.15 – 15.30  Standardization of VWF Activity Assays
   Imre Bodo Hungary

15.30 – 15.50  WHO 1st International Standard ADAMTS13, Plasma
   Anthony R. Hubbard United Kingdom

15.50 – 16.00  New ADAMTS 13 Activity Assay
   Joshua Muia USA

16.00 – 16.10  Collagen Assays
   Veronica Flood USA

16.10 – 16.25  Multimer Assays
   Sandra Haberichter USA

16.25 – 16.50  COFFEE BREAK  EXHIBITION HALL

**The Life Cycle of von Willebrand Factor**

   Co-Chairs  Paula James Canada | Alberto Tosetto Italy

16.50 – 17.05  Blood Outgrowth Endothelial Cells
   Paula James Canada

17.05 – 17.20  VWF Strings
   Jose Lopez USA

17.20 – 17.35  Platelet VWF
   Walter Kahr Canada
## PROGRAM DETAILS

**MONDAY, JUNE 23, 2014**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>17.35 – 18.15</td>
<td>Clearance of VWF</td>
<td>David Lillicrap, Peter Lenting</td>
<td>Room 202 A&amp;B</td>
</tr>
<tr>
<td><strong>Room 202 A&amp;B</strong></td>
<td><strong>Working Group on Genomics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Co-Chairs</strong></td>
<td>**Anne Goodeve United Kingdom</td>
<td>Willem H. Ouwehand United Kingdom</td>
<td>Pieter Reitsma The Netherlands</td>
</tr>
<tr>
<td><strong>Session 1</strong></td>
<td><strong>Chair</strong> Willem H. Ouwehand United Kingdom</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.15 – 14.25</td>
<td>Welcome</td>
<td>Willem H. Ouwehand United Kingdom</td>
<td></td>
</tr>
<tr>
<td>14.25 – 14.45</td>
<td>Human Phenotype Ontology Terms: Does it Work?</td>
<td>Kathleen Freson Belgium</td>
<td></td>
</tr>
<tr>
<td>14.45 – 15.00</td>
<td>Top Rated Abstract in Genomics: Use of Human Phenome Ontology (HPO)</td>
<td>Anne Kelly United Kingdom</td>
<td></td>
</tr>
<tr>
<td>15.00 – 15.20</td>
<td>The Clotting Factor Mutation Database</td>
<td>Daniel Hampshire United Kingdom</td>
<td></td>
</tr>
<tr>
<td>15.20 – 15.40</td>
<td>The Role of the Curator for the ThromboGenomics Database</td>
<td>Daniel B. Bellissimo USA</td>
<td></td>
</tr>
<tr>
<td>15.40 – 16.00</td>
<td>Sharing Sequence Data and Annotation Panel Discussion</td>
<td>All Speakers</td>
<td></td>
</tr>
<tr>
<td><strong>16.00 – 16.20</strong></td>
<td><strong>COFFEE BREAK</strong></td>
<td></td>
<td>EXHIBITION HALL</td>
</tr>
<tr>
<td><strong>Session 2</strong></td>
<td><strong>Chair</strong> Pieter Reitsma The Netherlands</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.20 – 16.25</td>
<td>Welcome</td>
<td>Pieter Reitsma The Netherlands</td>
<td></td>
</tr>
<tr>
<td>16.25 – 16.40</td>
<td>Targeted Enrichment – Underlying Design Principles</td>
<td>Ji Wu USA</td>
<td></td>
</tr>
<tr>
<td>16.40 – 16.55</td>
<td>A NGS Diagnostic Platform for Inherited Bleeding and Platelet Disorders</td>
<td>Ilenia Simeoni United Kingdom</td>
<td></td>
</tr>
<tr>
<td>16.55 – 17.15</td>
<td>Challenges in Interpreting NGS Results for Inherited Bleeding and Platelet Disorders</td>
<td>Augusto Rendon United Kingdom</td>
<td></td>
</tr>
<tr>
<td>17.15 – 17.35</td>
<td>NGS Approaches in Familial ITP</td>
<td>Jill Johnsen USA</td>
<td></td>
</tr>
</tbody>
</table>
Monday, June 23, 2014

17.35 – 17.55  Resequencing of 100 Cases with Familial Thrombophilia  
Pieter Reitsma  The Netherlands

17.55 – 18.15  ThromboGenomics Draft Policies for Gene Discovery  
Panel Discussion, all speakers

18.15 – 20.00  Poster Viewing Session & Reception  Ballroom A-C

Abstract listing for the poster session is located on page 65.
Tuesday, June 24, 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.15 – 08.15</td>
<td>MEET THE MENTOR</td>
<td>HILTON &amp; HYATT HOTELS</td>
</tr>
<tr>
<td>08.25 – 12.00</td>
<td>PLENARY SESSION</td>
<td>BALLROOM D</td>
</tr>
<tr>
<td></td>
<td>Supported by the BloodCenter of Wisconsin</td>
<td></td>
</tr>
<tr>
<td>08.30 – 08.40</td>
<td>Introduction</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker Robert R. Montgomery USA</td>
<td></td>
</tr>
<tr>
<td>08.40 – 09.10</td>
<td>Kenneth M. Brinkhous Memorial Lecture</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker Andrew Paterson Canada</td>
<td></td>
</tr>
<tr>
<td>09.10 – 09.40</td>
<td>Shirley Johnson Memorial Lecture</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker Howard Jacob USA</td>
<td></td>
</tr>
<tr>
<td>09.40 – 10.10</td>
<td>Armand J. Quick Memorial Lecture</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker Pierre Morange France</td>
<td></td>
</tr>
<tr>
<td>10.10 – 10.40</td>
<td>COFFEE BREAK</td>
<td>EXHIBITION HALL</td>
</tr>
<tr>
<td>10.40 – 11.10</td>
<td>Marion Barnhart Memorial Lecture</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker Frank Lebeek The Netherlands</td>
<td></td>
</tr>
<tr>
<td>11.10 – 11.40</td>
<td>Pia Glas-Greenwalt Memorial Lecture</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker William Ouwehand United Kingdom</td>
<td></td>
</tr>
<tr>
<td>11.40 – 12.00</td>
<td>Thrombogenomics and the Role of SSC in 2020</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker David Lillicrap Canada</td>
<td></td>
</tr>
<tr>
<td>12.15 – 13.45</td>
<td>SATELLITE SYMPOSIA</td>
<td></td>
</tr>
<tr>
<td>Room 201 A&amp;B</td>
<td>A New Option for the Management of Hemophilia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Supported by Biogen Idec</td>
<td></td>
</tr>
<tr>
<td>Room 203 C–E</td>
<td>Monitoring Hemostatic Therapeutics–Are Your Assays Accurate?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Supported by an educational grant from Novo Nordisk</td>
<td></td>
</tr>
<tr>
<td>14.15 – 18.00</td>
<td>SSC SUBCOMMITTEE SESSION 2</td>
<td></td>
</tr>
<tr>
<td>Room 201 A&amp;B</td>
<td>Hemostasis and Malignancy</td>
<td></td>
</tr>
<tr>
<td>Room 203 A&amp;B</td>
<td>Plasma Coagulation Inhibitors</td>
<td></td>
</tr>
<tr>
<td>Room 203 C–E</td>
<td>Platelet Physiology</td>
<td></td>
</tr>
<tr>
<td>Room 202 A&amp;B</td>
<td>Predictive Hemostatic Variables in Cardiovascular Disease</td>
<td></td>
</tr>
<tr>
<td>Room 202 C–E</td>
<td>von Willebrand Factor, Part II</td>
<td></td>
</tr>
<tr>
<td>19.00 – 23.00</td>
<td>60th Annual SSC Anniversary Celebration at Discovery World</td>
<td></td>
</tr>
</tbody>
</table>
Tuesday, June 24, 2014

07.15 – 08.15  MEET THE MENTOR SESSION  HILTON & HYATT HOTELS

Sign-ups for these sessions will be possible on-site at the registration desk 24 hours before the respective sessions. Please note these sessions are limited to 25 attendees.

MENTORS

Susan Smyth  USA
Mark Crowther  Canada
Flora Peyvandi  Italy
Michael Makris  United Kingdom
Guy Young  USA
Nigel Mackman  USA
Thomas Ortel  USA
Jorge Di Paola  USA

Paula James  Canada
Yukio Ozaki  Japan
Saskia Middeldorp  The Netherlands
Augusto Federici  Italy
Peter Lenting  France
Edward Conway  Canada
Jing-Fei Dong  USA
Margaret Ragni  USA

08.25 – 11.30  PLENARY SESSION  BALLROOM D

Co-Chairs  Robert R. Montgomery  USA | David Lillicrap  Canada
Gilbert C. White, II  USA

08.30 – 08.40  Introduction
Robert R. Montgomery  USA

08.40 – 09.10  Kenneth M. Brinkhous Memorial Lecture
Optimal Strategies for Complex Genetic Traits
Andrew Paterson  Canada

09.10 – 09.40  Shirley Johnson Memorial Lecture
Personalized Medicine - A Current Reality
Howard Jacob  USA

09.40 – 10.10  Armand J. Quick Memorial Lecture
GWAS and VTE
Pierre Morange  The Netherlands
Supported by the Armand J. Quick Memorial Fund and the Medical College of Wisconsin

10.10 – 10.40  COFFEE BREAK  EXHIBITION HALL

10.40 – 11.10  Marion Barnhart Memorial Lecture
GWAS and VWF: Implications for Disease?
Frank Leebeek  USA

11.10 – 11.40  Pia Glas-Greenwalt Memorial Lecture
Genomic Medicine in the Care Path of Patients with Bleeding and Platelet Disorders
Willem H. Ouwehand  United Kingdom

11.40 – 12.00  Thrombogenomics and the Role of SSC in 2020
David Lillicrap  Canada
## Tuesday, June 24, 2014

### 12.15 – 13.45  SATELLITE SYMPOSIA

**Room 201 A&B**  
**A New Option for the Management of Hemophilia**  
*Supported by Biogen Idec*

**Room 203 C–E**  
**Monitoring Hemostatic Therapeutics: Are Your Assays Accurate?**  
*Supported by an educational grant from Novo Nordisk*

**Chair**  
*Steve Kitchen United Kingdom*

- **Welcome**  
  *Steve Kitchen United Kingdom*

- **Use of Hemostatic Assays in the Diagnosis of Hemophilia**  
  *Michael Makris United Kingdom*

- **Use of Hemostatic Assays in the Management of Patients with Hemophilia**  
  *Steve Kitchen United Kingdom*

- **Use of Hemostatic Assays in the Management of Patients with Hemophilia with Inhibitor**  
  *Guy Young USA*

- **Panel Discussion and Closing Remarks**  
  *All Speakers*

### 14.00 – 18.00  SSC SUBCOMMITTEE SESSION 2

**Room 201 A&B**  
**Hemostasis and Malignancy**  

**Chair**  
*Alok A. Khorana USA*

**Co-Chairs**  
*Marc Carrier Canada | Howard Liebman USA | Nigel Mackman USA | Ingrid Pabinger Austria | Joseph Palumbo USA | Jeffrey Zwicker USA*

**Session 1**  
**Clinical Guidance**  

**Co-Chairs**  
*Alok A. Khorana USA | Ingrid Pabinger Austria*

- **14.00 – 14.15**  
  **Top Rated Abstract in Hemostasis and Malignancy: Factor VII Derived Egfp-Egf1 Protein Mediate Drug Delivery System to Tf-Highly Expressing Tumors**  
  *Bo Zhang China*

- **14.15 – 14.45**  
  **Thromboprophylaxis in Hospitalized Cancer Patients**  
  *Jeffrey Zwicker USA*

- **14.45 – 15.15**  
  **Prevention of VTE in Medical Outpatients**  
  *Alok A. Khorana USA*

- **15.15 – 15.30**  
  **Is There a Role for NOACs in Prevention of Cancer-Associated Thrombosis?**  
  *Howard Liebman USA*

- **15.30 – 15.45**  
  **Is There a Role for NOACs in Treatment of Cancer-Associated Thrombosis?**  
  *Marc Carrier Canada*
<table>
<thead>
<tr>
<th>Time</th>
<th>Session 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.45 – 16.00</td>
<td>COFFEE BREAK EXHIBITION HALL</td>
</tr>
<tr>
<td></td>
<td><strong>Clinical and Translational Updates</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Co-Chairs:</strong> Joseph Palumbo USA</td>
</tr>
<tr>
<td>16.00 – 16.15</td>
<td>Update on Vienna CATS: Role for Interleukins?</td>
</tr>
<tr>
<td></td>
<td><em>Ingrid Pabinger Austria</em></td>
</tr>
<tr>
<td>16.15 – 16.30</td>
<td>TF Standardization Projects: An Update</td>
</tr>
<tr>
<td></td>
<td><em>Nigel Mackman USA</em></td>
</tr>
<tr>
<td>16.30 – 17.00</td>
<td>Mouse Models of Cancer-Associated Thrombosis</td>
</tr>
<tr>
<td></td>
<td><em>Brian Cooley USA</em></td>
</tr>
<tr>
<td>17.00 – 17.30</td>
<td>Guidance Statement Proposal on Prevention of Venous Thromboembolism in Hospitalized Medical Cancer Patients</td>
</tr>
<tr>
<td></td>
<td>*Marcello Di Nisio Italy</td>
</tr>
<tr>
<td>17.30 – 18.00</td>
<td>Update on Active Clinical Trials, Including</td>
</tr>
<tr>
<td></td>
<td>• CATCH Alok A. Khorana USA</td>
</tr>
<tr>
<td></td>
<td>• PHACS Alok A. Khorana USA</td>
</tr>
<tr>
<td></td>
<td>• SOME Marc Carrier Canada</td>
</tr>
<tr>
<td></td>
<td>• PERIOP Marc Carrier Canada</td>
</tr>
<tr>
<td></td>
<td>• Unsuspected PE Marcello Di Nisio Italy</td>
</tr>
<tr>
<td></td>
<td>• CAT IQ Jeffrey Zwicker USA</td>
</tr>
</tbody>
</table>

Room 203 A&B  Plasma Coagulation Inhibitors  
Chair Richard Marlar USA  
Co-Chairs Elisabetta Castoldi The Netherlands | Steven Kitchen United Kingdom  
Hiroko Tsuda Japan | Jun Teruya USA  

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00 – 14.10</td>
<td>Welcome and Abstract Presentation</td>
</tr>
<tr>
<td></td>
<td><strong>Chair:</strong> Richard Marlar USA</td>
</tr>
<tr>
<td>14.10 – 14.40</td>
<td>Top Rated Abstract in Plasma Coagulation Inhibitors: Corn Trypsin Inhibitor Non-Loop Regions are Required for the Specific Inhibition of Factor XIIa</td>
</tr>
<tr>
<td></td>
<td><em>Vera Korneeva Russia</em></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.40 – 14.55</td>
<td>Molecular Genetics</td>
</tr>
<tr>
<td></td>
<td><strong>Co-Chairs:</strong> Jun Teruya USA</td>
</tr>
<tr>
<td>14.55 – 15.15</td>
<td>Subcommittee Project Update: Racial Differences in Genetic Risk Factors for Venous Thromboembolism</td>
</tr>
<tr>
<td></td>
<td><em>Hiroko Tsuda Japan</em></td>
</tr>
</tbody>
</table>
## PROGRAM DETAILS

### Tuesday, June 24, 2014

#### Session 3
**New Proteins**  
**Co-Chairs**  
*Steven Kitchen United Kingdom | Hiroko Tsuda Japan*

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.15 – 15.35</td>
<td>Tissue Factor Pathway Inhibitor–General Aspects</td>
<td>Jun Teruya USA</td>
<td></td>
</tr>
<tr>
<td>15.35 – 15.50</td>
<td>Tissue Factor Pathway Inhibitor–Clinical Assays</td>
<td>Dorothy Adcock USA</td>
<td></td>
</tr>
<tr>
<td>15.50 – 16.05</td>
<td>Tissue Factor Pathway Inhibitor–Clinical Relevance</td>
<td>Jun Teruya USA</td>
<td></td>
</tr>
</tbody>
</table>

#### Session 4
**Laboratory Testing**  
**Co-Chairs**  
*Ricard A. Marlar USA | Steven Kitchen United Kingdom*

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.25 – 16.45</td>
<td>Subcommittee Project Update: Protein S Activity Assays</td>
<td>Ian Jennings United Kingdom</td>
<td></td>
</tr>
<tr>
<td>16.45 – 17.25</td>
<td>Planned Manuscripts:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Laboratory Aspects of Protein C Testing</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Laboratory Aspects of Protein S Testing</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Laboratory Aspects of Antithrombin Testing</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Laboratory Aspects of APC Resistance Testing</td>
<td>Richard Marlar USA</td>
<td></td>
</tr>
<tr>
<td>17.25 – 18.00</td>
<td>Discussion and Future Plans</td>
<td>Richard Marlar USA</td>
<td></td>
</tr>
</tbody>
</table>

#### Room 203 C–E
**Platelet Physiology**  
**Chair**  
*Paul Harrison United Kingdom*

**Co-Chairs**  
*Andrew Frelinger III USA | Christian Gachet France | Paolo Gresele Italy | Diego Mezzano Chile | Andrew Mumford United Kingdom | Patrizia Noris Italy*

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00 – 14.15</td>
<td>Top Rated Abstract in Platelet Physiology: Morphological Distinction Unravels Mechanisms of Platelet Biogenesis from Bone Marrow Megakaryocytes</td>
<td>Satoshi Nishimura Japan</td>
<td></td>
</tr>
<tr>
<td>14.15 – 14.25</td>
<td>Overview of Platelet Physiology SSC and Project Updates</td>
<td>Paul Harrison United Kingdom</td>
<td></td>
</tr>
<tr>
<td>14.25 – 14.45</td>
<td>Diagnostic Algorithm Study</td>
<td>Paolo Gresele Italy</td>
<td></td>
</tr>
</tbody>
</table>
### Session 2

**Co-Chairs**  
*Diego Mezzano* **Chile** | *Patrizia Noris* **Italy**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.45 – 15.15</td>
<td>Update on PT VWD</td>
<td><em>Maha Othman</em></td>
<td><strong>Canada</strong></td>
</tr>
<tr>
<td>15.15 – 15.30</td>
<td>New Insights into Megakaryopoiesis and Proplatelet Formation in PT-VWD</td>
<td><em>Loredana Bury</em></td>
<td><strong>Italy</strong></td>
</tr>
<tr>
<td>15.30 – 16.00</td>
<td>GPCR Structure/Function Variants in Platelets</td>
<td><em>Andrew Mumford</em></td>
<td><strong>United Kingdom</strong></td>
</tr>
</tbody>
</table>

**16.00 – 16.30 COFFEE BREAK**  
**EXHIBITION HALL**

### Session 3

**Co-Chairs**  
*Andrew Frelinger III* **USA** | *Paul Harrison* **United Kingdom**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.30 – 17.00</td>
<td>Why Should Anti-P2Y12 Therapy be Monitored?</td>
<td><em>Udaya Tantry</em></td>
<td><strong>USA</strong></td>
</tr>
<tr>
<td>17.00 – 17.30</td>
<td>Why Have Studies on Tailored Antiplatelet Therapy Failed so Far?</td>
<td><em>Bernd Jilma</em></td>
<td><strong>Austria</strong></td>
</tr>
<tr>
<td>17.30 – 18.00</td>
<td>Anti-P2Y12 Therapy Should Not Be Currently Monitored</td>
<td><em>Marco Cattaneo</em></td>
<td><strong>Italy</strong></td>
</tr>
</tbody>
</table>

### Room 202 A&B

**Predictive Hemostatic Variables in Cardiovascular Disease**

**Chair**  
*Paul Kyrle* **Austria**

**Co-Chairs**  
*James Douketis* **Canada** | *Shinya Goto* **Japan** | *Karel Moons* **The Netherlands** | *Marc Samama* **France** | *Alex Spyropoulos* **USA**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00 – 14.05</td>
<td>Welcome and Overview of Session Objectives</td>
<td><em>Paul A. Kyrle</em></td>
<td><strong>Austria</strong></td>
</tr>
</tbody>
</table>

### Session 1

**Predictive Variables in Arterial Disease**

**Chair**  
*Alex Spyropoulos* **USA**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.30 – 14.55</td>
<td>Pharmacogenetics or Phenotyping as Predictors of Stent Thrombosis</td>
<td><em>Bernd Jilma</em></td>
<td><strong>Austria</strong></td>
</tr>
</tbody>
</table>

**15.20 – 15.45 COFFEE BREAK**  
**EXHIBITION HALL**
### Session 2
**Predictive Variables in Venous Disease**

**Chair:** James Douketis Canada

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.45 – 16.00</td>
<td>Top Rated Abstract in Predictive Hemostatic Variables: D-Dimer for the Diagnosis of Symptomatic Upper Extremity Deep Vein Thrombosis</td>
<td>Benilde Cosmi Italy</td>
<td></td>
</tr>
<tr>
<td>16.00 – 16.25</td>
<td>Role of D-Dimer in Predicting Recurrent VTE – An Update</td>
<td>Clive Kearon Canada</td>
<td></td>
</tr>
<tr>
<td>16.25 – 16.50</td>
<td>Predicting VTE in Cancer Patients – Is it Clinically Relevant?</td>
<td>Marc Carrier Canada</td>
<td></td>
</tr>
<tr>
<td>16.50 – 17.15</td>
<td>In Which Patients Should We Use Aspirin for VTE Prophylaxis?</td>
<td>Marc Samama France</td>
<td></td>
</tr>
<tr>
<td>17.15 – 18.00</td>
<td>Multicenter External Validation Studies of the IMPROVE RAM in Predicting VTE in Hospitalized Medical Patients</td>
<td>Alex Spyropoulos USA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>External Validation and Update of the Vienna Prediction Model Using Pooled Individual Patient Data</td>
<td>Maura Marcucci Italy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prospective Validation of the Vienna Prediction Model – the VALID-Study</td>
<td>Lisbeth Eischer Austria</td>
<td></td>
</tr>
</tbody>
</table>

### Room 202 C–E
**von Willebrand Factor, Part II**

**Chair:** Jorge Di Paola USA

**Co-Chairs:** Sandra Haberichter USA, Daniel Hampshire United Kingdom, Paula James Canada, Koichi Kokame Japan, Johanna Kremer Hovinga Switzerland, Alberto Tosetto Italy

### Session 1
**Genetics, Genomics and Population Studies**

**Co-Chairs:** Daniel Hampshire USA, Koichi Kokame Japan

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00 – 14.15</td>
<td>Effect of Age on VWF Levels</td>
<td>Frank Leebeek The Netherlands</td>
<td></td>
</tr>
<tr>
<td>14.15 – 14.30</td>
<td>Genetic Variants of ADAMTS13 in aHUS</td>
<td>Vahid Afshar-Kharghan USA</td>
<td></td>
</tr>
<tr>
<td>14.30 – 14.45</td>
<td>Genetic Variants in VWF that Influence the Diagnosis of VWD Type 1</td>
<td>Jorge Di Paola USA</td>
<td></td>
</tr>
<tr>
<td>14.45 – 15.00</td>
<td>Association and Linkage for VWF and VWFpp Levels</td>
<td>Karl Desch USA</td>
<td></td>
</tr>
</tbody>
</table>

### Session 2
**Report on VWD Projects**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.00 – 15.15</td>
<td>Report of VWF Database</td>
<td>Daniel Hampshire United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>
### Tuesday, June 24, 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.15 – 15.30</td>
<td>Report of the Zimmerman Project</td>
<td>Robert R. Montgomery</td>
<td>USA</td>
</tr>
<tr>
<td>15.30 – 15.45</td>
<td>Report of the EU Project</td>
<td>Giancarlo Castaman</td>
<td>Italy</td>
</tr>
<tr>
<td>15.45 – 16.00</td>
<td>Report of the Canadian Project</td>
<td>Paula James</td>
<td>Canada</td>
</tr>
<tr>
<td>16.00 – 16.15</td>
<td>Report of the Belgian-Czech Project</td>
<td>Alain Gadisseur</td>
<td>Belgium</td>
</tr>
<tr>
<td>16.15 – 16.25</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.25 – 16.45</td>
<td><strong>COFFEE BREAK &amp; DISCUSSION</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.45 – 17.05</td>
<td>Glycosylation of VWF: Functional Implications</td>
<td>Jill Johnsen</td>
<td>USA</td>
</tr>
<tr>
<td>17.05 – 17.25</td>
<td>Glycosylation of Platelet VWF and Resistance to ADAMTS13 Proteolysis</td>
<td>James O’Donnell</td>
<td>Ireland</td>
</tr>
<tr>
<td>17.25 – 17.45</td>
<td>O-linked Glycans in VWF and Interactions with ADAMTS13</td>
<td>Agata Nowak</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>17.45 – 18.00</td>
<td>O-linked Glycosylation of VWF and Interactions with GP1bα</td>
<td>Tom McKinnon</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>19.00 – 23.00</td>
<td><strong>60th Annual SSC Anniversary Celebration at Discovery World</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Glycosylation of VWF: Functional Implications**

**Co-Chairs: Imre Bodo** Hungary | **Jill Johnsen** USA

- **16.45 – 17.05** ABO is a Complex Modifier of VWF
  - Jill Johnsen USA

- **17.05 – 17.25** Glycosylation of Platelet VWF and Resistance to ADAMTS13 Proteolysis
  - James O’Donnell Ireland

- **17.25 – 17.45** O-linked Glycans in VWF and Interactions with ADAMTS13
  - Agata Nowak United Kingdom

- **17.45 – 18.00** O-linked Glycosylation of VWF and Interactions with GP1bα
  - Tom McKinnon United Kingdom

**60th Annual SSC Anniversary Celebration at Discovery World**

Join us in celebrating 60 years of the SSC! The 60th Annual SSC Anniversary Celebration at the beautiful Discovery World Museum will include a night of delicious hors d’oeuvres, music, U.S. Indigenous people performance and dance with an informative information session and a special celebratory firework display at 17:45 with festivities concluding at 23:00.

The Discovery World is situated on Milwaukee’s magnificent Lakefront and is surrounded by blue skies and the tranquil waters of Lake Michigan. From tall ships to tall buildings, this unique venue will excite all in attendance.

**Transportation**

Buses will begin to leave the Hilton and Hyatt hotels at 18:45 and will run on a continuous loop to Discovery World. The last bus will depart from Discovery World for return to the hotels at 23:15.

**Tickets**

Tickets are $10 per attendee and must be purchased in advance.
### PROGRAM OVERVIEW

**Wednesday, June 25, 2014**

#### 08.00 – 12.00  
**SUBCOMMITTEE SESSION 3**
- **Room 201 C&D**  
  Biorheology
- **Room 203 C–E**  
  Control of Anticoagulation, Part I
- **Room 202 C–E**  
  Factor VIII, Factor IX & Rare Coagulation Disorders, Part I
- **Room 203 A&B**  
  Fibrinolysis
- **Room 201 A&B**  
  Platelet Immunology
- **Room 202 A&B**  
  Women’s Health Issues in Thrombosis and Haemostasis

#### 12.15 – 13.45  
**SATELLITE SYMPOSIA**
- **Room 203 C–E**  
  Every Bleed Matters: Yesterday, Today and Tomorrow  
  Supported by Baxter
- **Room 201 A&B**  
  von Willebrand Disease and Angiodysplasia: A Challenge for the Clinician and Scientist  
  Supported in part by an educational grant from CSL Behring

#### 14.00 – 17.30  
**EDUCATIONAL SESSION 2**
- **Room 202 C–E**  
  Hemostasis and Inflammation  
  Co-Chairs: Andreas Greinacher Germany, Gines Escolar Spain
- **Room 201 A&B**  
  Pediatric and Perinatal Hemostasis  
  Co-Chairs: Debra Newman USA, Gili Kenet Israel
- **Room 203 C–E**  
  Therapeutics of Tomorrow  
  Co-Chairs: Alan Mast USA, Yohko Kawai Japan
- **Room 202 A&B**  
  Vascular Biology of Malaria  
  Co-Chairs: Dermot Kenny Ireland, Nevine Kassim Egypt
### Wednesday, June 25, 2014

#### Session 3: Biomechanics in Hemostasis and Thrombosis

**Room 201 C&D**

**Chair**: Judith Cosemans, The Netherlands | Michael King, USA | David Ku, USA

**Co-Chairs**: Owen McCarty, USA | Mitsuhiko Sugimoto, Japan

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
</tr>
</thead>
</table>
| 08.00 – 08.20 | Opening Comments & Update on Ongoing Subcommittee Projects  
Keith Neeves, USA |
| 08.20 – 08.40 | Top Rated Abstract in Biorheology: Platelets from Premature Neonates Have Increased Platelet Affinity for von Willebrand Factor (VWF) Under Arterial Shear Compared to Platelets from Term Neonates  
Jonathan Cowman, Ireland |
| 08.40 – 09.00 | Circulating Tumor-Derived Microparticles and Thrombosis  
Nigel Mackman, USA |
| 09.00 – 09.20 | The Role of Tissue Factor in Cancer-Associated Coagulation Activation and Metastasis  
Ali Amirkhosravi, USA |
| 09.20 – 09.40 | TRAIL-Coated Leukocytes that Kill Cancer Cells in the Circulation  
Michael King, USA |
| 09.40 – 10.00 | Procoagulant Phenotype of Circulating Tumor Cells  
Owen McCarty, USA |

**10.00 – 10.20 COFFEE BREAK  EXHIBITION HALL**

**Session 2: Biomechanics in Hemostasis and Thrombosis**

**Chair**: Judith Cosemans, The Netherlands

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
</tr>
</thead>
</table>
| 10.20 – 10.40 | Platelets and the Mechanical Microenvironment  
Wilbur Lam, USA |
| 10.40 – 11.00 | The Mechanical Properties of Single Fibrin Fibers  
Martin Guthold, USA |

**Session 3: In Vitro Flow Assays: Methods and Emerging Concepts**

**Chair**: Owen McCarty, USA

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
</tr>
</thead>
</table>
| 11.00 – 11.20 | Adherent Monocyte Promotion of Mural Microthrombus Formation in Flow via Platelet Sequestration  
Michael Lawrence, USA |
| 11.20 – 11.40 | Evaluation of Soluble or Immobilized Tissue Factor in von Willebrand Factor-Dependent Thrombus Formation Under Flow Condition  
Mitsuhiko Sugimoto, Japan |
Wednesday, June 25, 2014

11.40 – 12.00  Multi-parameter Assessment of Thrombus Formation: Identifying Platelet Function Defects
Judith Cosemans  The Netherlands

Room 203 C–E  Control of Anticoagulation, Part I
Chair  Walter Ageno  Italy
Co-Chairs  Rebecca Beyth  USA  |  Benilde Cosmi  Italy  |  Mark Crowther  Canada
Ismail Elalamy  France  |  Elaine Hylek  USA  |  Pieter Kamphuisen  The Netherlands
Peter Verhamme  Belgium  |  Henry Watson  United Kingdom

08.00 – 08.05  Introduction
Walter Ageno  Italy

08.05 – 08.20  Top Rated Abstract in Control of Anticoagulation: Reversal of Enoxaparin-Induced Anticoagulation in Healthy Subjects by Andexanet Alfa (prt064445), an Antidote for Direct and Indirect FXa Inhibitors–A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial
Mark Crowther  Canada

Session 1  Laboratory Issues with the New Oral Anticoagulants
Co-Chairs  Ismail Elalamy  France  |  Rebecca Beyth  USA

08.20 – 08.35  Laboratory Measurements of NOACs: Many Tests, Many Limits?
Jovan Antovic  Sweden

08.35 – 08.50  Laboratory Measurements of NOACs. Monitoring Drugs or Patients
Ismail Elalamy  France

08.50 – 09.05  NOACs and Thrombophilia Testing: Facts and Artifacts
Mark Crowther  Canada

09.05 – 09.35  Discussion

09.35 – 09.50  International Collaborative Study on Methods of Measurement for Dabigatran
Elaine Gray  United Kingdom

09.50 – 10.05  Determination of Dabigatran, Rivaroxaban, and Apixaban from Plasma, Serum, and Urine Samples of Patients on Treatment
Job Harenberg  Germany

10.05 – 10.45  COFFEE BREAK  EXHIBITION HALL

Session 2  Update on Current SSC Registries and Standardization Activities and New Proposals
Co-Chairs  Elaine Hylek  USA  |  Benilde Cosmi  Italy

10.45 – 11.00  Recurrent Venous Thromboembolism in Anticoagulated Patients with Cancer
Sam Schulman  Canada
Wednesday, June 25, 2014

11.00 – 11.15  Pregnancy Outcomes in Patients who Become Pregnant While on NOACs  
*Saskia Middledorp* The Netherlands

11.15 – 11.25  Splanchnic Vein Thrombosis: Long-term Follow-up  
*Walter Ageno* Italy

11.25 – 11.35  START-EVENTS SSC ISTH Register  
*Walter Ageno* Italy

11.35 – 11.45  Replacement of the Current International Standards for Thromboplastin  
*Ton van den Besselaar* The Netherlands

11.45 – 12.00  Standardizing the Definition of Clinically Relevant Non-major Bleeding in Clinical Investigations of Antihemostatic Medicinal Products in Surgical and Non-surgical Patients  
*Scott Kaatz* USA

---

**Room 202 C–E**  
**Factor VIII, Factor IX & Rare Coagulation Disorders, Part I**

Chair  
*Flora Peyvandi* Italy

Co-Chairs  
*Michael Makris* United Kingdom | *Danijela Mikovic* Serbia | *Steven Pipe* USA  
*Elena Santagostino* Italy | *Midori Shima* Japan | *Guy Young* USA

---

**Session 1**  

08.00 – 08.10  State of the Art  
*Flora Peyvandi* Italy

---

**Session 2**  
**Clinical Trials Design and Surveillance**

Co-Chairs  
*Donna Di Michele* USA | *Frits R. Rosendaal* The Netherlands

08.10 – 08.20  Report on the SSC Project. Definitions in Hemophilia  
*Victor Blanchette* Canada

08.20 – 08.30  Report on the SSC Project: Clinical Trial Design for Hemophilia  
*Donna Di Michele* USA

08.30 – 08.40  Too Many PUPs Studies, Not Enough PUPs  
*Guy Young* USA

08.40 – 08.50  New SSC Project: IRS-PTPs: Inhibitor Reporting Standardization in Previously Treated Patient  
*Alfonso Iorio* Canada

08.50 – 09.00  New SSC Project: Standardization of Post-registration Surveillance  
*Flora Peyvandi* Italy

09.00 – 09.20  Discussion

---

09.20 – 09.35 **COFFEE BREAK**  
EXHIBITION HALL
Wednesday, June 25, 2014

**Session 2**

**Safety and Efficacy Evaluation of Novel Drugs**

**Co-Chairs**
*Guy Young USA | Flora Peyvandi Italy*

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.35</td>
<td>Do We Need to Change the SSC Recommendations for Potency Labeling</td>
<td>Anthony Hubbard</td>
<td>United Kingdom</td>
</tr>
<tr>
<td></td>
<td>with Arrival of Long Acting Products?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.45</td>
<td>Report of the New Generation FIX Collaborative NIBSC Study.</td>
<td>Elaine Gray</td>
<td>United Kingdom</td>
</tr>
<tr>
<td></td>
<td>Announcement of the Replacement FIX Standard Study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.05</td>
<td>Factor VIII and Factor IX Long Acting Products. Which Assay Should</td>
<td>Peter Turecek</td>
<td>Baxter</td>
</tr>
<tr>
<td></td>
<td>Be Used to Evaluate Their Efficacy?</td>
<td>Nikolaus Muller</td>
<td>Bayer</td>
</tr>
<tr>
<td></td>
<td>10.05 – 10.20</td>
<td>Jurg Sommer</td>
<td>Biogen Idec</td>
</tr>
<tr>
<td></td>
<td>10.20 – 10.35</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>10.35 – 10.50</td>
<td>Debra Bensen-Kennedy</td>
<td>CSL Behring</td>
</tr>
<tr>
<td></td>
<td>11.05 – 11.20</td>
<td>Mirella Ezban</td>
<td>NovoNordisk</td>
</tr>
<tr>
<td>11.20</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Clotting Factor Concentrates (FVIII, FIX) with Respect to Potency</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Assays Used for Labeling and Testing of Post Infusion Samples”</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.45</td>
<td>FDA’s Current Considerations on Assays for Potency Determination of</td>
<td>Mark Weinstein</td>
<td>FDA</td>
</tr>
<tr>
<td></td>
<td>Long Acting Clotting Factor Concentrates</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.55</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Room 203 A&B**

**Fibrinolysis**

**Chair**
*Nicola Mutch United Kingdom*

**Co-Chairs**
*Jonathan Foley Canada | Ann Gils Belgium | Paul Kim Canada | Craig Thelwell United Kingdom | Shirley Uitte De Willige The Netherlands | Waander Van Heerde The Netherlands*

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00</td>
<td>Top Rated Abstract in Fibrinolysis. Differential Effect of Dabigatran,</td>
<td>Debra Hoppenstead</td>
<td>USA</td>
</tr>
<tr>
<td></td>
<td>Rivaroxiban and Apixaban on Thrombomodulin Mediated Activation of</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Protein C and Thrombin Activated Fibrinolysis Inhibitor (TAI) May</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Impact Their Safety and Efficacy Profiles</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Debra Hoppenstead</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08.15</td>
<td>Plasmin Dependent Thrombin Generation Enhancement</td>
<td>Waander Van Heerde</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>08.40</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Wednesday, June 25, 2014

08.40 – 09.10  Fibrinolysis When There is No Fibrin? The Role of t-PA and Plasmin in the Brain  
Robert Medcalf  Australia

09.10 – 09.40  The Relationship Between the Fibrinolytic System and S. Pyogenes Virulence  
Frank Castellino  USA

09.40 – 10.10  The Mechanism of Gamma'-Fg Resistance to Lysis  
Paul Kim  Canada

10.10 – 10.30  COFFEE BREAK  EXHIBITION HALL

10.30 – 11.00  Visualizing Plasmin on Cell Surfaces  
Tetsu Urano  Japan

11.00 – 11.30  Following Lysis in Real-Time – Lessons from Confocal Microscopy  
Nicola Mutch  United Kingdom

11.30 – 12.00  The WHO 4th International Standard for Plasmin and an Update on D-Dimer Standard Development  
Craig Thelwell  United Kingdom

Room 201 A&B  Platelet Immunology

Chair  Yves Gruel  France
Co-Chairs  Donald Arnold  Canada | Tamam Bakchoul  Germany | Sentot Santoso  Germany | Yoshiaki Tomiyama  Japan | Chris Ward  Australia

Part 1  Introduction

08.00 – 08.30  Welcome  
Yves Gruel  France

Top Rated Abstract in Platelet Immunology: The Effects of Different B-Cell Activating Factor Receptors on Lymphocyte Function and Secretion of Cytokines in Immune Thrombocytopenia  
Yanan Min  China

Part 2  Autoimmune and Drug-Induced Thrombocytopenia
Co-Chairs  Donald Arnold  Canada | Yoshiaki Tomiyama  Japan

08.30 – 09.30  Proposal for a Diagnostic Test for ITP: Measurement of Immature Platelet Fraction (IPF)  
Yoshiaki Tomiyama  Japan

Standardized Approach to the Investigation of DITP  
Donald Arnold  Canada | Tamam Bakchoul  Germany

Update on Mice Models of DITP  
Julia Fuhrmann  Germany | Tamam Bakchoul  Germany

Screening and Investigations for Inherited Thrombocytopenia  
Alessandro Pecci  Italy
**Wednesday, June 25, 2014**

### Part 3  
**Alloimmune Thrombocytopenia**

**Co-Chairs**  
*Tamam Bakchoul* Germany | *Sentot Santoso* Germany

09.30 – 10.30

- **Current Efforts to Standardize the Management of FNAIT**
  *James Bussel* USA

- **New Approaches in the Antenatal FNAIT Therapy**
  *Cedric Ghavaert* United Kingdom

- **MAIPA and Surface Plasmon Resonance, the Role of Low Avidity Antibodies in FNAIT**
  *Julie Peterson* USA

- **Genetic Variations Associated with HPA Typing Discrepancies: Practical Implications in Standardization of Alloantigen Typing**
  *Gerald Bertrand* France

10.30 – 10.45 **COFFEE BREAK** | **EXHIBITION HALL**

### Part 4  
**Heparin-Induced Thrombocytopenia**

**Co-Chairs**  
*Chris Ward* Australia | *Yves Gruel* France

10.45 – 11.55

- **Development of 5B9, a Monoclonal Antibody to PF4/Heparin Complexes with a Human Fc Fragment that Fully Mimics HIT Antibodies**
  *Jérôme Rollin* or *Yves Gruel* France

- **Comparative Evaluation of 5A1 and 5B9, Two Potential Standards for Platelet Activation Assays**
  *Jérôme Rollin* or *Yves Gruel* France

- **Performances of Flow Cytometric Analysis of Platelet Activation for the Diagnosis of HIT**
  *Bernard Tardy* France

- **Performances of Platelet Microparticle Generation Assay for the Diagnosis of HIT**
  *François Mullier* Belgium | *Valentine Minet* Belgium

- **Update on the Practical Use of Whole Blood Impedance Assay for HIT Diagnosis**
  *Chris Ward* Australia | *Bernard Tardy* France

11.55 – 12.00 **Conclusion**

*Yves Gruel* France

### Room 202 A&B  
**Women’s Health Issues in Thrombosis & Haemostasis**

**Chair**  
*Rezan Abdul Kadir* United Kingdom

**Co-Chairs**

- *Claudia Chi* Singapore | *Sabine Eichinger* Austria | *Takao Kobayashi* Japan
- *Ida Martinelli* Italy | *Saskia Middeldorp* The Netherlands
- *Rochelle Winikoff* Canada
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Co-Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00 – 08.05</td>
<td>Welcome and Introduction of Subcommittee Co-Chair</td>
<td><em>Rezan Abdul Kadir</em> United Kingdom</td>
</tr>
<tr>
<td>08.05 – 08.20</td>
<td>Top Rated Abstract in Women’s Health Issues in Thrombosis and Haemostasis: Association Between Newborn Birth Weight and Maternal Venous Thromboembolism in the Postpartum Period: A Population-Based Case-Control Study</td>
<td><em>Marc Blondon</em> Switzerland</td>
</tr>
<tr>
<td>08.20 – 08.25</td>
<td>Educational Program of SSC Meetings: Overview and Future Perspectives</td>
<td><em>Rezan Abdul Kadir</em> United Kingdom</td>
</tr>
<tr>
<td>08.25 – 08.30</td>
<td>Report on the Women’s Health Issues on Thrombosis and Haemostasis Symposium 2013</td>
<td><em>Benjamin Brenner</em> Israel</td>
</tr>
<tr>
<td>08.30 – 08.45</td>
<td>Update on International Registries and SSC Initiated Projects</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diagnosis of VTE and PE in Pregnancy</td>
<td><em>Menno Huisman</em> The Netherlands</td>
</tr>
<tr>
<td></td>
<td>Thrombophilia Screening After Recurrent Failures of Assisted Reproductive Techniques (ART)</td>
<td><em>Elvira Grandone</em> Italy</td>
</tr>
<tr>
<td></td>
<td>Mirena IUS and HMB in Women with Inherited Bleeding Disorders</td>
<td><em>Claudia Chi</em> Singapore</td>
</tr>
<tr>
<td></td>
<td>Menorrhagia Working Group Update</td>
<td><em>Claire Philipp</em> USA</td>
</tr>
<tr>
<td>08.45 – 09.10</td>
<td>Where Do We Go with Obstetric Antiphospholipid Syndrome</td>
<td><em>Guillermina Girardi</em> United Kingdom</td>
</tr>
<tr>
<td>09.10 – 09.35</td>
<td>Pregnancy and Postpartum: Thromboprophylaxis – Who and How Long</td>
<td><em>Saskia Middeldorp</em> The Netherlands</td>
</tr>
<tr>
<td>09.35 – 10.00</td>
<td>Uterine Vein Thrombosis – A New Gynaecological Challenge</td>
<td><em>Hannah Cohen</em> United Kingdom</td>
</tr>
<tr>
<td>10.00 – 10.25</td>
<td>Overview of von Willebrand Disease in Women</td>
<td><em>Peter Kouides</em> USA</td>
</tr>
<tr>
<td>10.25 – 10.50</td>
<td>Neonatal Intracranial Haemorrhage</td>
<td><em>Meera Chiltur</em> USA</td>
</tr>
</tbody>
</table>
### PROGRAM DETAILS

#### 10.50 – 11.00

**Cranial Bleeding In Neonates And Mode of Delivery – Systematic Review of Literature**  
*Rezan Abdul Kadir* United Kingdom

---

#### 11.00 – 11.15

**PPH – Evaluating the Evidence**

**Co-Chairs**  
*Claire McLintock* New Zealand | *Rezan Abdul Kadir* United Kingdom

11.00 – 11.15  
**Tranexamic Acid and PPH**  
*Sophie Susen* France

11.15 – 11.30  
**Fibrinogen and PPH**  
*Peter Collins* United Kingdom

11.30 – 11.45  
**rFVIIa and PPH**  
*Takao Kobayashi* Japan

11.45 – 12.00  
**Thromboelastography and PPH**  
*Susan Halimeh* Germany

---

#### 12.15 – 13.45

**SATELLITE SYMPOSIA**

**ROOM 203 C–E**  
**Every Bleed Matters: Yesterday, Today and Tomorrow**

*Supported by Baxter*

12.15 – 13.30  
**The presentation will cover the following topics:**  
- Biology of Blood-Induced Joint Disease  
- Clinical Impact of Joint Bleeding  
- Musculoskeletal System Assessment  
- Maintenance of Joint Health  
*Christopher E. Walsh* USA

13.30 – 13.45  
**Questions and Answers**  
*Christopher E. Walsh* USA

---

**ROOM 201 A&B**  
**von Willebrand Disease and Angiodysplasia: A Challenge for the Clinician and Scientist**  
*Supported in part by an educational grant from CSL Behring*

**Co-Chairs**  
*Cecile Denis* France | *Paula James* Canada

12.15 – 12.45  
**On the Versatility of VWF**  
*Peter Lenting* France

12.45 – 13.15  
**Acquired VWS and Clinical Aspects of Angiodysplasia**  
*Sophie Susen* France

13.15 – 13.45  
**Angiodysplasia: Investigating Dysfunctional Angiogenesis through BOEC**  
*Anna Randi* United Kingdom
### Wednesday, June 25, 2014

#### 14.00 – 17.30  EDUCATIONAL SESSION 2

**ROOM 202 C–E**  Hemostasis and Inflammation  
Co-Chairs  
*Andreas Greinacher*  Germany  |  *Gines Escolar*  Spain

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00 – 14.45</td>
<td>Inflammation and Thrombosis: Entangled in NETs</td>
<td><em>Denisa Wagner</em>  USA</td>
</tr>
<tr>
<td>14.45 – 15.30</td>
<td>Coagulation and Innate Immunity</td>
<td><em>Wolfram Ruf</em>  USA</td>
</tr>
</tbody>
</table>

#### 15.30 – 16.00  COFFEE BREAK  EXHIBITION HALL

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.00 – 16.30</td>
<td>Cytoprotective Actions of Activated Protein C in Diabetes</td>
<td><em>Christopher Jackson</em>  Australia</td>
</tr>
<tr>
<td>16.30 – 17.00</td>
<td>Basic and Translational Studies of Extracellular DNA in Sepsis</td>
<td><em>Patricia Liaw</em>  Canada</td>
</tr>
<tr>
<td>17.00 – 17.30</td>
<td>Platelet Mechanisms in Ischemic Stroke</td>
<td><em>Bernhard Nieswandt</em>  Germany</td>
</tr>
</tbody>
</table>

**ROOM 201 A&B**  Pediatric and Perinatal Hemostasis  
Co-Chairs  
*Debra Newman*  USA  |  *Gili Kenet*  Israel

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00 – 14.45</td>
<td>Obstetrical Hemostasis</td>
<td><em>Claire McClintock</em>  New Zealand</td>
</tr>
<tr>
<td>14.45 – 15.30</td>
<td>Neonatal Thrombosis and Hemostasis or Platelet Assessment and Treatment in the Newborn</td>
<td><em>Gili Kenet</em>  Israel</td>
</tr>
</tbody>
</table>

#### 15.30 – 16.00  COFFEE BREAK  EXHIBITION HALL

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.00 – 16.30</td>
<td>Newer Antithrombotics in Pediatrics</td>
<td><em>Guy Young</em>  USA</td>
</tr>
<tr>
<td>16.30 – 17.00</td>
<td>Post Thrombotic Syndrome in Children</td>
<td><em>Ulrike Nowak-Göttl</em>  Germany</td>
</tr>
<tr>
<td>17.00 – 17.30</td>
<td>Understanding the Neonatal Platelet</td>
<td><em>Martha Sola-Visner</em>  USA</td>
</tr>
</tbody>
</table>

**ROOM 203 C–E**  Therapeutics of Tomorrow  
Co-Chairs  
*Alan Mast*  USA  |  *Yohko Kawai*  Japan

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00 – 14.30</td>
<td>Impact of New Therapeutics in the Developing World</td>
<td><em>Margaret Ozelo</em>  Brazil</td>
</tr>
<tr>
<td>14.30 – 15.00</td>
<td>In Vitro Platelets</td>
<td><em>Morty Poncz</em>  USA</td>
</tr>
<tr>
<td>15.00 – 15.30</td>
<td>Gene Therapy for Hemophilia: Advancing Beyond the First Clinical Success</td>
<td><em>Paul Monahan</em>  USA</td>
</tr>
</tbody>
</table>
# Wednesday, June 25, 2014

## ROOM 202 A&B  
**Vascular Biology of Malaria**

Co-Chair: *Dermot Kenny* *Ireland* | *Nevine Kassim* *Egypt*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 14.00 – 14.30| **Clinical Impact of Malaria in Developing Countries and a Review of its Infectious Life-Cycle**  
*Chite Asirwa* *Kenya* |
| 14.30 – 15.00| **VWF Interactions and Reactions in Malaria**  
*James O'Donnell* *Ireland* |
| 15.00 – 15.30| **Blood Coagulation in Malaria**  
*Ivo Francischetti* *USA* |

## PROGRAM DETAILS

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.30 – 16.00</td>
<td><strong>COFFEE BREAK</strong></td>
</tr>
</tbody>
</table>
| 16.00 – 16.30| **Engineered FVIII and IX and Potency Assessment**  
*Koen Mertens* *The Netherlands* |
| 16.30 – 17.00| **Blocking TFPI-Mediated Inhibition of Prothrombinase or Tissue Factor to Mitigate Bleeding in Haemophilia**  
*Alan Mast* *USA* |
| 17.00 – 17.15| **Soluble Thrombomodulin as a DIC Therapeutic**  
*Tadashi Matsushita* *Japan* |
| 17.15 – 17.30| **Bi-Specific Antibodies as FVIII Mimetics in Hemophilia**  
*Midori Shima* *Japan* |

ROOM 202 A&B  
**Vascular Biology of Malaria**

Co-Chair: *Dermot Kenny* *Ireland* | *Nevine Kassim* *Egypt*
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
<th>Room</th>
</tr>
</thead>
</table>
| 07.30 – 08.30 | TECHNICAL SESSION                          | Room 203 C–E  
Clinical Utility of ADAMTS-13 Activity  
Supported by Immucor |
| 08.45 – 12.45 | SSC SUBCOMMITTEE SESSION 4                 | Room 201 A&B  
Animal, Cellular and Molecular Models of Thrombosis  
Room 203 C–E  
Control of Anticoagulation, Part II  
Room 202 C–E  
Factor VIII, Factor IX & Rare Coagulation Disorders, Part II  
Room 203 A&B  
Factor XI and the Contact System  
Room 202 A&B  
Vascular Biology |
**TECHNICAL SESSION**

**Clinical Utility of ADAMTS-13 Activity**  
*Supported by Immucor*

**Speakers**  
*Jun Teruya USA | Camille Bedrosian USA*

Since ADAMTS13 assay kits became commercially available, some hospitals in the US have implemented this assay in-house as a clinical test. When thrombotic microangiopathy is suspected, it is important to differentiate between thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). In addition, some disease conditions such as malignant hypertension or pernicious anemia can be misdiagnosed as TTP.

Cases will be presented on how we can avoid unnecessary or inappropriate management such as therapeutic plasma exchange or administration of eculizumab by performing stat ADAMTS13 assay. It can be resulted within one hour. Since there is no rapid assay available to positively rule in atypical HUS, exclusion of TTP is based on ADAMTS13 value, leading to an appropriate management as needed.

**SSC SUBCOMMITTEE SESSION 4**

**Animal, Cellular and Molecular Models of Thrombosis**

**Chair**  
*Susan Smyth USA*

**Co-Chairs**  
*Cecile Denis France | Tom Knudsen Denmark | Toshiyuki Miyata Japan | Leslie Parise USA | Denise Sabatino USA*

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.45 – 09.00</td>
<td>Top Rated Abstract in Animal Models of Thrombosis: Early Gene Expression Biomarkers Sensitive to a Micro Volume of Blood in the Joint</td>
<td>Narine Hakobyan USA</td>
<td>Room 201 A&amp;B</td>
</tr>
<tr>
<td>09.00 – 09.25</td>
<td>Strengths and Weaknesses of a New Mouse Model of Thrombosis Induced by Inferior Vena Cava Stenosis</td>
<td>Julia Geddings USA</td>
<td>Room 201 A&amp;B</td>
</tr>
<tr>
<td>09.25 – 09.50</td>
<td>Animal Models of Hemophilia and Immunogenicity</td>
<td>Paul Monahan USA</td>
<td>Room 201 A&amp;B</td>
</tr>
<tr>
<td>09.50 – 10.15</td>
<td>Characterization of a Novel Haemophilia A Rat Model</td>
<td>Lise Nikolic Nielsen Denmark</td>
<td>Room 201 A&amp;B</td>
</tr>
<tr>
<td>10.15 – 10.40</td>
<td>Acoustic Radiation Force Ultrasound (ARFI) Imaging of Bleeding in Hemophilic Dogs</td>
<td>Caterina Gallippi USA</td>
<td>Room 201 A&amp;B</td>
</tr>
<tr>
<td>10.40 – 11.05</td>
<td>Mouse Models of MYH9 Disorders</td>
<td>Nobuaki Suzuki Japan</td>
<td>Room 201 A&amp;B</td>
</tr>
<tr>
<td>11.05 – 11.30</td>
<td>Oral Anticoagulants in the Prevention of Experimental Atherosclerosis</td>
<td>Henri Spronk The Netherlands</td>
<td>Room 201 A&amp;B</td>
</tr>
</tbody>
</table>
Thursday, June 26, 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 11.30 – 11.55 | Rat Models for Thrombosis  
*Leslie Parise USA* |
| 11.55 – 12.20 | Animal Models of VT: Where We Are and Where We Are Going  
*Jose Diaz USA* |
| 12.20 – 12.45 | SSC Discussion and Project Updates |

**ROOM 203 C–E**  
**Control of Anticoagulation, Part II**

*Chair*  
*Walter Ageno* Italy

*Co-Chairs*  
*Rebecca Beyth USA* | *Benilde Cosmi Italy* | *Mark Crowther Canada*  
*Ismail Elalamy France* | *Elaine Hylekv USA* | *Pieter Kamphuisen The Netherlands*  
*Peter Verhamme Belgium* | *Henry Watson United Kingdom*

**Management of Patients on Novel Oral Anticoagulants or with Coronary Stents who Need Surgery (Joint Control of Anticoagulation and Perioperative Thrombosis and Hemostasis Symposium)**

*Co-Chairs*  
*Walter Ageno Italy* | *Jerrold Levy USA*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 08.45 – 09.10 | Update of Studies Assessing Perioperative Management of Dabigatran and Laboratory Sub-studies: Is This Approach Safe and Does It Correlate with Normalized Coagulation Tests?  
*James Douketis Canada* |
| 09.10 – 09.35 | French Society of Anesthesia Cohort Study: Bleeding and Urgent Surgery in Patients Treated with NOACs  
*Pierre Albaladejo France* |
| 09.35 – 10.00 | Post-PCI Patients Undergoing Non-cardiac Surgery: Measurements of Platelet Inhibition of Patients Having Major Adverse Cardiac Events  
*Summer Syed Canada* |
| 10.00 – 10.15 | Review of Planned and Ongoing Clinical Studies: What Are the Unanswered Questions?  
*Alex Spyropoulos USA* |
| 10.15 – 10.30 | Discussion |
| **10.30 – 11.00** | **COFFEE BREAK**  
**EXHIBITION HALL** |

**Reversal of Old and New Anticoagulant Drugs**

*Co-Chairs*  
*Mark Crowther Canada* | *Pieter Kamphuisen The Netherlands*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 11.00 – 11.20 | Recent Evidence for Reversal of Warfarin  
*C. Marc Samama France* |
| 11.20 – 11.40 | Available Evidence for Reversal of Dabigatran Using an Antibody Fragment  
*Joanne van Ryn Germany* |
| 11.40 – 12.00 | Available Evidence for Reversal of Xa Drugs Using Andexanet Alpha  
*Mark Crowther Canada* |
Thursday, June 26, 2014

12.00 – 12.10 General Discussion

12.10 – 12.45 Reports of Ongoing Studies and Registries
   FRED Ad UPGRADE Registries
   Sam Schulman Canada
   RADOA-Registry
   Edelgard Lindhoff-Last Germany

Standardization of the Definition of Clinical Outcome for Patients Treated
for a Major Oral Anticoagulant Related Bleed
   Nakisa Khorsand The Netherlands

ROOM 202 C–E Factor VIII, Factor IX & Rare Coagulation Disorders, Part II

Chair Flora Peyvandi Italy
Co-Chairs Michael Makris United Kingdom | Danijela Mikovic Serbia | Steven Pipe USA
   Elena Santagostino Italy | Midori Shima Japan | Guy Young USA

Clinical and Laboratory Evaluation

Co-Chairs Steven Pipe USA | Kathelijn Fischer The Netherlands

08.45 – 09.00 Top Rated Abstract in Factor VIII and Factor IX: In Vivo Selection of
   Genetically Manipulated Platelets Corrects Murine Hemophilic Phenotype
   and Induces Immune Tolerance Even Using a Low Multiplicity of Infection
   for Transduction
   Qizhen Shi USA

09.00 – 09.10 Report on the SSC Project: Bleeding Score in Hemophilia: A Prognostic Tool
   for Clinical Outcome
   Maria Elisa Mancuso Italy | Alberto Tosetto Italy

09.10 – 09.15 Report on the SSC Project: The Definition of Mild Hemophilia A
   Michael Makris United Kingdom

09.15 – 09.35 Discussion

Recommendations on Hemophilia Treatment

Co-Chairs Elena Santagostino Italy | Alok Srivastava India

09.35 – 09.45 Report on the SSC Project: Consensus Definitions and Recommendations for
   Immune Tolerance Induction (ITI) in Hemophilia with Inhibitors.
   Elena Santagostino Italy

09.45 – 10.00 Discussion

10.00 – 10.10 Report on the SSC Project: Prophylaxis in Hemophilic Patients without
   Inhibitor
   Victor Blanchette Canada

10.10 – 10.25 Discussion
Thursday, June 26, 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.25</td>
<td><strong>COFFEE BREAK</strong></td>
<td></td>
</tr>
<tr>
<td>10.40</td>
<td>By-Passing Agents</td>
<td>Midori Shima Japan</td>
</tr>
<tr>
<td>10.40</td>
<td>Global Assays for the Evaluation of the Efficacy of By-Passing Agents</td>
<td>Yesim Dargaud France</td>
</tr>
<tr>
<td>10.50</td>
<td>Thrombin Generation in Hemophilia Treated Patients</td>
<td>Maria Elisa Mancuso Italy</td>
</tr>
<tr>
<td>10.50</td>
<td>Application of Clot Waveform Analysis to Hemostatic Monitoring of Bypassing Therapy</td>
<td>Keiji Nogami Japan</td>
</tr>
<tr>
<td>11.00</td>
<td>Monitoring the Hemostatic Efficacy and Safety of New Therapeutic Drugs (What Assays Should be Used?)</td>
<td>Benny Sorensen Alnylam</td>
</tr>
<tr>
<td>11.00</td>
<td></td>
<td>Takehisa Kitazawa Chugai Pharma</td>
</tr>
<tr>
<td>11.10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.10</td>
<td>Rare Coagulation Disorders</td>
<td>Danijela Mikovic Serbia</td>
</tr>
<tr>
<td>11.10</td>
<td>Rare Coagulation Disorders Resource Room</td>
<td>Amy Shapiro USA</td>
</tr>
<tr>
<td>12.10</td>
<td>EAHAD Mutation Databases on Factor VII and Factor XI</td>
<td>Christopher Ludlam United Kingdom</td>
</tr>
<tr>
<td>12.15</td>
<td>Report on the SSC Project: Factor V Deficiency, Clinical Heterogeneity and Treatment</td>
<td>Danijela Mikovic Serbia</td>
</tr>
<tr>
<td>12.25</td>
<td>Factor X Concentrate: Registration of Novel Drugs for RBDs</td>
<td>Peter Feldman Bio Products Laboratory – BPL</td>
</tr>
<tr>
<td>12.40</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08.45</td>
<td><strong>ROOM 203 A&amp;B</strong></td>
<td></td>
</tr>
<tr>
<td>10.25</td>
<td><strong>FACTOR XI AND THE CONTACT SYSTEM</strong></td>
<td></td>
</tr>
<tr>
<td>08.45</td>
<td>Activators of the Contact System</td>
<td></td>
</tr>
<tr>
<td>08.45</td>
<td>FXI Activation and the Virulence of Infectious Agents</td>
<td>Owen McCarty USA</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------------------------------------</td>
<td></td>
</tr>
</tbody>
</table>
| 09.05 – 09.25 | **Visualizing polyP in Thrombi and Using Novel Anti-polyP Compounds to Stop Thrombosis**  
*Ricky Travers USA* |
| 09.25 – 09.45 | **Basic Research on FXI and the Contact System**                         |
| 09.45 – 10.05 | **COFFEE BREAK**                                                         |
| 10.05 – 10.25 | **Contact Activation Murine KOS: Unexpected Findings When Characterizing Mechanisms Related to Thrombosis Protection**  
*Evi Stavrou USA*  |
| 10.25 – 10.45 | **Plasmin Triggers Proteolytic Factor XII Activation on Endothelial Cells, Which is Accelerated by the Lysine Substitution T328K that Causes Type III Angioedema**  
*Coen Maas The Netherlands*  |
| 10.45 – 11.05 | **Factor XII Regulates the Pathological Process of Thrombus Formation on Ruptured Plaques**  
*Judith Cosemans The Netherlands*  |
| 11.05 – 11.15 | **An International Standard for Activated Factor XI (FXIa)**              |
|               | *Elaine Gray United Kingdom*                                             |
|               | **Inhibitors of FXI and the Contact System: Safer Anticoagulation**      |
| 11.15 – 11.35 | **Allosteric Inhibitors of FXIa**                                        |
|               | *Umesh Desai USA*                                                        |
| 11.35 – 11.55 | **Discovery and Characterization of a Highly Specific Antibody Inhibitor of Plasma Kallikrein**  
*Jon Kenniston USA*  |
| 11.55 – 12.15 | **Inhibiting the Contact Pathway with RNA Aptamers**                     |
|               | *Rebecca Smock USA*                                                      |
| 12.15 – 12.30 | **Top Rated Abstract in Factor XI and the Contact System: Characterisation and Development of Factor XIIa Inhibitors for Assaying Tissue Factor Triggered Coagulation**  
*Vladimir Kolyadko Russia*  |
| 12.30 – 12:45 | **Open Discussion**                                                      |
|               | **Polyphosphates and Activation of the Contact System. Is the Contact System Involved in Both Arterial and Venous Thrombosis?**  
*Joost Meijers and José Govers-Riemslag The Netherlands*  |

**ROOM 202 A&B**  
**Vascular Biology**  
Chair *Rienk Nieuwland The Netherlands*  
Co-Chairs  
*Françoise Dignat-George France* | *Elizabeth Gardiner Australia*  
*Anna Randi United Kingdom* | *Florence Toti France*
<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.45 – 09.00</td>
<td>Top Rated Abstract in Vascular Biology: Quantifying the Impact of Diet-Induced Atherosclerotic Plaque Erosions on Vessel Hypercoagulability with Semipermeable Nanoparticle Beacons</td>
<td>Rohun Palekar</td>
<td>USA</td>
</tr>
<tr>
<td></td>
<td><strong>Shedded Proteins and Receptors</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chair</strong></td>
<td>Elizabeth Gardiner</td>
<td>Australia</td>
</tr>
<tr>
<td>09.00 – 09.20</td>
<td>Background and Latest Developments of Metalloproteolytic Shedding in Vascular Biology</td>
<td>Bruce Walcheck</td>
<td>USA</td>
</tr>
<tr>
<td>09.20 – 09.40</td>
<td>Platelet Receptor Metalloproteolytic Regulation and Impact on Platelet Age and Function</td>
<td>Emma Josefsson</td>
<td>Australia</td>
</tr>
<tr>
<td>09.40 – 10.00</td>
<td>Discussion on Clinical Aspects of Receptor Shedding</td>
<td>Chris Ward</td>
<td>Australia</td>
</tr>
<tr>
<td></td>
<td><strong>Circulating Endothelial Progenitor Cells</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chair</strong></td>
<td>Anna Randi</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>10.00 – 10.20</td>
<td>Background and Latest Developments in Isolation of Circulating Endothelial Progenitor Cells</td>
<td>Reinhold Medina</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>10.20 – 10.40</td>
<td>Isolation of Blood Outgrowth Endothelial Cells</td>
<td>Anna Randi</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>10.40 – 11.00</td>
<td>Flow Cytometry Techniques to Detect Circulating Endothelial Progenitor Cells</td>
<td>Florence Sabatier</td>
<td>France</td>
</tr>
<tr>
<td></td>
<td><strong>Microparticles</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chair</strong></td>
<td>Françoise Dignat-George</td>
<td>France</td>
</tr>
<tr>
<td>11.00 – 11.20</td>
<td>Isolation and Characterization of Platelet-derived Vesicles</td>
<td>Pia Siljander</td>
<td>Finland</td>
</tr>
<tr>
<td>11.20 – 11.45</td>
<td>Measurements, Applications and Impact of the Refractive Index of Extracellular Vesicles</td>
<td>Edwin van der Pol</td>
<td>The Netherlands</td>
</tr>
<tr>
<td></td>
<td><strong>Standardization</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chair</strong></td>
<td>Rienk Nieuwland</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>11.45 – 12.15</td>
<td>Overview of Microparticle Standardization</td>
<td>Romaric Lacroix</td>
<td>France</td>
</tr>
<tr>
<td>12.15 – 12.45</td>
<td>Standardization of Vesicle Detection by Flow Cytometry Through Vesicle Size Approximation</td>
<td>Frank Coumans</td>
<td>The Netherlands</td>
</tr>
</tbody>
</table>
## Symposia Schedule Overview

### Special Symposia

**Monday, June 23, 2014**

<table>
<thead>
<tr>
<th>Time</th>
<th>Venue</th>
<th>Topic</th>
<th>Supporter</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.00–14.00</td>
<td>203 C–E</td>
<td>Clinical Perspectives on Longer-Acting Therapies</td>
<td><strong>Supported by Bayer HealthCare</strong></td>
</tr>
<tr>
<td></td>
<td>201 A&amp;B</td>
<td>FVIII Treatment and Tolerance – With or Without VWF?</td>
<td><strong>Supported in part by an educational grant from Grifols</strong></td>
</tr>
</tbody>
</table>

### Satellite Symposia

**Tuesday, June 24, 2014**

<table>
<thead>
<tr>
<th>Time</th>
<th>Venue</th>
<th>Topic</th>
<th>Supporter</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.15–13.45</td>
<td>201 A&amp;B</td>
<td>A New Option for the Management of Hemophilia</td>
<td><strong>Supported by Biogen Idec</strong></td>
</tr>
<tr>
<td></td>
<td>203 C–E</td>
<td>Monitoring Hemostatic Therapeutics: Are Your Assays Accurate?</td>
<td><strong>Supported by an educational grant from Novo Nordisk Inc.</strong></td>
</tr>
</tbody>
</table>

**Wednesday, June 25, 2014**

<table>
<thead>
<tr>
<th>Time</th>
<th>Venue</th>
<th>Topic</th>
<th>Supporter</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.15–13.45</td>
<td>203 C–E</td>
<td>Every Bleed Matters: Yesterday, Today and Tomorrow</td>
<td><strong>Supported by Baxter</strong></td>
</tr>
<tr>
<td></td>
<td>201 A&amp;B</td>
<td>von Willebrand Disease and Angiodysplasia: A Challenge for the Clinician and Scientist</td>
<td><strong>Supported in part by an educational grant from CSL Behring</strong></td>
</tr>
</tbody>
</table>

### Technical Session

**Thursday, June 26, 2014**

<table>
<thead>
<tr>
<th>Time</th>
<th>Venue</th>
<th>Topic</th>
<th>Supporter</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.30–08.30</td>
<td>203 C–E</td>
<td>Clinical Utility of ADAMTS-13 Activity</td>
<td><strong>Supported by Immucor</strong></td>
</tr>
</tbody>
</table>

For the relevant programs of the Special Symposia, Satellite Symposia and Technical Session, please refer to the detailed program overviews at the respective day.
Posters are presented during the entire duration of the meeting and are accessible at the same time as the exhibition opening hours. The official poster session and reception will take place on Monday, June 23, 2014, from 18.15-20.00. The Poster area is located in the Wisconsin Center Ballroom A–C.

Posters can be mounted starting as of Monday, June 23, 2014, at 9.00. Material for fixing your poster is provided at the poster desk. Dismantling is as of Wednesday, June 25, 2014, at 17.30. Posters not removed by the dismantling deadline will be removed and destroyed.

<table>
<thead>
<tr>
<th>Poster Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACM01 Animal</td>
<td>EARLY GENE EXPRESSION BIOMARKERS SENSITIVE TO A MICRO VOLUME OF BLOOD IN THE JOINT</td>
<td>N. Hakobyan* (USA) - L. Cong - X. Song - C. Enockson - J. O’Brien - L. A. Valentino</td>
</tr>
<tr>
<td>ACM02 Cellular</td>
<td>HIGH MOLECULAR WEIGHT KININ GEN BINDS</td>
<td>Z. Xie* (China) - A. Yang - R. W. Colman - Y. Wu</td>
</tr>
<tr>
<td>ACM03 Molecular</td>
<td>THROMBIN-INDUCED PODOCYTE INJURY IS PROTEASE ACTIVATED RECEPTOR (PAR) -3 AND -4 DEPENDENT</td>
<td>R. Sharma* (USA) - A. Waller - A. J. Guess - S. Agrawal - B. Isermann - W. E. Smoyer - M. T. Nieman - B. A. Kerlin</td>
</tr>
<tr>
<td>ACM04 Animal</td>
<td>PROTEINURIA SEVERITY IS DIRECTLY CORRELATED WITH EX VIVO AND IN VIVO MARKERS OF THROMBOTIC POTENTIAL IN AN EXPERIMENTAL MODEL OF NEPHROTIC SYNDROME</td>
<td>A. P. Waller* (USA) - R. Sharma - W. E. Smoyer - M. A. Chanley - M. T. Nieman - B. A. Kerlin</td>
</tr>
<tr>
<td>ACM05 Cellular</td>
<td>TISSUE FACTOR-EXPRESSING TUMOR CELLS CAN BIND TO TISSUE FACTOR PATHWAY INHIBITOR UNDER STATIC AND SHEAR CONDITIONS IN VITRO</td>
<td>S. Che* (USA) - C. DeLeonardis - M. Shuler - T. Stokol</td>
</tr>
<tr>
<td>ACM06 Molecular</td>
<td>EFFECT OF TRUNCIATIONS ON INTEGRIN 83 MIMICKING CALPAIN CLEAVAGE ON INTEGRIN SIGNAL TRANSDUCTION IN PLATELETS OF 83-TRANSGENIC MICE</td>
<td>X. Shi* (China) - X. Cui - J. Huang - J. Yang - P. Liu - Y. Zhou - Z. Ruan - Z. Long - X. Xi</td>
</tr>
<tr>
<td>ACM07 Cellular</td>
<td>THE EFFECT OF UC-MSC HOMING ON THE IMMUNE INFLAMMATORY MICROENVIRONMENT AND TARGETED IMPROVEMENT OF PROTHROMBOTIC STATE</td>
<td>J. Yin* (China) - W. Gu - C. Lin - M. Ren - X. Cai - J. Ni - W. Wu - J. Gu</td>
</tr>
<tr>
<td>ACM08 Molecular</td>
<td>SPATIAL DYNAMICS OF FIBRIN CLOT GROWTH INVESTIGATION: MEASUREMENT OF FROZEN PLASMA SAMPLES AND EVALUATION OF THE ASSAY SENSITIVITY TO THE DIFFERENT CONCENTRATION OF TRISODIUM CITRATE ADDED DURING BLOOD COLLECTION.</td>
<td>N. Korotina* (Russian Federation) - L. Sokolova - M. Panteleev - F. Ataullakhyan</td>
</tr>
<tr>
<td>ACM09 Animal</td>
<td>THE RELATION OF INFLAMMATORY FACTORS AND IMMUNE RELATED PROTHROMBOTIC STATE IN CIA RATS</td>
<td>J. Gu* (China) - M. Ren - W. Gu - H. Qiu - Z. Li - X. Cai - Y. Wang - X. Sun</td>
</tr>
<tr>
<td>ACM10 Cellular</td>
<td>INFERIOR VENA CAVA (IVC) BRANCH VARIATIONS IN C57BL/6 MICE IMPACT THROMBUS SIZE IN IVC LIGATION MODEL.</td>
<td>J. A. Diaz* (USA) - D. Farris - S. Wroblenski - D. Myers - T. Wakefield</td>
</tr>
</tbody>
</table>
ACM11 ORGAN-SPECIFIC TISSUE FACTOR ACTIVITY IS SIGNIFICANTLY ALTERED IN EXPERIMENTAL MALARIA
J. Moore* (USA) - T. C. Bracken - D. Sarr - A. Doyle - M. Ghobrial - T. Jenkinson

ACM12 NEUTRALIZATION OF HEMORRHAGE INDUCED BY DIRECT FACTOR XA AND THROMBIN INHIBITORS BY PROTHROMBIN COMPLEX CONCENTRATES IN A RAT MODEL

ACM13 EQUID HERPES VIRUS TYPE-1 ACTIVATES PLATELETS THROUGH THE PROCOAGULANT EFFECTS OF TISSUE FACTOR
T. Stokol* (USA) - W. M. Yeo - D. Burnett - J. L. Catalfmo

ACM14 DEVELOPMENT OF CELL LINES PRODUCING FULLY ACTIVE RECOMBINANT VITAMIN K-DEPENDENT (VKD) CLOTTING FACTORS WITHOUT VITAMIN K EPOXIDE REDUCTASE (VKOR) CO-EXPRESSIO

ACM15 ESTABLISHMENT OF ANTI-TETANUS HUMAN IMMUNOGLOBULIN NATIONAL STANDARD FOR POTENCY TEST

Biorheology

BR01 PLATELETS FROM PREMATURE NEONATES HAVE INCREASED PLATELET AFFINITY FOR VON WILLEBRAND FACTOR (VWF) UNDER ARTERIAL SHEAR COMPARED TO PLATELETS FROM TERM NEONATES

Control of Anticoagulation

COA01 REVERSAL OF ENOXAPARIN-INDUCED ANTICOAGULATION IN HEALTHY SUBJECTS BY ANDEXANET ALFA (PRT064445), AN ANTIDOTE FOR DIRECT AND INDIRECT FXA INHIBITORS - A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

COA02 STATIN USE REDUCES INCIDENCE OF ADVERSE EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION: ANALYSIS IN ACTIVE-W & A AND AVERROES STUDIES

COA03 DEVELOPMENT OF RENAL DYSFUNCTION IN ATRIAL FIBRILLATION PATIENTS: THE MICHIGAN ANTICOAGULATION QUALITY IMPROVEMENT INITIATIVE (MAQI2) EXPERIENCE
COA04 VITAMIN K ANTAGONISTS VERSUS HEPARIN FOR THE TREATMENT OF SPLANCHNIC VEIN THROMBOSIS IN THE ISTH REGISTRY: RESULTS OF 12-MONTH FOLLOW-UP AND A PROPENSITY SCORE ANALYSIS

COA05 SAFE IMPLEMENTATION OF THE NEW ORAL ANTICOAGULANTS (NOACS) REQUIRES PATIENT MONITORING
E. Loizou* (United Kingdom) - C.-H. Toh - T. Dutt

COA06 DEFINING TIME IN THERAPEUTIC RANGE FOR CLINICIANS: FREQUENCY OF DOSE CHANGES IS A GOOD SURROGATE MARKER FOR IDENTIFYING PATIENTS WITH SUBOPTIMAL ANTICOAGULATION WITH WARFARIN
A. Vijenthira* (Canada) - G. Le Gal - M. Carrier

COA07 WHAT IS THE BEST TIME SAMPLING FOR THE TWO DIRECT ORAL ANTICOAGULANTS (DOACS), DABIGATRAN AND RIVAROXABAN?
J. Douxfils* (Belgium) - J. Baudar - B. Devalet - M. M. Samama - B. Chatelain - J.-M. Dogné - F. Mullier

COA08 PRESENCE OF DIRECT FACTOR XA INHIBITORS LEADS TO A PROTRACTED THROMBIN GENERATION PEAK
S. Bloemen* (The Netherlands) - D. Huskens - B. de Laat - H. C. Hemker - R. Al Dieri

COA09 CLINICAL OUTCOME OF MAJOR BLEEDING IN PATIENTS ON ORAL ANTICOAGULANT TREATMENT: RESULTS FROM THE CLIMBING STUDY
L. Franco* (Italy) - C. Becattini - G. Lorenzini - R. Sbrojavacca - C. Nitti - R. Cappelli - S. Cattinelli - L. Masotti - G. Agnelli

COA10 THE EXPERIENCES OF CONSULTATIONS ON ORAL ANTICOAGULATION FOR AF: THE IMPORTANCE OF QUALITATIVE RESEARCH IN CARDIOVASCULAR SCIENCES
C. Borg Xuereb* (Malta) - R. L. Shaw - G. Y. H. Lip - D. A. Lane

COA11 VITAMIN K ANTAGONIST THERAPY INDUCES HIGH PLASMA LEVELS OF FACTOR VIII AND FIBRINOGEN AND REDUCES THICKNESS OF FIBRIN FIBERS

COA12 INTEREST OF THROMBIN TIME IN THE PERI-PROCEDURAL MANAGEMENT FOR PATIENTS ON DABIGATRAN ETIXILATE

COA13 IMPACT OF THROMBOPHILIA TESTING ON DIAGNOSIS AND TREATMENT OF PATIENTS WITH NEUROLOGIC DISORDERS: A SINGLE CENTER EXPERIENCE
G. Wasp* (USA) - J. Shatzel - J. Whyman - D. Harbin - M. Lane - J. Marehbian - D. Ornstein

COA14 MAJOR ORTHOPAEDIC SURGERY: IS THE RISK OF MAJOR BLEEDING HIGHER IN ELDERLY PATIENTS?
J. Quintero* (Colombia) - L. Cardenas - G. Bonilla - A. Llinás - M. Bautista - M. Navas - M. Gomez and The Clinical Care Program in Joint Replacement Surgery. Hospital Universitario Fundación Santa Fe de Bogotá
COA15  EFFECT OF ECULIZUMAB THERAPY ON THE COAGULATION STATUS OF PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

COA16  ORAL ANTICOAGULATION TREATMENT AND PT INR RESPONSE IN OUR DEPARTMENT - COMPARISON BETWEEN 2009 AND 2014
V. Jovanoska* (Macedonia) - I. Jovanoski

COA17  STREPTOKINASE AND LOW MOLECULAR WEIGHT HEPARIN AFFECT PLATELET AGGREGATION IN UKRAINIAN PATIENTS WITH ATHEROTHROMBOTIC AND CARDIOEMBOLIC ISCHEMIC STROKE
M. Burlova-Vasylieva* (Ukraine) - N. Kravchenko - T. Katrii - O. Savchuk

COA18  COUMIDIN INDUCED SKIN NECROSIS-CASE PRESENTATION
V. Jovanoska* (Macedonia) - I. Jovanoski

COA19  EFFECTS OF IMPAIRED RENAL FUNCTION ON LEVELS AND PERFORMANCE OF D-DIMER IN PATIENTS WITH SUSPECTED PULMONARY EMBOLISM
H. Robert-Ebadi* (Switzerland) - L. Bertoletti - C. Combescure - G. Le Gal - H. Bounameaux - M. Righini

COA20  EFFICACY AND SAFETY OUTCOMES OF TREATMENT OF ACUTE VENOUS THROMBOEMBOLISM: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
L. A. Castellucci* (Canada) - C. Cameron - G. Le Gal - M. Carrier

COA21  EFFECTIVENESS, SAFETY AND MANAGEMENT OF NOVEL DIRECT ORAL ANTICOAGULANTS IN DAILY CARE – UPDATED RESULTS OF THE PROSPECTIVE DRESDEN NOAC REGISTRY (NCT01588119)
J. Beyer-Westendorf* (Germany) - F. Michalski - C. Thieme - L. Tittl

COA22  REASONS FOR NOT-SWITCHING FROM VKA TO NOAC AND PERSISTENCE ON VKA – A VKA SUBGROUP ANALYSIS OF THE PROSPECTIVE DRESDEN NOAC REGISTRY (NCT01588119)
J. Beyer-Westendorf* (Germany) - F. Michalski - C. Thieme - L. Tittl

COA23  CENTRALLY ADJUDICATED CAUSE OF DEATH DURING ANTICOAGULANT TREATMENT – RESULTS OF THE PROSPECTIVE DRESDEN NOAC REGISTRY (NCT01588119)
J. Beyer-Westendorf* (Germany) - F. Michalski - C. Thieme - L. Tittl

COA24  HOW SHOULD WE MEASURE THE REVERSAL OF DIRECT FACTOR XA OR THROMBIN INHIBITORS BY PROTHROMBIN COMPLEX CONCENTRATE?
H. J. M. Brinkman* (The Netherlands) - J. Dinkelaar - S. Patiwaël - J. Harenberg - A. Leyte

COA25  NO EFFECT OF PLATELET SUPPLEMENTATION TO REVERSE THE P2Y12 INHIBITOR TICAGRELOR: AN IN VITRO STUDY
A.-C. Martin* (France) - C. Berndt - P. Gaussem - I. Gouin-Thibault - V. Siguret - B. Le Bonniec - C. Bachelot-Loza - A. Godier

COA26  THE EFFECT OF RIFAMPIN ON THE PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF EDOXABAN IN HEALTHY SUBJECTS
J. Mendell - S. Chen - L. He - M. Desai - D. Parasrampuria* (USA)

COA27  HEALTHCARE COST OF RECURRENT VENOUS THROMBOEMBOLISM AND BLEEDING EVENTS AMONG PATIENTS WITH ACUTE VENOUS THROMBOEMBOLISM
COA28  TIME COURSE OF RECURRENT VENOUS THROMBOEMBOLIC AND MAJOR BLEEDING EVENTS DURING ANTICOAGULANT THERAPY WITH APIXABAN OR ENOXAPARIN/WARFARIN: ANALYSIS OF THE AMPLIFY DATA USING LANDMARK METHOD

COA29  THE PROTHROMBINASE INDUCED CLOTTING TIME TEST (PICT®), A ROBUST ALTERNATIVE TO APTT IN THE MANAGEMENT OF UFH THERAPY
W. Korte* (Switzerland) - R. Marlar - M. Krause - S. Rathbun

COA30  EVALUATION OF MEDICAL COSTS ASSOCIATED WITH USE OF NEW ORAL ANTICOAGULANTS COMPARED WITH STANDARD THERAPY AMONG PATIENTS WITH VENOUS THROMBOEMBOLISM BASED ON CLINICAL TRIAL RESULTS
A. Amin* (USA) - Y. Jing - J. Trocio - J. Lin - M. Lingohr-Smith - J. Graham

COA31  INCREMENTAL HEALTHCARE BURDEN OF BLEEDING AMONG PATIENTS WITH VENOUS THROMBOEMBOLISM IN THE US
A. Amin - Y. Jing* (USA) - J. Trocio - J. Lin - M. Lingohr-Smith - J. Graham

COA32  SENSITIVITY OF PROTHROMBIN TIME TO THE PRESENCE OF RIVAROXABAN VARIES SUBSTANTIALLY BETWEEN REAGENTS AND SUBJECTS
R. Jones* (United Kingdom) - A. Woolley - R. Maclean - J. van Veen - S. Kitchen

COA33  APPROPRIATENESS OF MANAGEMENT OF TARGET SPECIFIC ANTICOAGULANTS IN AN INNER-CITY POPULATION

COA34  SPINART TRIAL 3-YEAR RESULTS: IMPROVED QUALITY OF LIFE IN ADULTS USING PROPHYLAXIS WITH BAYER’S SUCROSE-FORMULATED RECOMBINANT FACTOR VIII
J. Pocoski - C. Silverman* (USA) - T. Humphries - D. Walker - W. Hong

COA35  THE EFFECTS OF APIXABAN ON ROUTINE COAGULATION TESTS INCLUDING PROTHROMBIN TIME AND ACTIVATED PARTIAL THROMBOPLASTIN TIME
A. Lowe* (United Kingdom) - K. Hickey - R. Maclean - J. van Veen - S. Kitchen

COA36  DETERMINANTS OF ANTICOAGULATION ADHERENCE USING MORISKY MEDICATION ADHERENCE SCALE
L. A. Castellucci* (Canada) - J. Shaw - K. van der Salm - P. Erkens - M. Carrier

COA37  ANTICOAGULATION REVERSAL AND EVENT STUDY COLLABORATIVE (ARES) - INITIAL RESULTS

COA38  MEASURING DABIGATRAN WITH THE DILUTE RUSSELL VIPER VENOM CONFIRM ASSAY IN AN ANTICOAGULATION CLINIC POPULATION
D. L. McGlasson* (USA) - G. A. Fritsma - E. E. Ezzell - N. A. Anderson

COA39  MEASURING NEW ORAL ANTICOAGULANTS IN THROMBIN GENERATION ON CEVERON® ALPHA
N. Binder - L. Wagner* (Austria) - A. Olteanu
| COA40 | CHARACTERIZATION OF THE POPULATION PHARMACOKINETICS OF BAYER’S RFVIII-FS IN PHASE I/II SHOWS THAT CLEARANCE IS AFFECTED BY LEAN BODY WEIGHT AND VON WILLEBRAND FACTOR | D. Garmann* (Germany) - A. Shah - S. McLeay - P. Vis - B. Ploeger |
| COA41 | SWITCHING FROM DABIGATRAN OR RIVAROXABAN TO EDOXABAN: A BIOMARKER ASSESSMENT IN HEALTHY SUBJECTS | D. A. Parasrampuria* (USA) - D. Weilert - J.-F. Maa - V. Dishy - J. Kochan - M. Shi - K. S. Brown |
| COA42 | INFLAMMATORY AND THROMBOTIC RESPONSE TO ARTHROPLASTY IN PATIENTS UNDERGOING TOTAL HIP/KNEE ARTHROPLASTY | D. Syed* (USA) - A. Banos - W. Hopkinson - P. Bacher - H. Rees - D. Hoppensteadt - S. Abro - J. Fareed |
| COA43 | DILUTE FII/X PROTHROMBIN TIME AS A SINGLE TEST TO ASSESS THE ANTICOAGULANT EFFECT OF WARFARIN, DABIGATRAN AND RIVAROXABAN | L. R. Letertre - B. R. Gudmundsdottir - P. T. Onundarson* (Iceland) |
| COA44 | ASSESSMENT OF RIVAROXABAN AND EDOXABAN ON AUTOMATED ANALYZERS USING A LIQUID ANTI-XA ASSAY FOR APIXABAN | Z. Cao* (USA) - C. Kung - R. Bottenus - M. Triscott |
| COA45 | MEAN NORMAL PROTHROMBIN TIME DETERMINATION FOR USE IN THE PT INR CALCULATION: METHODS OF VERIFICATION AND PICKING THE “RIGHT” NUMBER | R. Pruthi - J. I. Tange* (USA) - K. Fylling - D. Chen |
| COA46 | UPPER EXTREMITY DEEP VEIN THROMBOSIS: A LONGITUDINAL FOLLOW-UP | M. T. Desancho* (USA) - K. Shillingford |
| COA47 | TISSUE FACTOR PATHWAY INHIBITOR (TFPI) IN PATIENTS WITH SEPSIS RECEIVING PROPHYLACTIC ENOXAPARIN | A. M. Abdelgadir* (Saudi Arabia) and Hadeel A Al Otair, Syed M Khurshid, AbdulAziz A. Alzeer, Abdul-Kareem AlMomen, Mashael AlShaikh, Farja Al Gahtani, Zuhair AlAssiri, Hossam A.H. Abdelrazik |
| COA50 | COMPARISON OF LOCAL AND SYSTEMIC INFLAMMATORY, FIBRINOLYTIC AND HEMOSTATIC PARAMETERS IN PATIENTS WITH VARICOSE VEINS | M. Jezovnik* (Slovenia) - D. Syed - D. Hoppensteadt - P. Poredos - S. Tetik - J. Fareed |

**Disseminated Intravascular Coagulation**

| DIC01 | ISOLATED A2 DOMAIN OF VON WILLEBRAND FACTOR THAT BINDS TO FIBRIN INHIBITS MICROVASCULAR THROMBOSIS AND REDUCES MORTALITY OF MICE WITH ENDOTOXEMIA-INDUCED DISSEMINATED INTRAVASCULAR COAGULATION | M. A. Cruz* (USA) - T. Nguyen - F. Gushiken - J.-F. Dong - P. Thiagarajan - S. Dasgupta |
DIC02  DISSEMINATED INTRAVASCULAR COAGULATION SCORING SYSTEM IN CARDIAC SURGERY PATIENTS WITH POSTOPERATIVE SEVERE SEPSIS
E. Rogalskaya* (Russian Federation) - N. Samsonova - L. Climovich - M. Yaroustovsky - N. Krotenko

DIC03  TRACKING PROGRESSION OF LPS INDUCED DISSEMINATED INTRAVASCULAR COAGULOPATHY USING A NATIVE WHOLE BLOOD THROMBIN GENERATION ASSAY
C. K. Baumgartner* (USA) - J. G. Mattson - Q. Shi - R. R. Montgomery

DIC04  UTILITY OF SOLUBLE FIBRIN MONOMER COMPLEX (SFMC) IN THE LABORATORY EVALUATION OF DISSEMINATED INTRAVASCULAR COAGULATION (DIC)
R. Pruthi - L. Cardel* (USA) - K. McGaffrey - D. Chen - J. Heit

DIC05  UP-REGULATION OF A NOVEL INFLAMMATORY MEDIATOR, ENDOCAN, IN PATIENTS WITH SEPSIS ASSOCIATED COAGULOPATHY
J. Fareed* (USA) - D. Syed - D. Hoppensteadt - M. Mosier - C. Low - M. George - D. VanThiel

DIC06  IMMUNITY-COAGULATION INTERFACE IN PATIENTS WITH STEVENS-JOHNSON SYNDROME/TOXIC EPIDERMAL NECROLYSIS
O. M. Iqbal* (USA) - D. Syed - J. Malais - M. Mosier - S. Abro - D. Hoppensteadt - A. Lin - C. Mata - J. Fareed - C. Bouchard

DIC07  THE INTENSITY OF THE INTRAVASCULAR MICROCOAGULATION AT THE PATIENTS WITH ATEROTHROMBOSIS AND THROMBOPHILIA

EHF02  EVIDENCE THAT EXTRAVASCULAR HUMAN FACTOR IX INFLUENCES PHARMACOKINETICS IN HEMOPHILIC B DOGS

EHF03  COMPARISON OF EFFICACY AND SAFETY BETWEEN ARYOGEN RECOMBINANT ACTIVATED FACTOR VII (ARYOSEVEN™) AND NOVOSEVEN® IN THE MAIN ON-LABEL (APPROVED) INDICATIONS OF RECOMBINANT ACTIVATED FACTOR VII IN IRAN

EHF04  IMPAIRMENT OF PLASMA CLOTTING BY CRYSTALLOID SOLUTIONS IS RELATED TO IONIC STRENGTH AND PRESENCE OF CHLORIDE IONS
G. Ogweno* (Kenya)

EHF05  ASSESSMENT OF PROTEIN AGGREGATES AND SUB-VISIBLE PARTICLES IN DIFFERENT RECOMBINANT FVIII PREPARATIONS
M. Malisauskas - C. Lubich - T. Prenninger - P. Matthiessen - P. Turecek - F. Scheiflinger - B. M. Reipert* (Austria)

EHF06  THE LABORATORY MEASUREMENT OF A GLYCOPEGLYLATED RECOMBINANT FVIII, N8-GP: A TWO CENTRE STUDY
A. Bowyer* (United Kingdom) - A. Hillarp - M. Persson - M. Ezban - P. Persson - S. Kitchen
Factor VIII and IX

FEN01 IN VIVO SELECTION OF GENETICALLY MANIPULATED PLATELETS CORRECTS MURINE HEMOPHILIC PHENOTYPE AND INDUces IMMUNE TOLERANCE EVEN USING A LOW MULTIPLICITY OF INFECTION FOR TRANSDUCTION J. A. Schroeder - Y. Chen - J. Fang - D. A. Wilcox - Q. Shi* (USA)

FEN02 REVASCULARIZATION STRATEGIES AND IN-HOSPITAL OUTCOMES IN ACUTE CORONARY SYNDROMES (ACS) COMPLICATED BY HEMOPHILIA A (HA) OR B (HB) M. J. Reilley* (USA) - A. Blair - W. H. Matthai - R. Vega - P. A. Gimotty - P. Fogarty

FEN03 RISK OF INHIBITOR DEVELOPMENT IN PREVIOUSLY TREATED PATIENTS WITH POSITIVE INHIBITOR HISTORY OR LOW TITER OF INHIBITOR AT BASELINE: RESULTS OF A SURVEY OF HEMOPHILIA EXPERTS M. Marcucci* (Canada) - K. Fisher - G. Kenet - G. Young - I. Walker - L. Thabane - A. Iorio


FEN05 APTT REAGENTS DO NOT INTERFERE WITH THE HEAT/COLD MODIFIED FIX BETHESDA ASSAY FOR DETECTION OF INHIBITORS IN SAMPLES WITH PEGYLATED FIX A. Millner* (Denmark) - H. T. Boesen
FEN06 POST TRANSLATIONAL MODIFICATIONS AND PHARMACOKINETICS OF RECOMBINANT FACTOR IX (RFIX) DERIVED FROM HEK293 AND CHO, AND PLASMA-DERIVED (PD) FIX
E. Böhm - B. Seyfried - M. Dockal* (Austria) - M. Hasslacher - W. Höllriegel - M. Kaliwoda - P. L. Turecek - E. M. Muchitsch - F. Scheiflinger

FEN07 HIGHLY DISCREPANT INHIBITOR TITRES IN THE BETHESDA ASSAY AS A FUNCTION OF FVIII SOURCE: PLASMA VERSUS ISOLATED FVIII
M. I. Bravo* (Spain) - B. Da Rocha-Souto - S. Grancha - J. I. Jorquera

FEN08 EFFECT OF APTT REAGENTS ON FACTOR XI ACTIVATION AND THROMBIN GENERATION IN ONE-STAGE CLOTTING ASSAYS AND ITS CORRELATION WITH FACTOR IX PRODUCT ACTIVITY DETERMINATION
Y. Buyue* (USA) - J. M. Sommer

FEN09 IDENTIFICATION OF BINDING PARTNERS FOR B DOMAIN OF FVIII BY YEAST TWO HYBRID SCREEN

FEN10 SENSITIVITY AND VARIABILITY OF THE THROMBIN GENERATION ASSAY USING RECOMBINANT FACTOR VIII (TUROCTOCOG ALFA) AND FACTOR IX, AND THEIR GLYCOPEGULYLATED DERIVATIVES WITH EITHER TISSUE FACTOR OR FACTOR XIA TO TRIGGER THE REACTION
E. Waters* (Denmark) - I. Hilden - B. Sørensen - M. Ezban - P. Holm

FEN11 COMPARISON BETWEEN SPIKED AND POST-INFUSION SAMPLES OF N9-GP EVALUATED BY ELISA, ONE-STAGE CLOT ASSAY AND CHROMOGENIC ASSAY
M. H. Sørensen* (Denmark) - S. Andersen - M. Ezban

FEN12 FEASIBILITY OF HIGH THROUGHPUT RAPID TURNAROUND MUTATIONAL ANALYSIS FOR PATIENTS WITH HEMOPHILIA USING DRIED BLOOD SPOTS
S. L. Carpenter* (USA) - E. G. Farrow - N. Miller - L. Amos - M. Gibson - S. Streeter - B. Yoo - S. Herd - S. Soden - S. Kingsmore

FEN13 LATEST RESULTS FROM THE PUP-GCP CLINICAL TRIAL: A LOW INHIBITOR RATE IN PREVIOUSLY UNTREATED PATIENTS WITH SEVERE HEMOPHILIA A TREATED WITH OCTANATE
A. Klukowska - M. Jansen - V. Komrska - P. Laguna - V. Vdovin - S. Knaub* (Switzerland)

FEN14 IN-VITRO CHARACTERISATION OF THE FIRST PLASMA DERIVED FACTOR V CONCENTRATE IN DEVELOPMENT
A. S. Lawrie - C. Berbenni - I. Nardini - I. Mackie - S. Machin - F. Peyvandi* (Italy)

FEN15 COMPARISON OF RIXUBIS WITH ANOTHER RECOMBINANT FACTOR IX PRODUCT FOR FUNCTION, SAFETY AND EFFICACY WITH FOCUS ON FACTOR IXA CONTENT

FEN16 INVESTIGATION OF HEMOSTASIS AND FIBRINOLYSIS IN FVIII-SENSITIVE THROMBOELASTOMETRY
M. Palige - S. Knappe - F. Scheiflinger - M. Dockal* (Austria)

FEN17 A GENERIC VERSION OF RECOMBINANT FACTOR VIIA IS COMPARABLE TO THE BRANDED PRODUCT (NOVOSEVEN)
N. Sadeghi* (USA) - D. Kahn - W. Jeske - D. Hoppensteadt - R. Wahl - J. Fareed
FEN18 COMPARISON OF RIXUBIS WITH ANOTHER RECOMBINANT FIX PRODUCT FOR BEHAVIOR IN CHROMOGENIC AND 1-STAGE CLOTTING ASSAYS USING DIFFERENT APTT REAGENTS
H. Gritsch - S. Romeder-Finger - F. Scheiflinger - P. L. Turecek* (Austria)

FEN19 MOLECULAR PROFILE AND PROTHROMBIN COMPLEX ACTIVATION STUDIES ON A BRANDED FACTOR VIIA AND A BIOSIMILAR PRODUCT
D. Kahn* (USA) - N. Sadeghi - D. Hoppensteadt - J. Fareed - J. Fareed

FEN20 VARIABILITY IN THE THROMBOPLASTIN-MEDIATED THROMBIN GENERATION IN COMMERCIALY AVAILABLE PROTHROMBIN COMPLEX CONCENTRATES
J. Fareed* (USA) - N. Sadeghi - W. Jeske - D. Hoppensteadt - R. Wahi

FEN21 OBSERVATIONAL IMMUNE TOLERANCE INDUCTION RESEARCH PROGRAM (OBSITI) – A MULTIFACETED APPROACH TO EXPLORE IMMUNE TOLERANCE INDUCTION

FEN22 IMPACT OF CORN TRYSIN INHIBITOR (CTI) ON THE THROMBIN GENERATION ASSAY OF PLASMA SAMPLES COLLECTED FROM A PHASE 3 MULTI-CENTER CLINICAL TRIAL IN SEVERE HEMOPHILIA A SUBJECTS
Y. Buyue* (USA) - H. Jiang - A. Brennan - J. M. Sommer

FEN23 LARGE EXTERNAL QUALITY ASSESSMENT SURVEY ON THROMBIN GENERATION WITH CAT: FURTHER EVIDENCE FOR THE USEFULNESS OF NORMALISATION WITH EXTERNAL REFERENCE PLASMA
J. Perrin* (France) - F. Depasse - T. Lecompte and French-speaking CAT Club

FEN24 PERSONALIZING PROPHYLACTIC TREATMENT IN ADULT PATIENTS WITH SEVERE HAEMOPHILIA A
R. Klamroth - T. Lissitchkov - O. Walter - S. Knaub - J. Bichler* (Switzerland) - A. Tiede

FEN25 ANTI-INHIBITOR COMPLEX CONCENTRATE PROPHYLAXIS IN HAEMOPHIACS WITH INHIBITORS
O. B. Zulfikar* (Turkey) - B. Koc - N. Ozdemir

FEN26 THE COHERENCE OF MENORRHAGIA AND RARE BLEEDING DISORDERS
S. Halimeh* (Germany) - H. Rott - G. Kappert - M. Siebert

FEN27 ACUTE DEEP CEREBRAL VENOUS THROMBOSIS ASSOCIATED WITH CEREBRAL HEMORRHAGE IN AN ELDERLY FEMALE: A CASE REPORT

FEN28 ANALYSIS OF CALRETICULIN MUTATIONS IN CHINESE PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA: CLINICAL IMPLICATIONS IN DIAGNOSIS, PROGNOSIS AND TREATMENT

FEN29 MOLECULAR GENETIC ANALYSIS OF GLANZMANN THROMBASTHENIA IN PAKISTANI COHORT REVEALS NOVEL MUTATIONS
M. Borhany* (Pakistan) - A. R. Haghighi - J. Sayer - N. Fatima - T. Shamsi
FEN30 IMPACT OF ADAMT13 DEFICIENCY ON THE PATHOGENESIS AND TREATMENT OF THROMBOTIC THROMBOCYTOPAENIC PURPURA (TTP): A SYSTEMATIC REVIEW
S. Abegunde* (Nigeria)

FEN31 THE VALIDITY OF ALGORITHMS FOR IDENTIFYING SUSPECTED AND CONFIRMED HEPARIN-INDUCED THROMBOCYTOPENIA
V. Patel* (USA) - S. Walton - W. Galanter - T. Lee - G. Schumock - E. Nutescu

FEN32 PSYCHIATRIC DISORDER AS EXPRESSION OF BETA-THALASSEMA INTERMEDIA
V. Olaya* (Colombia) - M. F. Alvarez - R. Restrepo - G. Gomez - K. Galvez

Factor XI and the Contact System

FNCS01 CHARACTERIZATION AND DEVELOPMENT OF FACTOR XIIA INHIBITORS FOR ASSAYING TISSUE-FACTOR TRIGGERED COAGULATION
V. Kolyadko* (Russian Federation) and Dr. T.A. Vuimo, Dr. S.S. Surov, Ms. R.A. Ovsepyan, Ms. V.A. Korneeva, Dr. I.I. Vorobiev, Dr. N.N. Orlova, Dr. L. Minakhin, Dr. K. Kuznedelov, Prof. K. Severinov, Prof. F.I. Ataullakhanov, Prof. M.A. Pantelev

FNCS02 A RETROSPECTIVE REVIEW OF RARE COAGULATION FACTOR DEFICIENCIES IN A TERTIARY HOSPITAL (SINGAPORE)
M. R. De Guzman - M. H. Tha - G. M. Ng - S. L. Tien * (Singapore)

FNCS03 EVALUATION OF ASSAYS FOR FXIA TO REDUCE THE THROMBOTIC RISK OF IMMUNOGLOBULINS
Y. Liang* (USA) - S. A. Woodle - M. Weinstein - T. K. Lee - D. Scott - M. V. Ovaneso

Factor XIII and Fibrinogen

FF01 IDENTIFICATION OF SEQUENCE VARIATIONS IN FIBRINOGEN GENES CAUSING HAEMORRHAGIC OR THROMBOTIC DIATHESIS
M. Ekhlasi-Hundrieser - C. Halves - C. Detering - M. von Depka* (Germany)

FF02 CONGENITAL FIBRINOGEN DEFICIENCY IN PAKISTAN AND IDENTIFICATION OF FIVE NOVEL MUTATIONS

FF03 IDENTIFICATION OF NOVEL MUTATIONS IN FIBRINOGEN GENE ALPHA(FGA) AND FREQUENCY OF MUTATIONS IN PAKISTANI POPULATION

FF04 MEASURING PLASMA FIBRINOGEN LEVELS BELOW 40 MG/DL USING THE STA®-LIQUID FIB REAGENT
M. Grimaux* (France) - C. Carrion - D. Chtourou - A. Magdelaine - F. Nicham - C. Mazet

FF05 CLINICALLY RELEVANT DISCREPANCIES BETWEEN FIBRINOGEN ANALYSIS METHODS IN PATIENTS UNDERGOING THROMBOLYTIC THERAPY FOR ACUTE IlioFemoral Deep Venous Thrombosis
Fibrinolysis

FBL01 DIFFERENTIAL EFFECT OF DABIGATRAN, RIVAROXIBAN AND APIXABAN ON THROMBOMODULIN MEDIATED ACTIVATION OF PROTEIN C AND THROMBIN ACTIVATED FIBRINOLYSIS INHIBITOR (TAFI) MAY IMPACT THEIR SAFETY AND EFFICACY PROFILES
D. Hoppensteadt* (USA) - J. Harenberg - B. Lewis - J. Fareed

FBL02 PURIFICATION AND CHARACTERISATION OF NOVEL ENZYMES WITH ANTIPLATELET AND ANTICOAGULANT ACTIVITIES FROM SNAKE VENOM
B.-E. Jugder* (Mongolia) - P. Dashnyam - B. Buyanbadrakh - S. Byambasuren - A. Buyanbat - T. Purev

FBL04 INTRODUCTION OF A POINT OF CARE D-DIMER EQA PROGRAMME TO INCLUDE ASSESSMENT OF TESTING AND POST ANALYTICAL INTERPRETATION OF RESULTS

FBL05 MST-188 INCREASES RATES OF FIBRIN ASSEMBLY AND SUBSEQUENT UROKINASE/TPA-MEDIATED LYSIS IN VITRO
D. Syed* (USA) - M. Emanuele - D. Hoppensteadt - J. Fareed

Hemostasis and Malignancy

HM01 FACTOR VII DERIVED EGFP-EGF1 PROTEIN MEDIATE DRUG DELIVERY SYSTEM TO TF-HIGHLY EXPRESSING TUMORS
B. Zhang* (China) - Y. Hu

HM02 THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR GENE POLYMORPHISM G-438A IS ASSOCIATED WITH VENOUS THROMBOEMBOLISM IN CANCER PATIENTS: A CASE-CONTROLLED STUDY
Y.-B. Yu* (Taiwan, Province of China) - J.-P. Gau - H.-C. Hsu - C.-H. Tseng - T.-S. Lee

HM03 STUDY OF SNAKE VENOM DERIVED ANTI-PLATELET AGENTS
A. Buyanbat* (Mongolia) - B.-E. Jugder - P. Dashnyam - B. Buyanbadrakh - S. Byambasuren - T. Tseveg

HM04 CHEMOTHERAPY ASSOCIATED THROMBOCYTOPENIA IN BREAST CANCER PATIENTS: A RETROSPECTIVE HOSPITAL-BASED COHORT STUDY

HM05 PLATELET-MICROPARTICLES (PMP) IN ESSENTIAL THROMBOCYTHEMIA (ET): CHARACTERIZATION OF PROCOAGULANT AND PROANGIOGENIC ACTIVITIES

HM06 PRO-COAGULANT PROPERTIES OF PROSTATE CANCER CELL LINES AND THE EFFECT OF ANDROGEN DEPRIVATION
B. Sterniczuk - M. Toukh - H. Kaur - S. Barr - R. Siemens - C. Graham - M. Othman* (Canada)

HM07 INFERIOR VENA CAVA FILTER USAGE, COMPLICATIONS AND RETRIEVAL RATE IN CANCER PATIENTS
Lupus and Anticoagulant/Phospholipid

LA01 SOLID PHASE ASSAYS IN ANTIPHOSPHOLIPID SYNDROME (APS): VARIATION BETWEEN RESULTS AMONGST UK NEQAS (BLOOD COAGULATION) PARTICIPANTS

LA02 “WEAK” EFFECTS SHOWED SIMILAR CHANCES OF BEING CONFIRMED AS POSITIVE LUPUS ANTICOAGULANT (LA) AS THOSE WITH STRONG EFFECTS ON DRVVT

LA03 ACTIVATED PROTEIN C RESISTANCE DETECTED BY THE CALIBRATED AUTOMATED THROMBOGRAM AS THE MOST PREVALENT PROTHROMBOTIC FACTOR IN PATIENTS WITH EARLY MANIFESTATIONS OF VENOUS THROMBOEMBOLISM

Pediatric/Neonatal Hemostasis and Thrombosis

PHT01 VENOGRAPHY (VE) IN CHILDREN WITH CLINICAL ASSESSMENT OF POST-THROMBOTIC SYNDROME (PTS) FOLLOWING UPPER VENOUS SYSTEM THROMBOTIC EVENT (UVSTE)

PHT02 DEVELOPMENT OF A NEW RISK MODEL FOR HOSPITAL-ASSOCIATED VENOUS THROMBOEMBOLISM (HA-VTE) IN THE PEDIATRIC INTENSIVE CARE UNIT (PICU): FINDINGS FROM A LARGE SINGLE-INSTITUTIONAL CASE-CONTROL STUDY
PHT03  ITEM REDUCTION ANALYSIS OF THE SELF-PBQ (SELF-ADMINISTERED PEDIATRIC BLEEDING QUESTIONNAIRE): HEALTHY CHILDREN AND CHILDREN PREVIOUSLY DIAGNOSED WITH TYPE 1 VON WILLEBRAND DISEASE (VWD)

PHT04  IDIOPATHIC THROMBOSIS IN TEENAGERS: THE ROLE OF THROMBOPHILIA
A. Ryan* (Australia) - P. Monagle - F. Newall

PHT06  FV DEFICIENCY PATIENTS: NO CORRELATION OF PHENOTYPE WITH FACTOR ACTIVITY AND REPORT OF 3 NEW MUTATIONS IN EGYPTIAN CHILDREN
M. Abdelwahab* (Egypt) - D. Stefano - R. Asselta - E. M. Paraboschi - F. Peyvandi

PHT07  ACQUIRED FVII DEFICIENCY AND GLOMERULOPATHY IN EGYPTIAN CHILDREN: A REPORT OF 5 CASES...AN ASSOCIATION AND/OR AN IMMUNE TRIGGERED PHENOMENON
M. Abdelwahab* (Egypt) - H. Bazarra

PHT08  EFFECT OF 22Q11.2 DELETION ON BLEEDING RISK FOLLOWING CARDIAC SURGERY IN CHILDREN WITH CONGENITAL HEART DISEASE

PHT09  DALTEPARIN TREATMENT FOR ACUTE PEDIATRIC VENOUS THROMBOEMBOLISM: A MULTICENTER DOSE-FINDING, SAFETY, AND EFFICACY STUDY

PHT10  HEIGHT AND AGE HAVE MORE IMPACT ON ANTI-VITAMIN K ANTAGONIST DOSE REQUIREMENT THAN VKORC1 GENOTYPE IN CHILDREN/PAEDIATRIC PATIENTS

PHT11  UTILITY OF THROMBOPHILIA SCREENING IN CHILDREN AWAITING KIDNEY TRANSPLANTATION
R. Bhat* (USA) - M. Bock - A. Bobrowski

PHT12  RISK FACTORS FOR HOSPITAL-ASSOCIATED VENOUS THROMBOEMBOLISM IN THE NEONATAL INTENSIVE CARE UNIT

PHT13  SITE, RECURRENCES AND OUTCOMES OF DEEP VEIN THROMBOSIS IN NEONATES AND CHILDREN

PHT14  WHOLE BLOOD VERSUS RECONSTITUTED WHOLE BLOOD FOR CARDIOPULMONARY BYPASS SURGERY IN INFANTS

PHT15  USE OF WARFARIN ORAL SUSPENSION FOR ANTITHROMBOTIC THERAPY AND PREVENTION OF THROMBOSIS IN INFANTS AND CHILDREN
<table>
<thead>
<tr>
<th>Abstract ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCI01</td>
<td>CORN TRYPsin INHIBitor NON-LOOP REGIONS ARE REQUIRED FOR THE SPECIFIC INHIBITION OF FACTOR XIIa</td>
<td>V. Korneeva* (Russian Federation) and Mikhail M. Trubetskoy, Alena V. Korshunova, Vladimir N. Kolyadko, Mikhail A. Panteleev, Fazoi I. Ataullakhanov</td>
</tr>
<tr>
<td>PCI02</td>
<td>MEASUREMENT OF PLASMA AND PLATELET TISSUE FACTOR PATHWAY INHIBITOR (TFPI) IN BLOOD DONORS</td>
<td>P. Ellery* (USA) - C. Augustsson - S. Maroney - J. Wood - L. Peterson - I. Hilden - A. Mast</td>
</tr>
<tr>
<td>PCI03</td>
<td>UNFRACtionATED AND LOW MOLECULAR WEIGHT HEPARINS, BUT NOT FONDAPARI NuX, BLOCK INHIBITION OF PROTHROMBINASE BY TFPI-ALPHA</td>
<td>J. Wood* (USA) - L. M. Baumann Kreuziger - R. M. Camire - A. E. Mast</td>
</tr>
<tr>
<td>PCI04</td>
<td>RISK FACTORS OF THROMBOSIS IN AN AFRICAN POPULATION</td>
<td>A. O. Touré* (Senegal)</td>
</tr>
<tr>
<td>PCI05</td>
<td>PROTEIN Z INTRON FG79A POLYMORPHISM S ARE NOT ASSOCIATED WITH HYPERLIPIDEMIA</td>
<td>H.-Y. Hua* (China) - S.-L. He - M.-X. He</td>
</tr>
<tr>
<td>PCI06</td>
<td>A NEW REPORT OF FVII-INHIBITOR IN A PATIENT SUFFERING FROM SEVERE CONGENITAL FVII DEFICIENCY</td>
<td>M. Borhany* (Pakistan) - C. Delbes - M. Giansily-Blaizot - M. Zubair - N. Fatima - T. S. Shamsi</td>
</tr>
<tr>
<td>PCI08</td>
<td>TIMING OF CORN TRYPsin INHIBiTOR TO PLATELET POOR PLASMA ALTERS THRoMIN GENERATION</td>
<td>M. S. Park* (USA) - A. Xue - J. K. Rosedahl - W. S. Harmsen - M. M. Kuntz - J. A. Heit</td>
</tr>
<tr>
<td>PCI09</td>
<td>INTERIM RESULTS FROM THE PROSPECTIVE OBSERVATIONAL STUDY ON NOVOSEVEN® ROOM TEMPERATURE STABLE (VII25) IN PATIENTS WITH HEMOPHILIA A OR B</td>
<td>K. Kavakli* (Turkey) - P. Arkhammar - G. Benson - H. Chambost - F. De Martis - A. Rosholm</td>
</tr>
<tr>
<td>PCI11</td>
<td>TECHNOClOT® PROTEIN S - A NEW SIMPLIFIED ASSAY FOR THE DETERMINATION OF PROTEIN S ACTIVITY</td>
<td>N. Binder* (Austria) - M. Leitner - M. Riha</td>
</tr>
</tbody>
</table>
PCI14 INVESTIGATING DETERMINANTS OF INHIBITOR DEVELOPMENT TO FACTOR VIII MOLECULES IN PREVIOUSLY TREATED HEMOPHILIA A PATIENTS

Platelet Immunology

PI01 THE EFFECTS OF DIFFERENT B-CELL ACTIVATING FACTOR RECEPTORS ON LYMPHOCYTE FUNCTION AND SECRETION OF CYTOKINES IN IMMUNE THROMBOCYTOPENIA
Y. Min* (China) - Y. Shi

PI02 STANDARDIZATION OF THE NOD SCID MOUSE MODEL FOR THE ASSESSMENT OF ANTIBODY-MEDIATED THROMBOCYTOPENIA
J. Fuhrmann* (Germany) - H. Zöllner - J. Wesche - A. Greinacher - T. Bakchoul

PI03 P-SELECTIN BASED FUNCTIONAL PLATELET FLOW CYTOMETRY ASSAY FOR HEPARIN-INDUCED THROMBOCYTOPENIA (HIT): PLATELET DONOR VARIABILITY AND LABORATORY SELECTION CRITERIA FOR IDENTIFYING ADEQUATE DONORS
D. Warad* (USA) - R. Miller - R. He - D. Chen - W. L. Nichols - R. K. Pruthi

PI04 REGULATION OF PLATELET AND NEUTROPHIL INTERACTION IN THE FORMATION OF DNA EXTRACELLULAR TRAPS
A. Carestia* (Argentina) - L. Rivadeneyra - L. P. D’Atri - S. Negrotto - M. Schattner

PI05 VARIABLE IMPACT OF NORMAL IGG SUBCLASSES ON HEPARIN-DEPENDENT PLATELET AGGREGATION INDUCED BY A HIT MONOClonAL ANTIBODY ACCORDING TO FCGAMMA11A H131R POLYMORPHISM
J. Rollin* (France) - C. Pouplard - A. Saada - V. Gouilleux-Gruard - G. Thibault - Y. Gruel

PI06 RAPID DETECTION OF IGG, IGA, IGM ANTIBODIES ASSOCIATED WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT)
M. J. Sullivan* (USA) - S. Grady - J. G. McFarland - B. Curtis

PI07 PLATELET-ACTIVATING HIT ANTIBODIES BIND PREFERENTIALLY TO PF4 TREATED PLATELETS IN THE ABSENCE OF HEPARIN: IMPLICATIONS FOR HIT PATHOGENESIS
A. Padmanabhan* (USA) - C. Jones - D. Bougie - B. Curtis - J. McFarland - D. Wang - R. Aster

PI08 RATIONALE FOR THE USE OF NEWER ORAL ANTICOAGULANTS IN THE LONG TERM MANAGEMENT OF HEPARIN INDUCED THROMBOCYTOPENIA
J. Fareed* (USA) - D. Hoppensteadt - E. Kalodiki - J. M. Walenga - B. Lewis

PI09 EVIDENCE THAT CLOPIDOGREL METABOLITES CAN TRIGGER DRUG-INDUCED IMMUNE THROMBOCYTOPENIA (DITP)
D. Bougie* (USA) - D. Nayak - R. H. Aster

PI10 SEROTONIN RELEASE ASSAY AND FLOW CYTOMETRIC ASSAY IN THE DIAGNOSIS OF HIT BASED ON EXPERTS’ OPINION
B. Tardy* (France) - B. Tardy - A. Montmartin - M. Piot and HIT Study Group
Platelet Physiology

PP01 MORPHOLOGICAL DISTINCTION UNRAVELS MECHANISMS OF PLATELET BIOGENESIS FROM BONE MARROW MEGAKARYOCYTES
S. Nishimura* (Japan) - K. Eto - R. Nagai

PP02 PHOSPHORYLATION OF CLEC-2 BY SRC-FAMILY KINASES IS ESSENTIAL FOR ANTI-CLEC-2 ANTIBODY-INDUCED RECEPTOR INTERNALIZATION
V. Lorenz* (Germany) - D. Stegner - S. Stritt - B. Walzog - F. Kiefer - B. Nieswandt

PP03 COMBINED DEFICIENCY OF PLATELET ALPHA AND DENSE GRANULE RELEASE ABROGATES PLATELET AGGREGATION AND ADHESION BUT HAS NO EFFECT ON VASCULAR INTEGRITY UPON INFLAMMATION
C. Deppermann* (Germany) - K. Wolf - D. Stegner - B. Nieswandt

PP04 AN ESSENTIAL ROLE OF THE INHIBITORY FC GAMMA RECEPTOR IIB IN ANTIBODY-INDUCED GLYCOPROTEIN VI ECTODOMAIN SHEDDING IN VIVO
D. Stegner* (Germany) - M. Popp - S. Dütting - V. Lorenz - J. E. Gessner - B. Nieswandt

PP05 THROMBUS DEVELOPMENT PROCESSES DEPENDENT ON ENDOTHELIAL INJURIES: VISUALIZED BY IN VIVO TWO-PHOTON IMAGING
S. Nishimura* (Japan) - R. Nagai - K. Eto

PP06 PSI DOMAIN OF B3 INTEGRIN CONTAINS ENDOGENOUS THIOL ISOMERASE FUNCTION THAT CAN BE INHIBITED BY A PDI INHIBITOR BACITRACIN AND ANTI-PSI MONOCLONAL ANTIBODIES

PP07 ARGINASE II KO REDUCES PLATELET AGGREGATION WHILE SPARING COAGULATION IN AGED MICE

PP08 ESCITALOPRAM MODIFIES PLATELET CYTOSKELETAL ASSEMBLY AND HAS A DIRECT INHIBITORY EFFECT ON THROMBIN-INDUCED ACTIVATION
I. Lopez-Vilchez* (Spain) - M. Diaz-Ricart - P. Molina - V. Sanz - J. G. White - C. Gasto - G. Escolar

PP09 ELEVATED IMMATURE PLATELET FRACTION (IPF) IS USEFUL FOR IDENTIFYING MYH9 RELATED DISORDERS: A REPORT OF TWO CASES
R. A. Higgins - A. Moritz* (USA) - K. Holder - J. Olson

PP10 COMPARISON OF FISH OIL AND CORN OIL ON THE THROMBIN GENERATION OF PLATELET-RICH PLASMA AS MEASURED BY THE CALIBRATED AUTOMATED THROMBOGRAM
J. Harbert* (USA) - K. Pagano - D. Heartfield - M. Ero

PP11 EVALUATION OF PLATELETS SURFACE MORPHOLOGY AND THEIR LOCAL ELASTIC PROPERTIES IN PATIENTS WITH IMPLANTED HEART VENTRICLE IN THE EARLY AND LATE POSTOPERATIVE PERIOD BY AFM
L. Drozd* (Italy) - L. Kukharenko - T. Schimmel - S. Chizhik - N. Maroz-Vadalashskaya

PP12 NOD2 RECEPTOR IS EXPRESSED IN PLATELETS AND ENHANCES PLATELET ACTIVATION AND THROMBOSIS
PAIRED IMMUNOGLOBIN-LIKE RECEPTOR B REGULATES
PLATELET ACTIVATION
X. Fan* (China) - P. Shi - J. Dai - J. Liu

EFFECTS OF GARLIC (ALLIUM SATIVUM) ON SOME
HAEMATOLOGICAL PARAMETERS USING NEW ZEALAND WHITE
RABBITS
A. A. Rose* (Nigeria)

IDENTIFICATION OF THE
MECHANOSENSORY DOMAIN IN
THE PLATELET MECHANOSENSOR
GPIB-IX COMPLEX
(USA)

MACROTROMBOCYTOPENIA OF
CASES WITH TUBB1 MUTATIONS
IDENTIFIED IN THE BRIDGE
COHORT
P. Nurden* (France)

IN VITRO EFFECT OF
PROCOAGULANT AND
ANTIFIBRINOLYTIC AGENTS
ON BLOOD CLOT QUALITY AND
STABILITY IN A MODEL OF SEVERE
THROMBOCYTOPENIA
B. Shenkman* (Israel) - Y. Einav - T. Livnat - U. Martinowitz

EVALUATION OF LIGHT TRANSMISSION AGGREGOMETRY
(LTA) PROCEDURES AND VARIATIONS BETWEEN
LABORATORIES IN THE
NETHERLANDS.
Y. Henskens* (The Netherlands) - P. Verhezen - E. van Wijk - C. Hudig - A. Stroobants - D. van de Kerkhof

THERAPEUTIC PLATELET-RICH
PLASMA: CHARACTERIZATION
OF PLATELET ACTIVATION AND
PROCOAGULANT MARKERS,
GROWTH FACTOR RELEASE, AND
CELL PROLIFERATION FOLLOWING
PULSE ELECTRIC FIELD
STIMULATION

SYSTEMATIC COMPARATIVE
ANALYSIS OF BLEEDING
PHENOTYPE IN PT-VWD AND TYPE
2B VWD USING AN ELECTRONIC
BLEEDING QUESTIONNAIRE
H. Kaur - M. Ozelo - S. Scovil - P. James - M. Othman* (Canada)

DEVELOPMENT OF A LABORATORY
MODEL OF THROMBOCYTOPENIA IN
HUMAN WHOLE BLOOD
R. S. Bercovitz* (USA) - M. K. Brenner - D. K. Newman

VALIDATION OF TWO FLOW
CYTOMETRIC METHODS TO
MEASURE PLATELET SURFACE
GLYCOPROTEIN PROTEINS
R. S. Miller* (USA) - R. Lingineni - S. C. Bryant - J. A. Heit - D. Chen

ANALYZING PLATELET THROMBUS
FORMATION UNDER ARTERIAL
BLOOD FLOW CONDITIONS
T. Ito* (Japan) - T. Nagasato - Y. Oda - K. Hosokawa - I. Maruyama

RAPID PLATELET CONCENTRATE
DELIVERY BY PNEUMATIC TUBE
SYSTEM AND PRESSURED
TRANSFUSION IS A FEASIBLE
OPTION

ROLE OF INTRACELLULAR
REACTIVE OXYGEN SPECIES
GENERATION IN PLATELET SHAPE
CHANGE
C. Terada* (Japan) - M. Satake - K. Tadokoro
Predictive Hemostatic Variables

PHV01 D-DIMER FOR THE DIAGNOSIS OF SYMPTOMATIC UPPER EXTREMITY DEEP VEIN THROMBOSIS
M. Sartori - L. Migliaccio - E. Favaretto - C. Legnani - G. Palareti - B. Cosmi* (Italy)

PHV02 HYPOXIA INDUCES A PROTHROMBOTIC STATE: RESULTS FROM THE “RED MEETS WHITE” STUDY

PHV03 THE IMPACT OF BLOOD TRANSFUSIONS AND THE AGE OF TRANSFUSED RED BLOOD CELLS ON LONG-TERM PROGNOSIS AFTER TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI)

PHV04 NEUTROPHIL EXTRACELLULAR TRAP FORMATION (NETS) IN DIABETES. CORRELATION WITH INFLAMMATORY MARKERS
A. Carestia* (Argentina) - G. Frechtel - G. Cerrone - C. Gonzalez - M. Schattner - P. Casais

PHV05 POOR RESPONSE TO THIENOPYRIDINES AND THROMBOTIC RECURRENT EVENTS IN PATIENTS WITH ISCHAEMIC HEART DISEASE

PHV06 CAN A MULTIDISCIPLINARY CARDIAC SURGERY BLOOD CONSERVATION PROGRAM SUCCEED? A SINGLE CENTER, 6 YEAR, 687 PATIENT RETROSPECTIVE BLOOD/BLOOD PRODUCT UTILIZATION REVIEW
A.D. Sharma* (USA) - D. Behrend - J. F. Secombe - A. Al-Achi - D. Nissen - R. Hummel - M. Preston

PHV07 A NOVEL FLOW CHAMBER SYSTEM FOR MODELING HUMAN VENOUS THROMBOSIS
N. Sugita* (Japan) - H. Hirakata - K. Inoue - K. Tatsumi - T. Murai

PHV08 THROMBIN GENERATION IS A PREDICTOR OF STROKE IN PATIENTS WITH NON VALVULAR ATRIAL FIBRILLATION
C. Bagot* (United Kingdom) - E. Leishman - G. Lowe - C. Tait

PHV09 OBSERVATION OF CLOT FORMATION AND LYSIS IN CONJUNCTION WITH THE THROMBIN GENERATION ASSAY
W. C. Chang* (USA) - K. Z. Xin - T. K. Lee - M. V. Ovanesov

PHV10 A LARGE-SCALE COMPARISON STUDY OF PLASMA FIBRINOGEN BY CLAUSS AND PROTHROMBIN TIME DERIVED METHODS: AN ATTEMPT TO DEFINE CRITICALLY LOW VALUE OF PROTHROMBIN TIME DERIVED FIBRINOGEN FOR BLEEDING PATIENTS WHEN CLAUSS FIBRINOGEN IS NOT READILY AVAILABLE
P. Sun* (Canada) - Q. Wang - C. Morales - M. Nasr - G. Turnbull - C. Musuka
PHV11 THE FREQUENCIES OF THROMBOPHILIC ALLELES KNOWN FROM GWAS STUDIES IN HEALTHY POPULATION AND IN GROUP OF PATIENTS WITH VENOUS THROMBOEMBOLISM (VTE) IN CZECH REPUBLIC

PHV12 DETECTION OF A HIGH RFVIIA BINDING SUBPOPULATION AND OF DONOR VARIATION IN THE INTERACTION OF ACTIVATED RECOMBINANT FACTOR VII (RFVIIA) WITH HUMAN PLATELETS BY FLOW CYTOMETRY
J. Koehn - E. Böhm - A. Sedivy - M. Dockal* (Austria) - F. Scheiflinger

PHV13 THROMBIN GENERATION AND BLOOD COAGULATION ACTIVATION IN PATIENTS WITH A TRANSIENT ISCHEMIC ATTACKS
E. Favaretto - M. Sartori - L. Migliaccio - F. Rondelli - M. Guarino - C. Legnani - G. Palareti - B. Cosmi* (Italy)

Vascular Biology

VB01 QUANTIFYING THE IMPACT OF DIET-INDUCED ATHEROSCLEROTIC PLAQUE EROSIONS ON VESSEL HYPERCOAGULABILITY WITH SEMIPERMEABLE NANOPARTICLE BEACONS

VB02 ANTI-THROMBIN NANOPARTICLES PRESERVE RENAL FUNCTION AFTER ACUTE ISCHEMIC INJURY

VB03 CYCLOSPORINE A PREVENTS REPLICATIVE SENESCENCE-RELATED ENDOTHELIAL DYSFUNCTION, PRO-THROMBOTIC AND PRO-COAGULANT RESPONSES AND MP SHEDDING IN PRIMARY CORONARY ARTERY ENDOTHELIAL CELLS

VB04 MICROPARTICLES RELEASED BY REPLICATIVE SENESCENCE IN PRIMARY ENDOTHELIAL CELLS PROMOTE PREMATURE SENESCENCE ASSOCIATED WITH AN IMPAIRED NO FORMATION AND OXIDATIVE STRESS
M. Abbas* (France) - F. Toti - F. Zobairi - B. Yver - V. Schini-Kerth - O. Morel

VB05 UTILIZATION OF ELASTIC COMPRESSION STOCKINGS (ECS) FOLLOWING FIRST EPISODE OF DEEP VENOUS THROMBOSIS (DVT): 15 YEAR EXPERIENCE AT A SINGLE VETERANS AFFAIRS MEDICAL CENTER (VAMC)
N. A. Bade* (USA) - A. Aggarwal - J. El Amm - D. Mobarek - B. O’Neill - C. Faselis - F. R. Rickles

VB06 ALTERED ENDOTHELIUM-DEPENDENT RELAXATION INDUCED BY ERYTHROCYTE MEMBRANE FROM SUBJECTS WITH DIFFERENT HAEMOGLOBIN GENOTYPES IN ISOLATED RABBIT CAROTID ARTERIES
O. I. Ajayi* (Nigeria) - W. O. Usunobun

VB07 EFFECT OF HISTONES ON ANGIOGENIC RESPONSES OF PROGENITOR AND MATURE ENDOTHELIAL CELLS
H. A. Mena* (Argentina) - M. Centurión - M. Schattner - S. Negrotto
VB08 FREQUENCY OF POST THROMBOTIC SYNDROME (PTS) IN PATIENTS WITH PROXIMAL DEEP VENOUS THROMBOSIS – A PROSPECTIVE OBSERVATIONAL STUDY FROM A TERTIARY CARE HOSPITAL IN NORTH INDIA

VB09 MIR-503 MODULATION OF NOS3 SIGNALING VIA RICTOR
M. Yamakuchi* (Japan) - T. Hashiguchi - C. J. Lowenstein

VB10 CIRCULATING ENDOTHELIAL CELLS AND PROGENITORS AS PROGNOSIS FACTORS DURING AUTO-IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA: RESULTS OF A PROSPECTIVE MULTICENTER FRENCH STUDY

VB11 RETROSPECTIVE DATABASE ANALYSIS OF THE PREVALENCE OF CARDIOVASCULAR COMORBIDITIES IN A US PATIENT POPULATION WITH HEMOPHILIA A: CONFIRMATION OF FINDINGS
J. Pocoski - R. Kamalakar - T. Humphries* (USA)

VB12 ANALYSIS OF TISSUE FACTOR PATHWAY INHIBITOR ISOFORMS ON MACRO- AND MICRO-VASCULAR ENDOTHELIAL CELLS

VB13 MICROPARTICLES INHIBIT ANGIогENIC ACTIVITIES OF MICROVASCULAR ENDOTHELIAL CELLS THROUGH A CD36 DEPENDENT SIGNALING PATHWAY INVOLVING REACTIVE OXYGEN SPECIES
D. P. Ramakrishnan* (USA) - R. L. Silverstein

VB14 ENHANCED PRESENCE ENDOTHELIAL DYSFUNCTION BIOMARKERS IN MAJOR DEPRESSION DISEASE AND PROGRESSIVE DOWN-REGULATION DURING ANTIDEPRESSANT TREATMENT

VB15 MICROPARTICLE LEVELS IN PATIENTS UNDERGOING CORONARY REVASCULARIZATION SURGERY
W. Jeske* (USA) - J. M. Walenga - V. Escalante - J. Schwartz - M. Bakhos

VB16 PROTECTIVE EFFECTS OF CONNEXINS IN ATHEROSCLEROTIC PLAQUES IN PATIENTS WITH CAROTID ARTERY STENOSIS
T. Nakase* (Japan) - T. Ishikawa - H. Miyata

Von Willebrand Factor

VWF01 MISFOLDING OF THE VON WILLEBRAND FACTOR A1 DOMAIN IN TYPE 2 VON WILLEBRAND DISEASE
M. Auton* (USA)

VWF02 ALLOSTERIC ACTIVATION OF ADAMTS13 INVOLVES CONFORMATIONAL CHANGES INDUCED BY ITS SUBSTRATE VON WILLEBRAND FACTOR
VWF03 PHENOTYPE ASSIGNMENT OF TYPE 2 VON WILLEBRAND DISEASE (VWD) VARIANTS BY A SINGLE ELISA-BASED ASSAY OF VON WILLEBRAND FACTOR (VWF) FUNCTIONS
Program Investigators

VWF04 PATIENT-DERIVED BLOOD OUTGROWTH ENDOTHELIAL CELLS FROM A TYPE 2B VON WILLEBRAND DISEASE PATIENT EXHIBIT INCREASED ANGIOGENESIS
L. Casey* (Canada) - M. Bowman - B. Umana - D. Maurice - P. James

VWF05 ASSOCIATION BETWEEN VON WILLEBRAND FACTOR AND FACTOR VIII LEVELS AND THEIR CHANGES DURING THE AGING PROCESS
S. Albánez* (Canada) - K. Ogiwara - J. Grabell - P. James - D. Lillicrap

VWF06 DIURNAL VARIATION OF VON WILLEBRAND FACTOR IN PLASMA: THE BISPEBJERG STUDY OF DIURNAL VARIATIONS

VWF07 INCREASED ACTIVE VON WILLEBRAND FACTOR AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE

VWF08 MOLECULAR CHARACTERISTICS AND RECOMBINANT PROTEIN EXPRESSION OF TYPE 2 AND TYPE 3 VON WILLEBRAND DISEASE: STUDIES OF A CHINESE COHORT OF 25 PATIENTS
J. Yin* (China) - J. SU - Z. MA - X. ZHAO - Z. WANG - Z. YU - W. OUYANG - X. BAI - C. RUAN

VWF09 EFFECT OF FACTOR VON WILLEBRAND ON FIBRIN STRUCTURE AND LYSIS
R. Marchi* (Venezuela, Bolivarian Republic Of) - H. Rojas - M. De Agrela

VWF10 GENOTYPE CHARACTERISTICS OF VON WILLEBRAND DISEASE TYPE III IN PAKISTANI PATIENTS

VWF11 IDENTIFICATION OF A NOVEL POLYMORPHISM IN P.N258 OF THE GP1BA GENE.

VWF12 CONTRIBUTION OF DEFECTIVE VON WILLEBRAND FACTOR (VWF) MULTIMERIZATION, REGULATED STORAGE, AND SECRETION TO TYPE 1C VON WILLEBRAND DISEASE (VWD)
D. A. Jakab* (USA) - P. M. Jacobi - S. L. Haberichter

VWF13 DIAGNOSIS OF VON WILLEBRAND DISEASE USING A COMPREHENSIVE PANEL OF ASSAYS INCLUDING GENE ANALYSIS BY NEXT GENERATION SEQUENCING
M. von Depka* (Germany) - C. Detering - H. Martensen - C. Halves - M. Ekhlausi-Hundrieser

VWF14 OVERLAP OF COLLAGEN 4 AND PLATELET BINDING SITES IN VWF A1 DOMAIN

VWF15 EVALUATION OF SIX COMMERCIAL VON WILLEBRAND FACTOR COLLAGEN BINDING ASSAY KITS
L. R. Rachel* (USA) - D. M. Warad - J. G. Cayou - R. K. Pruthi - D. Chen
<table>
<thead>
<tr>
<th>VWF16</th>
<th>UPDATE ON BLEEDING SCORES IN THE ZIMMERMAN PROGRAM: COMPARISON OF ISTH BAT, PBQ, AND MCMDM-1VWD SCORING SYSTEMS</th>
<th>VWF21</th>
<th>PERFORMANCE OF AN AUTOMATED LATEX PARTICLE-ENHANCED IMMUNOTURBIDIMETRIC VON WILLEBRAND FACTOR (VWF) ACTIVITY ASSAY ON SAMPLES FROM PATIENTS RECEIVING DDAVP OR VWF CONCENTRATES</th>
</tr>
</thead>
<tbody>
<tr>
<td>VWF17</td>
<td>IMPROVED DIAGNOSIS OF VWD IN AFFECTED FAMILY MEMBERS USING THE ISTH BLEEDING SCORE</td>
<td>VWF22</td>
<td>NEW INSIGHTS INTO TYPE 3 VON WILLEBRAND DISEASE: THE 3WINTERS-IPS PROJECT UPDATE</td>
</tr>
<tr>
<td></td>
<td>P. A. Christopherson* (USA) - J. C. Gill - V. H. Flood - K. D. Friedman - S. L. Haberichter - R. R. Montgomery and The Zimmerman Program Investigators</td>
<td></td>
<td>A. B. Federici* (Italy) and For the European and Iranian Investigators of 3Winters-Ips</td>
</tr>
<tr>
<td>VWF18</td>
<td>CLASSIFICATION OF PATIENTS WITH VON WILLEBRAND DISEASE AFTER SYSTEMATIC GENOTYPIC ANALYSIS</td>
<td>VWF23</td>
<td>DETERMINATION OF THE VWF ACTIVITY WITH THE RISTOCETIN INDEPENDENT GAIN OF FUNCTION GLYCOPROTEIN 1B INNOVANCE VON WILLEBRAND ACTIVITY ASSAY.</td>
</tr>
<tr>
<td>VWF19</td>
<td>EFFECT OF RECOMBINANT VON WILLEBRAND FACTOR AND FRACTIONS THEREOF ON THE PROCOAGULANT ACTIVITY OF FACTOR VIII</td>
<td>VWF24</td>
<td>FULLY AUTOMATED CHEMILUMINESCENT ASSAY FOR THE DETECTION OF VON WILLEBRAND FACTOR COLLAGEN BINDING (VWF:CB)</td>
</tr>
<tr>
<td>VWF20</td>
<td>IN VITRO CHARACTERISATION OF MISSENSE MUTATIONS LOCATED IN THE VON WILLEBRAND FACTOR (VWF) D1 DOMAIN ASSOCIATED WITH QUANTITATIVE VWF DEFICIENCY</td>
<td>VWF25</td>
<td>SECONDARY PROPHYLAXIS IN VON WILLEBRAND DISEASE WITH HIGHLY PURIFIED VWF/ FVIII CONCENTRATES: INTERIM RESULTS OF THE PRO.WILL STUDY</td>
</tr>
<tr>
<td>VWF21</td>
<td>IN VITRO CHARACTERISATION OF MISSENSE MUTATIONS LOCATED IN THE VON WILLEBRAND FACTOR (VWF) D1 DOMAIN ASSOCIATED WITH QUANTITATIVE VWF DEFICIENCY</td>
<td>VWF26</td>
<td>ACQUIRED VON WILLEBRAND DISEASE SYNDROME ASSOCIATED WITH KLEBSIELLA PNEUMONIAE INFECTION</td>
</tr>
<tr>
<td>VWF22</td>
<td>PERFORMANCE OF AN AUTOMATED LATEX PARTICLE-ENHANCED IMMUNOTURBIDIMETRIC VON WILLEBRAND FACTOR (VWF) ACTIVITY ASSAY ON SAMPLES FROM PATIENTS RECEIVING DDAVP OR VWF CONCENTRATES</td>
<td>VWF27</td>
<td>SURGICAL EXPERIENCE IN PATIENTS WITH VON WILLEBRAND DISEASE: ONE CENTER REPORT</td>
</tr>
<tr>
<td></td>
<td>M. A. Nardi* (USA)</td>
<td></td>
<td>K. Kavakli* (Turkey) - C. Balkan - D. Y. Karapinar</td>
</tr>
</tbody>
</table>
Women's Health Issues in Thrombosis and Hemostasis

**WH01** ASSOCIATION BETWEEN NEWBORN BIRTH WEIGHT AND MATERNAL VENOUS THROMBOEMBOLISM IN THE POSTPARTUM PERIOD: A POPULATION-BASED CASE-CONTROL STUDY.
M. Blondon* (Switzerland) - B. Quon - L. Harrington - H. Bounameaux - N. Smith

**WH02** PREGNANCY COMPLICATIONS IN ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA

**WH03** THE ASSOCIATION BETWEEN BILATERAL SALPINGOOOPHORECTOMY AND INCIDENT VENOUS THROMBOSIS AMONG POSTMENOPAUSAL WOMEN WITH HYSTERECTOMY

**WH04** CLINICAL UTILITY OF ANTITHROMBOTIC PROPHYLAXIS IN IVF/ICSI
M. Villani* (Italy) - G. L. Tiscia - F. Dentali - D. Colaizzo - F. Cappucci - L. Fischetti - W. Ageno - M. Margaglione - E. Grandone

**WH05** MODE OF DELIVERY AND CRANIAL BLEEDING IN NEWBORNS WITH HAEMOPHILIA, A SYSTEMATIC REVIEW OF THE LITERATURE
J. Davies* (United Kingdom) - R. A. Kadir

**WH06** ASSOCIATION OF FACTOR V LEIDEN G1691A AND PROTHROMBIN GENE G20210A MUTATION WITH ADVERSE PREGNANCY OUTCOMES
S. Asad* (Pakistan) - B. Moiz

**WH07** OBSTETRIC PATIENTS IN THE INTENSIVE CARE UNIT (ICU): HEMATOLOGIC ASPECTS.

**WH08** EFFECTS OF SERUM ADIPONECTIN LEVELS ON PLATELET DISAGGREGATION IN PREGNANT WOMEN WITH GESTATIONAL DIABETES MELLITUS AND TYPE 1 DIABETES MELLITUS
V. Bichan* (Belarus) - Z. Zabarovskaya

**WH09** OUTCOMES OF 339 PREGNANCIES IN 181 WOMEN SUFFERING FROM 13 DIFFERENT FORMS OF INHERITED THROMBOCYTOPENIA ENROLLED IN A RETROSPECTIVE AND MULTICENTRIC STUDY (ON BEHALF OF EHA-SWG ON THROMBOCYTOPENIAS AND PLATELET FUNCTION DISORDERS)

**WH10** INCIDENCE OF THROMBOPHILIA TESTING IN PREGNANCIES COMPLICATED BY CURRENT OR PRIOR THROMBOEMBOLISM
V. Barros* (Brazil) - I. Torres - F. S. Baptista - R. P. Francisco - M. Zugaib

**WH11** DESCRIPTIVE ANALYSIS OF PREGNANT WOMEN WITH RECURRENT FETAL DEATH AND THROMBOPHILIA
Working Group on Genomics in Hemostasis

GH01 USE OF HUMAN PHENOME ONTOLOGY (HPO) IS AN EFFECTIVE APPROACH TO CLUSTER 519 CASES OF INHERITED BLEEDING AND PLATELET DISORDERS ENROLLED BY 12 REFERRAL CENTRES IN AN EXOME SEQUENCING STUDY
A. Kelly* (United Kingdom) and on behalf of the BRIDGE consortium

GH02 THROMBOPHILIA TESTING AMONG PATIENTS WITH VENOUS THROMBOEMBOLISM
M. R. Meyer* (USA) - T. Delate - S. G. Johnson - D. M. Witt

GH03 IDENTIFICATION OF CODING VARIANTS IN SUSCEPTIBILITY GENES THROUGH GENOME-WIDE ASSOCIATION AND NEXT GENERATION SEQUENCING IMPLICATED IN PEDIATRIC VENOUS THROMBOSIS
M. Stoll* (Germany) - A. Barysenka - A. Arning - A. Witten - U. Nowak-Göttl

GH04 THE PREVALENCE OF GENE POLYMORPHISMS OF THROMBOCYTES IN PATIENTS WITH EVIDENTIAL VENOUS THROMBOEMBOLISM (VTE)
T. Kvasnicka* (Czech Republic) - J. Hajkova - P. Bobcikova - V. Cverhova - P. Kvasnickova - J. Ulrych - J. Briza - I. Malikova - J. Kvasnicka

GH05 THE EAHAD COAGULATION FACTOR VARIANT DATABASES
The SSC 2014 Industry Exhibition is located in Ballroom A-C on the ground level.

Exhibition hours

<table>
<thead>
<tr>
<th>Day</th>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday</td>
<td>June 23, 2014</td>
<td>09.00 – 20.00</td>
</tr>
<tr>
<td>Tuesday</td>
<td>June 24, 2014</td>
<td>09.30 – 18.00</td>
</tr>
<tr>
<td>Wednesday</td>
<td>June 25, 2014</td>
<td>09.00 – 16.30</td>
</tr>
</tbody>
</table>

Complimentary coffee and tea as well as lunch boxes will be served in the exhibition hall. Complimentary lunch boxes will also be available in front of the lunch time symposia rooms. Please refer to the program details for timings.

### Affinity Biologicals

**Email** greg.fullerton@affinitybiologicals.com

**Phone International** +1 905-304-9896

**Toll Free USA/Canada** +1 800-903-6020

**Website** www.affinitybiologicals.com

Affinity Biologicals, Inc. is a primary manufacturer of products used worldwide in thrombosis and haemostasis research and medical diagnostics. Products include an extensive line of antibodies, conjugates, antibody pairs for immunoassay of human and animal analytes, the VisuLize™ line of complete ELISA kits, and a full line of immuno-depleted human plasma products, VisuCal™ Calibrator Plasma, VisuCon™ Normal, Abnormal and Low Fibrinogen Control Plasmas and VisuDep™ Factor Deficient Plasmas. Services include protein purification, antibody production, assay development, custom lyophilization and custom plasma production.

### Aggredyne, Inc.

**Email** info@aggredyne.com

**Phone** +1 713-636-5996

**Website** www.aggredyne.com

Aggredyne is a medical device manufacturing company. Our current product is the AggreGuide A-100 which is an In Vitro Diagnostic Aggregometer allowing physicians to simply and easily perform platelet function testing within 5 minutes at the point-of-care. There is no blood preparation, reagent mixing or centrifugation requirements and only requires 1 standard blue top tube of whole blood. There is no specialized training required and is about 1/3 the cost of our competitors. Our device was recently FDA cleared and is being sold in 15+ countries.
Bayer HealthCare

Website  www.bayer.com

With more than 20 years of experience, Bayer HealthCare continuously strives to be a leader in the research and development of safe, effective biotechnology products that transform hemophilia care. Our mission is to enable people with hemophilia to live the lives they choose.

Platinum Level Sponsor
Support for
Final Program
Mobile App
Reach-the-World Travel Stipends
Trainee and Reach-the-World Travel Networking Event
Special Symposium
As the world’s oldest independent biotechnology company, Biogen Idec brings an incredible 35-year history of cutting-edge science and a passion for progress in serious chronic conditions. We have combined this long-standing tradition of excellence with a highly experienced team in hemophilia to work towards developing and delivering potential treatment options.

**Gold Level Sponsor**

**Support for**
- Charging Stations
- Hand Sanitizer Stations
- Satellite Symposium

**BioMed Central**

**Email** editorial@thrombosisjournal.com

**Phone** +44 0 203-192-2009

**Website** www.thrombosisjournal.com/

*Thrombosis Journal* is a peer-reviewed, online, open access journal that aims to publish biologically significant findings with clinical relevance in the field of acute and chronic vascular thrombotic disease.

*Thrombosis Journal* is published by BioMed Central, The Open Access Publisher. The journal publishes original articles on aspects of clinical and basic research, new methodology, case reports and review in the areas of thrombosis. For further details on any BioMed Central journal please visit www.biomedcentral.com.

**BloodCenter of Wisconsin**

**Email** labinfo@bcw.edu

**Phone** +1 800-245-3117 ext. 6250

**Website** www.bcw.edu

BloodCenter of Wisconsin advances patient care by delivering unparalleled medical and scientific expertise. We provide a continuum of care that includes discovery, diagnosis, treatment and cure. Our Diagnostic Laboratories help you to improve patient outcomes through innovative clinical testing, rapid turnaround times, and expert consultation.

**Support for**
- Plenary Session
Chrono-log Corp.

Email chronolog@chronolog.com
Phone +1-610-853-1130
Website www.chronolog.com

With a Chrono-log Model 700 Whole Blood/Optical Lumi-Aggreometer, you can: Detect platelet defects, Monitor anti-platelet drug therapy, Measure ATP Release simultaneously with Aggregation, Screen VWD and sub-types such as 2B. Results are obtained quickly, accurately and cost effectively. Please visit us at Booth 423 to discuss your specific platelet testing needs.

Cleveland Clinic Laboratories

Email ClientServices@ccf.org
Phone +1 800-628-6816
Website Clevelandcliniclabs.com

Cleveland Clinic Laboratories has more than 25 years experience providing clinicians with the most appropriate test, rapid turnaround, and superior customer service. With the opening of the nation’s foremost state-of-the-art laboratory and interpretive skills of more than 100 pathologists, we serve clients from around the corner and across the world.

CSL Behring GmbH

Email dieter.pluennecke@cslbehring.com
Phone +49 642-139-4191
Website www.cslbehring.com

CSL Behring is a global leader in the protein biotherapeutics industry. Passionate about improving the quality of patients’ lives, CSL Behring manufactures and markets a range of plasma-derived and recombinant products for the treatment of Hemophilia, von Willebrand’s disease and other bleeding disorders. For more information, visit www.cslbehring.com.

Support for
Educational Grant
Satellite Symposium
diaPharma supplies laboratory reagents for thrombophilia diagnosis, anticoagulation monitoring, bleeding disorder management, and hemostasis research. We pride ourselves in providing helpful customer support and highly trained technical support teams. Please visit diaPharma, and see our newest assays for thrombin generation, ADAMTS13, microparticles, and platelet function.

DVTlite has partnered with the Canadian medical device manufacturer, Saringer Life Science Technologies to provide their patented Venowave Technology to the U.S. market. The Venowave is a revolutionary mobile device for the prevention of DVT and treatment of several vascular conditions.

Hematology Advance is the online assembly point for all Hematology scientists, students, practitioners, industry professionals and all others who are interested. The place to find out more about Elsevier’s Hematology journals & books, cutting-edge research news, submitting your paper and information about upcoming events/ conferences. Let hematologyadvance.com help you to stay current and provide you with useful resources for your work or studies.
Enzyme Research Laboratories provides coagulation and fibrinolytic proteins from human plasma, other source plasmas and platelets. r2 Diagnostics strives to provide high quality, innovative and economical products for the hemostasis market. We place major emphasis on the production of optimized and versatile products for the detection of thrombophilia, including kits for quantitation of PC, PS, and Lupus Anticoagulants.

George King Bio-Medical, Inc., is proud to be a pioneer in the field of diagnostic coagulation and thrombosis. Much of our success is attributed to the excellent and ongoing relationships established with our valued customers over the last 41 years. Call us for solutions for your laboratory needs.

Grifols improves people’s lives with high quality innovative hospital products and services. Our plasma derived Therapies have outstanding records of efficacy and safety and we are also a world-leading manufacturer of medical devices, analyzers and reagents used by blood banks, transfusion centers and clinical laboratories.

Support for
Educational Grant
Special Symposium
Haematologic Technologies, Inc. (HTI) is a manufacturer of research reagents, specializing in the plasma proteins involved in the regulation of blood coagulation and fibrinolysis. Our product line of highly purified proteins includes zymogens, enzymes, cofactors, and inhibitors as well as monoclonal and polyclonal antibodies.

Hematology Vision was launched in 2011 to provide Hematologists and allied Healthcare Professionals with a valuable and easily accessible educational resource that showcases the best content from the global Hematology community and conferences. Hematologists, internists, nurses and allied healthcare professionals visit HematologyVision.com each month to be kept up-to-date and engage with our content.

Hemostasis Reference Laboratory Inc (HRL) is a Canadian Laboratory with over 20 years of experience in providing quality coagulation testing services to customers internationally. HRL offers a complete range of testing for clinical trials, sample analysis, research projects, product evaluation, value assignments, instrument validation, and more servicing pharmaceutical companies, diagnostic manufacturers, veterinarians, and researchers.
Hemostasis & Thrombosis Research Society  
Booth 110

**Email** htrs@bcw.edu  
**Phone** +1 414-937-6569  
**Website** www.htrs.org

Incorporated as a nonprofit in 1994, the Hemostasis and Thrombosis Research Society, Inc. (HTRS) is a North American professional medical society dedicated to advancing care for people with bleeding and thrombotic disorders through investigator-initiated research, mentoring, and continuing medical education.

HYPHEN BioMed  
Booth 109

**Email** jamiral@hyphen-biomed.com  
**Phone** +33 (0)1 3440 6510  
**Website** www.hyphen-biomed.com

HYPHEN BioMed is a highly specialized company for developing, manufacturing and distributing research and laboratory reagents for thrombosis and hemostasis, offering innovative solutions to laboratory work (eg. DOAC, HIT, Hemophilia) and to pharmaceutical industry (customized offer). Our reagents are available in North America exclusively through Aniara.

Immucor  
Booth 108

**Email** wkscustomerservice@immucor.com  
**Phone** +1 800 233 1843  
**Website** www.immucor.com

Immucor is a global provider of transfusion and transplantation diagnostics. Our transfusion products include a complete line of reagents and scalable automation for immunohematology. For transplant, we provide molecular and antibody-based assays for HLA compatibility between donors and recipients. Our molecular and specialty diagnostic assays provide advanced technology for compatibility, hemostasis and platelet antibody testing.

**Bronze Level Sponsor**  
**Support for**  
Final Program  
Technical Session
Instrumentation Laboratory is passionate about delivering the most innovative solutions to address a range of hemostasis testing needs. The advanced ACL™ family of systems brings complete automation to the hemostasis lab—including the ACL TOP® Family of Hemostasis Testing Systems, featuring the new ACL TOP 300 CTS; and, the ACL AcuStar®, the first fully automated, chemiluminescent analyzer for hemostasis specialty testing. Combined with the HemosIL line of reagents, a comprehensive panel of fully automated assays, IL offers complete disease state management for the hemostasis lab.

The ISTH is a global not-for-profit organization advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders. Dedicated to transformative scientific discoveries and clinical practices, the development of young professionals and the education of physicians, scientists and allied health professionals wherever they may live. The Society also publishes JTH, the official Journal of the Society, which is the leading medical journal in the fields of thrombosis and hemostasis and has an impact factor of 6.081.

The ISTH initiates and promotes education and outreach initiatives, research activities, scientific meetings - such as SSC 2014, peer-reviewed publications, expert committees and the development of standards allowing a common language and approach to basic and clinical science all over the world. Stop by the ISTH booth to learn more about JTH, the programs and activities of the ISTH and the Society’s future meetings.
Karger Publishers

Email f.suter@karger
Phone +41 61 306 11 11
Website www.karger.com

Karger Publishers is a leading international publisher of books and journals in the basic and medical sciences. Our publications cover both research and clinical practice and provide authors with a worldwide platform to present their research findings. We are pleased to present our publication SickKids Handbook of Pediatric Thrombosis and Hemostasis.

Kedrion Biopharma, Inc.

Email jgibbons@kedrionusa.com
Phone +1 201-242-8900
Website www.kedrionusa.com

Kedrion Biopharma Inc. proudly offers Koate-DVI. Kedrion is a biopharmaceutical company that focuses on life saving therapies derived from human plasma. Kedrion has over 40 years of experience and dedication to human-derived therapies. Our focus is within: critical care, hematology, immunology, transfusion medicine & women’s health. To learn more about Koate-DVI, please visit our website at www.koate-dviusa.com.

Medical College of Wisconsin

Website www.mcw.edu

Support for
Armand J. Quick Memorial Lecture
Novo Nordisk Health Care AG

Email zobi@novonordisk.com
Phone +41 43 222 4300
Website www.novonordisk.com

Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 38,000 employees in 75 countries, and markets its products in more than 180 countries. For more information, please visit novonordisk.com.

Platinum Level Sponsor

Support for
Abstracts USB Stick
Conference Capture
Final Program

Meeting Stools and Tables
Pocket Program
Reminder/Informational e-blasts
Satellite Symposium

Hematolo Octapharma AG

Email enquiry@octapharma.com
Phone +41 55 451 21 21
Website www.octapharma.com

Headquartered in Switzerland, Octapharma is the largest privately owned human protein products manufacturer in the world. Dedicated to the development of human proteins from human plasma and human cell-lines, Octapharma has been committed to medical innovation since 1983. Octapharma owns five state-of-the-art production facilities in Austria, France, Germany, Sweden and Mexico.

Precision BioLogic Inc.

Email info@precisionbiologic.com
Phone +1 800-267-2796
Website www.precisionbiologic.com

Precision BioLogic manufactures CRYOcheck™ frozen controls, reagents and diagnostic kits. Our approach to doing business is built on superior products, commitment to service and attention to detail. With our laboratory, biotech and pharmaceutical partners, we’re developing new products to improve patient outcomes by addressing challenges in the diagnosis and therapeutic monitoring of disease.
Thrombosis and Haemostasis provides position, state-of-the-art and guideline papers, expert analysis and dedicated Theme issues covering recent developments and key topics in the field. Thrombosis and Haemostasis provides a forum for the exchange of ideas and concepts fostering cross-disciplinary insights in basic and clinical research.

Siemens Healthcare Diagnostics, a global leader in clinical diagnostics, provides healthcare professionals in hospital, reference, and physician office laboratories and point-of-care settings with the vital information required to accurately diagnose, treat, and monitor patients. Our innovative portfolio of performance-driven solutions and personalized customer care combine to streamline workflow, enhance operational efficiency, and support improved patient outcomes. www.siemens.com/diagnostics

SINNOWA specializes in researching, developing and manufacturing clinical laboratory equipments and reagents, including fully/semi automatic automatic biochemistry analyzer, platelet function analyzer, coagulometer, electrolyte analyzer, hematology analyzer and reagents. SINNOWA has been ranked in Credit AAA enterprises in China and granted CE, SFDA and ISO 9001:2000 and ISO 13485:2003 certificates.
STAGO

Email webmaster@stago.com
Phone +33 1 46 88 20 20
Website www.stago.com

Stago, created in 1945, is an IVD Company which develops and markets reagents and automated systems for the investigation of blood coagulation disorders. Stago is a leading player in Haemostasis. Headquarters, as well as R&D, manufacturing and logistics activities are located mainly in the Paris area (France). Stago products are available in more than 110 countries throughout the world. In 2013, Stago Group had over 2200 employees worldwide.

Technoclone

Email sales@technoclone.com
Phone +43 1 86373-0
Website www.technoclone.com

Technoclone is a diagnostic company, specialized in development and production of high quality test systems for the in vitro diagnostics use with special emphasis on the area of haemostasis, thrombosis, and cardiovascular diseases.

Wiley

Email moferns@wiley.com
Phone +1 201-748-7859
Website onlinelibrary.wiley.com/subject/hematology

Wiley is one of the foremost academic and professional publishers, with a combined list of more than 1,400 scholarly-reviewed journals and an extensive collection of books. Our hematology portfolio includes titles like Journal of Thrombosis and Haemostasis and British Journal of Haematology, and books like Victor Hoffbrand’s Postgraduate Hematology.

Wolters Kluwer

Website www.wolterskluwer.com
Showcasing the latest presentations and discussion from hematology conferences from around the world.

www.hematologyvision.com
Visit the website for more information about Elsevier Hematology journals

www.hematologyadvance.com
An expertly written and practical handbook

**SickKids Handbook of Pediatric Thrombosis and Hemostasis**

*Editors:*
- Victor S. Blanchette, Toronto, Ont.
- Vicky R. Breakey, Hamilton, Ont.
- Shoshana Revel-Vilk, Jerusalem

XVIII + 254 p., 23 fig., 9 in color, 9 algorithms, 59 tab., soft cover, 2013
CHF 98.– / EUR 82.– / USD 115.00

Written and reviewed by international experts in the field, this handbook is intended for health care professionals involved in the assessment and care of children with inherited and acquired bleeding and clotting disorders, including general and specialist pediatricians (in particular intensivists, neonatologists, cardiologists/cardiac surgeons, rheumatologists and nephrologists), hematologists/oncologists (pediatric and adult), as well as medical trainees, nurses, nurse practitioners and pharmacists.

[www.karger.com/sickkids](http://www.karger.com/sickkids)

Management of children with inherited and acquired bleeding and clotting disorders

**Pediatric and Adolescent Hematology**

*Editors:*
- Angela E. Thomas, Edinburgh
- Christina Halsey, Glasgow

VIII + 178 p., 13 fig., 19 tab., hard cover, 2014
List price: CHF 148.– / EUR 123.– / USD 174.00
Special price: CHF 104.– / EUR 86.– / USD 122.00

In this book an internationally acclaimed panel of authors, each chosen for expertise in their field, have produced a state-of-the-art collection of review articles focusing on the very latest advances and controversies in the management of pediatric and adolescent hematological problems.

Providing an up-to-date look at both specific hematologic disorders and also hematologic problems that arise in association with systemic disease, this book is essential reading not only for pediatric and adult haematologists but also for pediatricians, pediatric or hematologic specialist nurse practitioners and pediatric pharmacologists.

Go to [www.karger.com/pamed17](http://www.karger.com/pamed17) and use the promotional code PedHem14 to profit from this special offer.
Today’s Science for Tomorrow’s Results

Thrombosis and Haemostasis, a leading journal in its field for more than 55 years publishes reports on basic and clinical research dedicated to novel results and highest quality in any area of thrombosis and haemostasis research, vascular biology and medicine, inflammation and infection, platelet and leukocyte biology, from genetic, molecular & cellular studies, diagnostic, therapeutic & preventative studies to high-level translational and clinical research.

Subscribers to and readers of Thrombosis and Haemostasis enjoy:
- A reliable publication platform in vascular biology and medicine
- Renowned authors – leaders in their field of research
- Electronic Table of Contents – register online today!
- Online submission and PrePrint publication: TH First
- A broad scope covering expanded areas of interest including:
  - Blood coagulation, fibrinolysis and cellular haemostasis
  - Platelets and blood cells
  - Endothelium and vascular development
  - Wound healing and inflammation/infection
  - Cardiovascular biology and cell signalling
  - Cellular proteolysis and oncology
  - Animal models
  - New technologies, diagnostic tools and drugs

Thrombosis and Haemostasis
International Journal for Vascular Biology and Medicine
Volumes 111 and 112 in 2014
6 issues per volume
ISSN 0340-6245

Thrombosis and Haemostasis
Publishes original contributions of basic and original research and clinical studies in vascular biology and medicine, serving as an international platform for the dissemination and debate of scientific information. The Journal appears monthly in both print and online.

Visit our homepage and register for eTOC today at:

www.thrombosis-online.com
Visit Us in Booth 113 in the Exhibition Hall

2015 Congress
TORONTO JUNE 20-25
Reaching for Unprecedented Peaks

isth2015.org
BAYER HEMOPHILIA AWARDS PROGRAM

SUPPORTING HEMOPHILIA RESEARCH, TREATMENT AND EDUCATION AROUND THE WORLD

The Bayer Hemophilia Awards Program is our flagship hemophilia and hemostasis grants program, underlining our commitment to driving forward the scientific understanding of hemophilia and hemostasis, and to improving care for patients around the world.

Since 2003, over 200 grants have been awarded to clinicians, researchers and caregivers from 30 countries.

For more information, visit:
www.bayer-hemophilia-awards.com